
$3KDVH5DQGRPL]HG'RXEOH% OLQG3ODFHER&RQWUROOHG3HUL RG&URVVRYHU3RVLWLYH
&RQWURO47(YDOXDWLRQ6WXG \RI$3/LQ6XEMHFWVZLWK3DU NLQVRQ¬∂V'LVHDVH
&RPSOLFDWHGE\0RWRU)OXFWXD WLRQV¬≥2))¬¥(SLVRGHV


35272&2/
180%(5&7+
,1' 
(8'5$&7 
35272&2/'$7( $XJXVW
35272&2/9(56,21 
6321625('%< 6XQRYLRQ3KDUPDFHXWLFDOV,QF
:DWHUIRUG'ULYH
0DUOERURXJK0$86$


Sunovion Pharmaceuticals Inc.  Page 2 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 RESTRICTED DISTRIBUTION OF PROTOCOLS  
This document contains information confidential and/or of proprietary interest to Sumitomo 
Dainippon Pharma Co. Ltd. and/or Sunovion Pharmaceuticals Inc. (including their 
The information cannot be disclosed to any third party or predecessors,  subsidiaries or affiliates). 
used for any purpose other than the purpose for which it is being submitted without the prior written consent of the appropriate Sumitomo Dainippon Pharma company. 
This information is being provided to you for the purpose of conducting a clinical study for 
Sumitomo Dainippon Pharma Co. Ltd. and  You may disclose /or Sunovion Pharmaceuticals Inc.
the contents of this protocol to the study personnel under your supervision and to your Institutional Review Board or Independent Ethics Committee for the above purpose. You may not disclose the contents of this protocol to any other parties, unless such disclosure is required by government regulations or laws, without the prior written permission of Sumitomo Dainippon Pharma Co. Ltd. and  /or Sunovion Pharmaceuticals Inc.
Any data gathered during the conduct of this protocol and supplemental information (eg, a  
protocol amendment) that may be added to this document is also proprietary to Sumitomo 
Dainippon Pharma Co. Ltd. and , and should be  handled /or Sunovion Pharmaceuticals Inc.
consistently with that stated above. 
 
Sunovion Pharmaceuticals Inc.  Page 3 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 1 EMERGENCY CONTACT  INFORMATION  
Sponsor Con tact: 
  
Senior Dire
ctor Clinical Development  
Sunovion Pharmaceuticals Inc. 
84 Waterford Drive Marlborough, MA  
  
 
 
North American Medical Monitor:  
  
Medical Di
rector  
INC Research  
  
  
 
European Union Medical Monitor  
  
Execut
ive Medical Director   
INC Research  
  
   
 
SAE Reporting  
 
 
 
 

Sunovion Pharmaceuticals Inc.  Page 4 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 2 INVESTIGATOR APPROVAL  STATEMENT 
I have read the protocol, CTH -201, Version 5.0, ‚ÄúA Phase 2, Randomized, Double -Blind, 
Placebo Controlled 3-P eriod Crossover, Positive Control, QT -Evaluation S tudy of APL -130277 
in Subjects  with Parkinson‚Äôs Disease Complicated by Motor Fluctuations (‚ÄúOFF‚Äù Episodes), ‚Äù 
and agree that it contains all necessary details for conducting the study and to conduct the study 
in strict accordance with the specifications outlined herein.  
I agree that no additional procedure(s) will be added during the conduct of the study  except 
through protocol amendment by Sunovion Pharmaceuticals Inc. and after documentation of IRB/REB/ IEC approval. 
Principal Investigator   
Printed Name:   
Signature:   
Date:   
  
PROTOCOL  
A Phase 2, Randomized, Double -Blind, Placebo Controlled,  3-Period Crossover, Positive 
Control, QT-Evaluation S tudy  of APL -130277 in Subjects  with Parkinson‚Äôs Disease 
Complicated by Motor Fluctuations (‚ÄúOFF‚Äù Episodes) 
Protocol: 28 Aug 2017  
 
Version: 5.0 
 
Sunovion Pharmaceuticals Inc.  Page 5 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 3 PROTOCOL  SYNOPSIS  
TITLE  A Phase 2, Randomized, Double -Blind, Placebo Controlled 3 -Period Crossover, Positive 
Control, QT -Evaluation Study of APL -130277 in Subjects  with Parkinson‚Äôs Disease 
Complicated by Motor Fluctuations (‚ÄúOFF‚Äù Episodes)  
STUDY PHASE  Phase 2  
OBJECTIVES  The primary objective is to evaluate the effect of APL -130277 compared to placebo  on 
QTc intervals in subjects  with Parkinson‚Äôs disease (PD)  complicated by motor 
fluctuations.  
The secondary objectives include the evaluation of safety and pharmacokinetics of APL -
130277 and the comparison of efficacy of  the highest tolerated dose level and the lowest 
APL -130277 dose resulting in a full ‚ÄúON‚Äù durin g the Dose Titration Phase.  
NUMBER OF 
SUBJECTS  The study will require forty -two (42) subjects to complete the 3 -period, single dose 
crossover phase. Recruitment  will continue until the required number of subjects 
complete the study . 
PATIENT POPULATION  Inclusion Criteria  
Subjects  who meet each of the following criteria will be eligible for participation in the 
study:  
1. Male or female ‚â•  18 years of age. 
2. Clinical diagnosis of Idiopathic PD, consistent with UK Brain Bank Criteria (excluding the ‚Äúmore than one affected relative‚Äù criterion).  
3. Clinically meaningful response to Levodopa (L -Dopa) . Subjects with or without 
well-defined ‚ÄúOFF‚Äù episodes, as determined by the Investigator , will be allowed . 
4. Receiving stable doses of L- Dopa/carbidopa (immediate or sustained release) 
administered at least 3  times per day OR Rytary‚Ñ¢  administered 3  times per day, 
for at least 4 weeks before the initial Screening Visit (SV1). Subjects receiving 
L-Dopa/carbidopa 3 times a day must also be on stable treatment with a djunctive 
PD medication regimens . These regimens  must be maintained at a stable dose 
for at least 4 weeks prior to the initial Screening Visit (SV1) with the exception that MAO -B inhibitors must be maintained at a stable level for at least 8  weeks 
prior to the initial Screening Visit (SV1).  
5. No planned medication change(s) or surgical intervention anticipated during the course of study . 
6. The subject must be able to have a drug withdrawal induced ‚ÄúOFF‚Äù episode. 
7. Stage III or less on the modified Hoehn and Yahr scale in the ‚ÄúON‚Äù state.  
8. Mini ‚ÄìMental State Examination (MMSE) score > 21. 
9. If female and of childbearing potential, must agree to us e one of the following 
methods of birth control  throughout the study and until at least 30 days after 
final drug administration:  
‚Ä¢ Oral contraceptive;  
‚Ä¢ Contraceptive patch;  
Sunovion Pharmaceuticals Inc.  Page 6 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 ‚Ä¢ Barrier (diaphragm, sponge or condom) plus spermicidal preparations;  
‚Ä¢ Intrauterine cont raceptive system;  
‚Ä¢ Levonorgestrel implant;  
‚Ä¢ Medroxyprogesterone acetate contraceptive injection;  
‚Ä¢ Complete abstinence from sexual intercourse;  
‚Ä¢ Hormonal vaginal contraceptive ring; or  
‚Ä¢ Surgical sterilization or partner sterile (must have documented proof).  
10. Male subjects  must be either surgically sterile, agree to be sexually abstinent or 
use a barrier method of birth control (e.g., condom) from first study drug 
administration until at least 30 days after final drug administration.  
11. Willing and able to comply with  scheduled visits, treatment plan, laboratory 
tests, and other study -related procedures to complete the study.  
12. Able to understand the consent form, and to provide written informed consent.  
13. Must be approved as a s atisfactory candidate by the Enrollment Auth orization 
Committee (EAC)  and the Sponsor . 
 Exclusion Criteria  
Subjects  will be excluded from participation in the study for any of the following reasons:  
1. Atypical or secondary parkinsonism.  
2. Nausea associated with the use of dopamine agonist s that require s treatment with 
an anti -emetic.  
3. Previous treatment with any of the following: a neurosurgical procedure for PD; 
continuous subcutaneous (s.c.) apomorphine infusion; or Duodopa/Duopa.  
4. Treatment with any form of s.c. apomorphine within 7 days prior to the initial 
Screening Visit (SV 1). Subjects  that stopped s.c. apomorphine for any reason 
other than systemic safety concerns or lack of efficacy may be considered.  
5. Contraindications to moxifloxacin or APOKYN¬Æ or hypersensitivity to 
apomorphine hydrochloride or any macrolide antibiotic or any of the ingredients 
of APOKYN¬Æ (notably sodium metabisulfite) . 
6. Female who is pregnant or lactating.  
7. Participation in a clinical trial within 30 days prior to the initial Screening Visit (SV1) , with the exception of clinical studies related to APL -130277. 
8. Receipt of any investigational (i.e., unapproved) medication within 30  days prior 
to the initial Screening Visit (SV1 ), with the exception of APL -130277. 
9. Any selective 5HT 3 antagonists (i.e., ondansetron, granisetron, dolasetr on, 
palonosetron, alosetron), dopamine antagonists ( including Tigan 
[trimethobenzamide] and domperidone, but excluding quetiapine or clozapine) 
or dopamine depleting agents  within 30 days prior to initial Screening Visit 
(SV1) . 
10. Drug or alcohol dependency i n the past 12  months.  
11. Subject has a history of malignancy within 5  years prior to SV1, except for 
adequately treated basal cell or squamous cell skin cancer or in situ cervical 
Sunovion Pharmaceuticals Inc.  Page 7 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 cancer. Pituitary tumo rs of any duration are excluded . 
12. Documented abnormalities  with ECGs including, arrhythmias, clinically 
meaningful interval irregularities, structural heart abnormalities, myocardial 
infarction, presence or history of a pacemaker , or any abnormality of the ECG, 
that in the opinion of the  Investigator, would interfere with the ability to measure 
the QT interval, or correct the QT interval for heart rate.  
13. Male subjects  with a screening corrected QT interval using Fridericia‚Äôs formula 
(QTcF)  of ‚â• 450 ms; female subjects  with a screening QT interval ‚â• 470 ms. 
Eligibility will be based on the core laboratory ECG interpretation report. 
14. HR at screening < 45 bpm or >  100 bpm. 
15. QRS duration at screening > 120 ms. 
16. PR interval at screening > 200 ms. 
17. Subject s with a history of cataplexy, unexplained syncope or seizures . 
18. Family history of sudden cardiac death . 
19. Heart failure (NYHA Class II or greater) and/or a myocardial infarction.  
20. Current use of any concomitant mediations that prolong the QT/QTc interval. 
Refer to https://crediblemeds.org for listing.  
21. History of additional risk factors for TdP (i.e., heart failure, hypokalemia, family 
history of Long QT Syndrome) . 
22. Clinically significant medical, surgical, or laboratory abnormality in the opinion of the Investigator.  
23. Subject has a positive screening laboratory test  result for h uman 
immunodeficiency virus (HIV) . 
24. Subject has a positive screening laboratory test  result for  hepatitis B surface 
antigen or hepatitis C antibodies  and has liver function test results at screening 
above the ULN  for the reference laboratory . 
25. Major psychiatric  disorder including, but not limited to, dementia, bipolar 
disorder, psychosis  (including Parkinson‚Äôs disease psychosis) , or any disorder 
that, in the opinion of the Investigator, requires ongoing treatment that would make study participation unsafe or mak e treatment compliance difficult.  
26. History of clinically significant impulse control disorder(s).  
27. Dementia that precludes providing informed consent or would interfere with participation in the study.  
28. Current suicidal ideation within one year prior to the s econd Screening Visit 
(SV2) as evidenced by answering ‚Äúyes‚Äù to Questions 4 or 5 on the suicidal 
ideation portion of the Columbia -Suicide Severity Rating Scale (C -SSRS) or 
attempted suicide within the last 5  years.  
29. Donation of blood plasma in the 30 days p rior to first dosing.  
STUDY DESIGN  Study Procedures  
Screening  
Before any study procedures are performed on any subject , informed consent must be 
obtained at an initial Screening Visit (SV1). Subjects  recruited to participate in the study, 
Sunovion Pharmaceuticals Inc.  Page 8 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 and who have pro vided full consent to participate, will be asked to attend a second 
Screening Visit (SV2), having taken their last dose of L -Dopa and any other adjunctive 
PD medication no later than midnight the evening prior to the visit. Their normal morning 
dose of L -Dopa ( without adjunctive PD medication)  will be administered in the clinic 
following confirmation of an ‚ÄúOFF‚Äù episode by the Investigator, to ensure that they experience an ‚ÄúON‚Äù response. Eligibility criteria will be assessed  by the Investigator and 
approve d by the EAC prior to  enrollment.  
Subjects  will be asked to return to the clinic the morning of Titration Visit 1 (TV1) for 
the Dose Titration Phase of the study.  
Dose Titration Phase  
Depending on the Investigator's decision, subjects  will be asked to arri ve at the clinic : 
‚Ä¢ after their usual morning dose of PD medications; but before taking their next dose of medication ; OR  
‚Ä¢ after withholding their normal morning dose of L -dopa (ie, in the practically 
defined "OFF" state with no anti -parkinsonian medication a fter midnight the 
night prior).  
During the Dose Titration Phase of the study, subjects will start with a dose of 10 mg 
APL -130277 and increase in 5 mg increments up to 40 mg and then in 1 0 mg increments 
for the 5 0 mg and 60 mg dose levels  until the subject  reaches a full ‚ÄúON‚Äù state. Once a 
full ‚ÄúON‚Äù state is achieved, dosing will continue for 2 additional visits to a maximum 
dose of 60 mg (i.e., if a subject  experiences the first full ‚ÄúON‚Äù at 1 0 mg, dosing will 
continue up until a dose of 20 mg). 
For those subjects who do not achieve a full "ON" response, titration should continue 
until the maximum tolerated dose of APL -130277 is determined.  
Note:  For subjects who have previously participated in the CTH -300 or CTH -301 study, 
the subject will begin titration at the effective dose used in the respective previous study. 
Similarly dose titration of these subjects will increase in 5 mg increments up to 40 mg 
and then in 10  mg increments for the 50  mg and 60  mg dose levels until the subject 
reaches a full ‚ÄúON‚Äù stat e. Once a full ‚ÄúON‚Äù state is achieved, dosing will continue for 
2 additional visits to a maximum dose of 60 mg (i.e., if a subject  experiences the first full 
‚ÄúON‚Äù at 35 mg, dosing will continue up until a dose of 50 mg). 
At Titration Visit 1 (TV1), once th e subject's ‚ÄúOFF‚Äù state  has been confirm ed by both the 
Investigator and subject,  the subject will be treated with 1 0 mg APL -130277. Subjects  
who tolerate the 1 0 mg APL -130277 will restart their normal PD medications and will be 
asked to return to the clinic the next business day for Titration Visit 2 (TV2), to assess the 
next highest dose (i.e., 1 5 mg) in a manner identical to that of Titration Visit 1 (TV1) . 
Doses of APL -130277 will increase in 5 mg increments up to 4 0 mg and then in 10 mg 
increments for the 50 mg and 60 mg dose levels  until a full ‚ÄúON‚Äù state is achieved , then 
dosing will continue for 2 additional visits  to a maximum dose of 60 mg. This will 
sequentially be 2 0 mg [TV3], 2 5 mg [TV4], 3 0 mg [TV5], 3 5 mg [TV6] , 40 mg [TV7] , 
50 mg [TV8] and 6 0 mg [TV9] . 
For Titration Visit 3 (TV3), Titration Visit 4 (TV4), Titration Visit 5 (TV5), and Titration 
Visit 6 (TV6) subjects should be dosed with the next highest dose of study medication 
within 4 hours of the initial dose, as long as the subject achieves  another ‚ÄúOFF‚Äù state that 
Sunovion Pharmaceuticals Inc.  Page 9 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 day. TV3 should be paired with TV4 (2 0 mg and 2 5 mg can be dosed on the same day),  
TV4 should be paired with TV5 (25 mg and 3 0 mg can be dosed on the same day), TV5 
should be paired with TV6 (3 0 mg and 3 5 mg can be dosed on the sa me day) and TV6 
should be paired with TV7 (3 5 mg and 4 0 mg can be dosed on the same day).  
Should the subject be unable to tolerate either  of the two additional dose levels after 
reaching a full ‚ÄúON‚Äù state, in the Investigator‚Äôs opinion, due to adverse events commonly 
associated with apomorphine (e.g., orthostatic hypotension, nausea, vomiting, etc.), 
subjects will be randomized to the previous dose . 
Dosing days in the Dose Titration Phase should be scheduled on consecutive business 
days and a maximum of 2 days between visits may be permitted with Medical Monitor approval. All visits in the Dose Titration Phase must be completed within 14 days .  
Safety and efficacy assessments will be performed at each visit  according to the protocol.  
Three -Way Balanced Rando mized Crossover Assessment Phase  (Period 1, Period 2, 
Period 3)  
Subjects  who successfully complete the Dose Titration Phase of the study , and are 
approved by the Sponsor to proceed to randomization, will  be asked to return to the clinic 
for Period 1 Dosing Visit  1 (P1V1) . This visit will occur between 2 and 7  days after the 
final visit in the Dose Titration Phase of the study. Depending on the Investigator's 
decision, subjects  will be asked to arrive at the clinic : 
‚Ä¢ after their usual morning dose of PD medic ations; but before taking their next 
dose of medication ; OR  
‚Ä¢ after withholding their normal morning dose of L -dopa (ie, in the practically 
defined "OFF" state with no anti -parkinsonian medication after midnight the 
night prior).  
Subjects will be randomized in equal numbers to six possible sequences of each of the 
three treatments being studied:  
1. Treatment A: APL -130277 at the dose determined in the Dose Titration 
Phase, 
2. Treatment B: Matched placebo  APL -130277, 
3. Treatment C: A single 40 0 mg dose of mox ifloxacin.  
Following confirmation by both the Investigator and subject that the subject is in the 
‚ÄúOFF‚Äù state, the subject will be dosed according to the subject's random treatment 
assignment. APL -130277 and placebo APL -130277 will be administered in a dou ble-
blind fashion and moxifloxacin will be administered open -label in a three- way balanced 
crossover. All subjects will be exposed to all three treatments. The six possible treatment sequences are: 1) ABC; 2) ACB; 3) BCA; 4) BAC; 5) CAB; and 6) CBA.  
Subjec ts will return to clinic 3 days after Period 1 and will be dosed for Period 2 with one 
of the other two treatments.  
Subjects will return to clinic 3 days after Period 2 and will be dosed for Period 3 with the 
third and last treatment.  
INVESTIGATIONAL DRUG  APL -130277 (1 0 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg [given as 2 sublingual thin 
films consisting of 20 mg followed by  15 mg], 40 mg [given as 2 sublingual thin films 
consisting of 2 0 mg followed by  20 mg], 50 mg [given as 2 sublingual thin films 
Sunovion Pharmaceuticals Inc.  Page 10 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 consisti ng of 2 5 mg followed by  25 mg] and 6 0 mg [given as 2 sublingual thin films 
consisting of 3 0 mg followed by  30 mg]). 
To administer the 35  mg dose, study staff will administer the 20  mg sublingual thin film 
under the tongue  first, and then after 3 minutes has elapsed, immediately administer the 
15 mg sublingual thin film for another 3 minutes (total dosing time should be 6 minutes) . 
To administer the 40  mg dose, study staff will administer the 20  mg sublingual thin film 
under the tongue  first, and then after 3 minutes has elapsed, subjects will be instructed to 
consume approximately 1 teaspoon of water immediately prior to dosing the second 
20 mg dose, and staff will ensure the sublingual space is free of excess water . The second 
20 mg sublingual thin film will be administered under the tongue  for another 3  minutes 
(total dosing time should be 6 minutes) . To adm inister the 50  mg dose, st udy staff will 
administer the 25  mg sublingual thin film under the tongue  first, and then after 3  minutes 
has elapsed, subject s will be instructed to consume approximately 1 teaspoon of water 
immediately prior to dosing the second 25 mg dose, and staff will ensure the sublingual 
space is free of excess water . The second 25  mg sublingual thin film will be administered 
under the tongue  for another 3 minutes (total dosing time should be 6 minutes) . To 
administer the 60  mg dose, s tudy staff will administer the 30  mg sublingual thin film 
under the tongue  first, and then after 3 minutes has elapsed, subjects will be instructed to 
consum e approximately 1 teaspoon of water immediately prior to dosing the second 30 
mg dose, and staff will ensure the sublingual space is free of excess water . The second 
30 mg sublingual thin film will be administered under the tongue  for another 3  minutes 
(total dosing time should be 6 minutes) . 
REFERENCE 
PRODUCT  Matching Placebo  APL -130277 
Moxifloxacin 40 0 mg 
TREATMENT REGIMENS  Dose Titration starting at 10 mg APL -130277 will be administered in 5 mg increments up 
to 40 mg and then in 1 0 mg increments for th e 50 mg and 60 mg dose levels  until the 
subject reaches  a full ‚ÄúON‚Äù state and will continue titration for two additional visits to a 
maximum dose of 60 mg. This will be followed by  a three -way balanced randomized 
crossover  phase using the highest APL -130277 tolerated dose  or matched placebo  
APL -130277, in a double -blind fashion , or treatment with  open -label moxifloxacin. 
CONCOMITANT AND CO - 
ANALGESIC TREATMENT  All subjects : stable doses of a L -Dopa formulation and other stable adjunctive PD 
medications.  
PROHIBITED 
TREATMENT  ‚Ä¢ Any form of s.c. apomorphine from 7 days prior to the initial Screening Visit 
(SV1) until study completion.  
‚Ä¢ Any selective 5HT 3 antagonist (i.e., ondansetron, granisetron, dolasetron, 
palonosetron, alosetron) from 30  days prior to the in itial Screening Visit (SV1) 
until study completion . 
‚Ä¢ Dopamine antagonists (including Tigan [t rimethobenzamide] and domperidone, 
but excluding quetiapine or clozapine) or dopamine depleting drugs.  
‚Ä¢ Deep brain stimulation or other neurosurgical PD treatment, c ontinuous s.c.  
apomorphine infusion , or Duodopa/Duopa.  
Sunovion Pharmaceuticals Inc.  Page 11 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 ‚Ä¢ Any medication that can prolong  QT. Refer to https://crediblemeds.org for listing.  
STUDY DURATION  Participation is anticipated to be a maximum of 46  days. 
INVESTIGATIVE 
SITES  OR 
COUNTRIES  This is a m ulticenter study to be conducted at up to 10 sites in Europe and up to 20 sites 
in North America.  
STUDY ENDPOINTS  Primary Endpoint  
1. Time -matched change from baseline in QTc, placebo -adjusted and corrected for 
HR based on the Fridericia correction method (QTcF) method (‚àÜ‚àÜQTcF) . Assay 
sensitivity will be demonstrated by inclusion of a positive control, moxifloxacin.  
Secondary Endpoints  
1. Pharmacokinetics of apomorphine and apomorphine metabolites . 
2. Evaluation of safety and tolerability of APL -130277 as measured by adverse 
events , physical examination including assessment of oropharyngeal  adverse 
events , 12-lead ECGs, vital signs including o rthostatic hypotension (OH), 
clinical laboratory tests, and C -SSRS  assessments . 
3. ECG  assessments including QTc with Bazett correction (QTcB), heart rate, PR 
interval, QRS interval, uncorrected QT interval, ECG morphology and presence 
of cardiac arrhythmias such as ventricular tachycardia or Torsade de 
Pointes  (TdP) . 
4. MDS -UPDRS Part III change from pre -dose to 30, 60, 90 minutes af ter dosing 
during the titration phase  at the highest tolerated APL -130277 dose level and the 
lowest APL -130277 dose resulting in a full ‚ÄúON‚Äù . 
5. Time to ‚ÄúON‚Äù during Titration Phase  at the highest tolerated APL -130277 dose 
level and the lowest APL -130277 dose resulting in a full ‚ÄúON‚Äù. 
6. Duration of ‚ÄúON‚Äù during Titration Phase at the highest tolerated APL --130277 
dose level and the lowest APL -130277 dose resulting in a full ‚ÄúON‚Äù.  
 
STATISTICAL METHODS SUMMARY  All subject s who receive at least one dose of study med icine `will be included in the 
safety analysis set. The PK analysis set includes all subject s with at least one PK 
evaluation. The efficacy analysis set includes subject s who have efficacy assessments at 
the lowest dose level resulting in a full ‚ÄúON‚Äù. The super-efficacy analysis set includes 
subject s who have efficacy assessments at both the lowest dose that provides a full ‚ÄúON‚Äù , 
the highest tolerated dose level during the Titration Phase.  
The evaluation of the ECG data is focused on the corrected QT interv al (QTc). Both the 
formula by Bazett and by Fridericia will be used for the correction , though the Fridericia 
correction will be considered primary, and the Bazett correction data is presented for historical purposes . Both central tendency (mean changes fr om pre -dose) and outliers will 
be evaluated.  
Assay sensitivity will be demonstrated by evaluating the placebo corrected change from baseline for QTcF for the positive control, moxifloxacin, at predesignated timepoints.  
The pharmacokinetic parameters will be summarized with descriptive statistics for each dose level. 
Sunovion Pharmaceuticals Inc.  Page 12 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 The safety data other than ECG ( vital signs including orthostatic blood pressure, physical 
examinations including oral assessments, premature discontinuations, adverse events, 
C-SSRS, and safety  laboratory variables) will be summarized with descriptive statistics 
for APL -130277 overall and separately for each dose level.  
The main efficacy endpoint of this study is the change in MDS -UPDRS Part III at 
30 minutes. The MDS -UPDRS Part III will be anal yzed using a Mixed Model for 
Repeated Measures with data from the lowest dose level resulting in a full "ON" and at the highest tolerated dose level during the Titration Phase as response variables. The 
baseline (SV2) value will be included as a covariate and the day (1 = assessment at the lowest dose level resulting in a full ‚ÄúON‚Äù, 2 = assessment at the highest tolerated dose 
level) and dose level (1 0 mg, 15 mg, 20 mg, ‚Ä¶, 60 mg) as fixed factors in the model. 
Separate models will be used for each time poin t (30, 60 and 90 minutes).  
 
SAMPLE SIZE CALCULATION  Forty -two (42) subjects will provide approximately 8 0% power to detect a mean 
difference of 7 ms in the change in QTc between APL -130277 and placebo, assuming 
that the true difference between APL -130277 and placebo can be up to 3  ms, (adding up 
to the predefined threshold of 10 ms) and a standard deviation of 14 ms  12 for ŒîŒîQTcF 
with one -sided significance level of 0.05.  
 
Sunovion Pharmaceuticals Inc.  Page 13 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 4 STUDY DESIGN FLOW CHART  
4.1 Schedule of Events Table  
Procedures  
Screening Visits2 
Titration Visit 11 
Titration Visit 21 
Titration Visit 31, 15 
Titration Visit 41, 15 
Titration Visit 51, 15 
Titration Visit 61, 15 
Titration Visit 71 
Titration Visit 81 
Titration Visit 91 
Randomization Procedures16 
Period 1 Dosing Visit  
Period 2 Dosing Visit  
Period 3 Dosing visit  
End of Study  
Visit  
Study Visit  SV1 SV2 TV1  TV2  TV3  TV4  TV5  TV6  TV7  TV8  TV9 P1V1  P2V2  P3V3  EOS  
Day  -14 to -3 1 2 3 4 5 6 7 8 9 1 3 days 
after 
P1V1  3 days 
after 
P2V2  3-5 days 
after 
P3V3  
Maximum  Study Duration 
(days)  1 to 14  15 to 28   35 38 41 44 to 46  
Outpatient Visit3 X X X3 X3 X3 X3 X3 X3 X X X  X X X X 
Written Informed Consent  X                
Reconfirmation of Consent   X X X X X X X X X X  X X X X 
Review Entry Criteria  X X               
Review Restriction Criteria    X X X X X X X X X  X X X  
Medical History/Demographics   X2               
Complete Physical Exam, 
including Oropharyngeal 
Exam4  X2           
   X 
Abbreviated Physical Exam, 
including Oropharyngeal 
Exam5   X X X X X X X X X  
X X X  
BMI, Weight and Height6  X2           X X X X 
Vital Signs (BP, HR, RR and 
Temp)7, 8  X2 X X X X X X X X X  X X X X 
12-Lead ECG  (Holter)8, 9             X X X  
12-Lead ECG (Resting)8, 10  X2 X X X X X X X X X  X X X X 
Sunovion Pharmaceuticals Inc.  Page 14 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 Procedures  
Screening Visits2 
Titration Visit 11 
Titration Visit 21 
Titration Visit 31, 15 
Titration Visit 41, 15 
Titration Visit 51, 15 
Titration Visit 61, 15 
Titration Visit 71 
Titration Visit 81 
Titration Visit 91 
Randomization Procedures16 
Period 1 Dosing Visit  
Period 2 Dosing Visit  
Period 3 Dosing visit  
End of Study  
Visit  
Study Visit  SV1 SV2 TV1  TV2  TV3  TV4  TV5  TV6  TV7  TV8  TV9 P1V1  P2V2  P3V3  EOS  
Day  -14 to -3 1 2 3 4 5 6 7 8 9 1 3 days 
after 
P1V1  3 days 
after 
P2V2  3-5 days 
after 
P3V3  
Maximum  Study Duration 
(days)  1 to 14  15 to 28   35 38 41 44 to 46  
Clinical Laboratory Tests11  X              X 
PK8, 12             X X X  
MMSE   X               
Modified Hoehn and Yahr   X               
MDS -UPDRS Part III8, 13  X X X X X X X X X X      
Confirmation of L -Dopa 
Responsiveness   X               
Clinical Confirmation of ‚ÄúOFF‚Äù 
or full ‚ÄúON‚Äù   X X X X X X X X X X  X X X  
Subject  Confirmation of ‚ÄúOFF‚Äù 
or full ‚ÄúON‚Äù   X X X X X X X X X X  X X X  
Subject ‚ÄúOFF‚Äù versus ‚ÄúON‚Äù 
Training   X               
In-Clinic Dosing    X X X X X X X X X  X X X  
AEs/Serious AEs (SAEs)  X X X X X X X X X X X  X X X X 
Previous/Current Concomitant 
Medications   X X X X X X X X X X  X X X X 
C-SSRS14  X X X X X X X X X X  X X X X 
1 Dosing days in the Dose Titration Phase should be scheduled the following business day of the previous visit and all visits must be completed within 14 days. 
A maximum of 2 days between visits may be permitted with Medical Monitor approval.  
2 All screening procedures to be conducted wi thin 14 days prior to Titration Visit 1 (TV1). If required by the Investigator, and following receipt of subject 
Sunovion Pharmaceuticals Inc.  Page 15 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 consent, the Investigator may review the subjects ‚Äô medical history, BMI, height, weight, vital signs, 12 -Lead ECG (in triplicate) and perform a complete 
physical examination at SV1 to determine if the subject may be eligible for study participation. Procedures performed on SV1 will not be repeated at SV2.  
3 Subjects  may be monitored in the clinic overnight before Dose Titration Visits if such facilities exist and the subject  consents.  
4 Physical examination to include the following: head -eyes-ears-nose and throat; respiratory system; cardiovascular system; gastrointestinal system, including 
mouth ‚Äì oral cavity; musculoskeletal system; central and peripheral nervous system; and skin. The oropharyngeal cavity examination should include a visual 
inspection of the inside of each cheek, the inside of the upper and lower lip, the surface of the tongue, and under the tongu e. 
5 Abbreviated physical exam to  include head -eyes-ears-nose and throat; heart; lungs; abdomen; and skin; to be done at t = 0 (just prior to dosing) and 120 minutes 
after dosing at TV1 to TV 9, Period  1, Period 2, and Period 3. The oropharyngeal cavity examination should include a visual inspection of the inside of each 
cheek, the inside of the upper and lower lip, the surface of the tongue, and under the tongue.  
6 Both height and weight captured at the Screening Visit (SV2) to calculate BMI; only weight captured at all other indicated visits. 
7 Vital signs will be assessed at the Screening Visit (SV2)  and End of Study ( EOS ); TV1 to TV 9 and during Period 1, 2 and 3 at t  = 0 minutes (just prior to 
dosing) , 15, 45 and 60 minutes. Blood pressure to be measured supine and standing (measured wit hin 3 minutes of standing) at all timepoints.  
8 Suggested Sequence of Assessments at Pre- Dose: ECG ‚Äì PK ‚Äì Vitals  ‚Äì Efficacy . Sequence of Assessments after dosing (where applicable) : MDS -UPDRS Part 
III - Subject ‚ÄúOFF‚Äù/‚ÄùON‚Äù status  ‚Äì ECG  ‚Äì PK ‚Äì Vitals.  
9 12-lead ECG (Triplicate; Holter) : Period 1 : Obtain three ( 3) sets of triplicate ECGs  over approximately 1 -hour (prior to dosing) as the baseline assessment ; and 
obtain triplicate ECG at t = 15, 30, 45, 60 minutes and 2, 3, 4, 8, 12, 24 hours after dosing. Period 2 and Period 3 : Obtain triplicate ECG at t = 0 (just prior to 
dosing), 15, 30, 45, 60 minutes and 2, 3, 4, 8, 12, 24 hours after dosing .  
10 12-lead ECG ( Single; Resting): Obtain at the Screening Visit in triplicate  (SV2). TV1 to TV 9: ECG at t = 0 (just prior to  dosing) and 45 minutes after  dosing. 
Period 1, Period 2 and Period 3 at 60 m inutes after  dosing . EOS:  A triplicate ECG will be obtained . ECGs will be assessed by the Investigator at each visit.  
11 Blood and urine collection for clinical laboratory tests will occur at Screening Visit (SV2) and at the End of Study Visit (EOS) . In addition, serum pregnancy 
test will be performed on all females of childbearing potential.  
12 PK will be assessed for APL -130277 and placebo dosing days  at t = 0 (just pri or to dosing) , 30, 45, 60 minutes  and 2, 4 hours  after dosing . PK will be assessed 
on the moxifloxacin dosing day at t = 0 (just prior to dosing),  30, 60 minu tes and 2, 3, 4, 6, 8 hours after  dosing.  
13 MDS -UPDRS Part III (Motor Function) to be assessed at  t = 0 (just prior to dosing), 30, 60 and 90 minutes after L -Dopa administration  at the second 
Screening Visit (SV2) ; the modified Hoehn and Yahr will be used during the Screening Visit (SV2) . Assessments during the Titration  Phase at t = 0 (just prior 
to dosing), 30, 60 and 90 minutes after dosing ; these assessments will e xclude the ‚ÄúDyskinesia Impact on Part III Ratings‚Äù and the Hoehn and Yahr staging. 
14 ‚ÄúScreening‚Äù scale to be used at the Screening Visit (SV2); ‚ÄúSince Last Visit‚Äù to be used at all other  visits . 
15 Optional Dosing Regimen:  For TV3, TV4, TV5 and TV6 only subjects can be dosed with the next highest dose of study medication within 4 hours of the 
previous  dose, as long as the subject achieves another ‚ÄúOFF‚Äù state that day.  
16 Following completion of the Dose Titration Phase of the study , Sponsor approval is required prior to r andomization in the Three -Way  Balanced Crossover 
Phase . Additional details are available in the Enrollment a nd Randomization Adjudication Process , which is contained in a  separate document.  
6XQRYLRQ3KDUPDFHXWLFDOV,QF 3DJH
&7+
$XJ &21),'(17,$/  9HUVLRQ6WXG\'HVLJQ
APL-130277APL-130277
APL-130277
3-5 days
Screening
Three-Way Balanced Randomized 
Crossover Assessment Phase 
Randomized to Highest APL-130277 
Dose Tolerated 
Open-Label Titration Phase 
APL-130277 Dose Titration 
Moxifloxacin  Placebo Strip APL-130277
1 day
 1 day
 1 day
3 days
15 mg
20 mg
25 mg
30 mg
35 mg
40 mg
Forced Titration Until ‚ÄúON‚Äù is 
Achieved and then Two 
Additional Doses if Tolerated 
—áœ≠œ∞ƒöƒÇ«á∆ê
Placebo Strip  APL-130277
Period 1
 Period 3
 Period 2
10 mg
2 - 7 days
3 days
10 mg
60 m
50 mg
60 mg
ifloxacin
 Moxi
 acebo Stri p
 Pl
 APL
-
1302 77
APL
-
1302 77
APL
-
130277
APL
-
1302 77
APL-130277
 APL
lacebo Stri p
 P
 -
1302 77
 APL
End of Study Visit 
< 14 days
 —áœ≠œ∞ƒöƒÇ«á∆ê
10
mg
2
2
7
7
7
 4d a y s
4days
Sunovion Pharmaceuticals Inc.  Page 17 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 4.3 Titration Phase Dosing Paradigm 
  
‚ÄúOFF‚Äù  
20 mg 
‚ÄúOFF ‚Äù 
Dose Titration Phase  
TV2  
15 or 20 or 
25 mg 
50 or 60 mg 
Full ‚ÄúON‚Äù  
TV4  
‚ÄúOFF‚Äù  
25 or 30 or 
35 mg 
Full ‚ÄúON‚Äù  
30 mg 
 35 mg 
20 mg 
 25 mg 
Full ‚ÄúON‚Äù  
60 mg 
 60 mg 
 TV9  
TV7  
TV6  
‚ÄúOFF ‚Äù 
35 or 40  or 
50 mg 
Full ‚ÄúON‚Äù  
40 mg 
 50 mg 
 35 mg 
TV3  
‚ÄúOFF‚Äù  
20 or 25 or 
30 mg 
Full ‚ÄúON‚Äù  
30 mg 
 25 mg 
Continue 2 Additional Titratio n 
Visits after Full ‚ÄúON‚Äù State Has 
Been Achieved  (if tolerated)  
TV1  
 
10 or 15 or 
20 mg 
Full ‚ÄúON‚Äù  
Randomized to 
Highest dose of APL -
130277 Tolerated  
 
20 mg 
 10 mg 
 15 mg 
15 mg 
TV5  
‚ÄúOFF‚Äù  
30 or 35 or 
40 mg 
Full ‚ÄúON‚Äù  
30 mg 
 40 mg 
25 mg 
40 or 50 or 
60 mg 
Full ‚ÄúON‚Äù  
50 mg 
 60 mg 
 40 mg 
‚ÄúOFF‚Äù  
TV8  
Full ‚ÄúON‚Äù  
60 mg 
50 mg 
35 mg 
‚ÄúOFF ‚Äù 
Sunovion Pharmaceuticals Inc.  Page 18 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 4.4 Titration Phase Optional Dosing Regimen 
 

Sunovion Pharmaceuticals Inc.  Page 19 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 5 TABLE OF CONTENTS  
1 EMERGENCY CONTACT  INFORMATION  ....................................................3  
2 INVESTIGATOR APPROVAL  STATEMENT ..................................................4  
3 PROTOCOL  SYNOPSIS  ......................................................................................5  
4 STUDY DESIGN FLOW CHART  .....................................................................13  
4.1 Schedule of Events Table .....................................................................................13  
4.2 Study Design  .........................................................................................................16  
4.3 Titration Phase Dosing Paradigm ......................................................................17  
4.4 Titration Phase Optional Dosing Regimen ........................................................18  
5 TABLE OF CONTENTS  .....................................................................................19  
6 LIST  OF ABBREVIATIONS  ..............................................................................23  
7 INTRODUCTION................................................................................................25  
7.1 Background ..........................................................................................................25  
7.2 Drug Substance  ....................................................................................................26  
7.3 Drug  Product  (APL -130277 Sublingual Film)  ...................................................27  
7.4 Clinical Experience ..............................................................................................29  
7.5 Summary of Potential Risks and Benefits  .........................................................30  
7.6 Rationale ...............................................................................................................31  
8 ETHICS  ................................................................................................................32  
9 OBJECTIVES AND STUDY ENDPOINTS  ......................................................33  
9.1 Objectives ..............................................................................................................33  
9.2 Study Endpoints  ...................................................................................................33  
9.2.1  Primary Endpoint ...................................................................................................33  
9.2.2  Secondary Endpoints .............................................................................................33  
10.1  General Overview  ................................................................................................34  
10.1.1  Screening Visits  .....................................................................................................34  
10.1.2  Dose Titrat ion Phase ..............................................................................................34  
10.1.3  Three- Way Balanced Randomized Crossover Assessment Phase: Period 1, 
Period  2, Period 3 ......................................................................................................................36  
10.1.4  Enrollment Adjudication Committee (EAC)  .........................................................36  
11 PATIENT POPULATION  ..................................................................................38  
11.1  Selection  of Study  Population ..............................................................................38  
11.1.1  Inclusion Criteria  ...................................................................................................38  
11.1.2  Exclusion Criteria  ...................................................................................................39  
11.2  Prior  and Concomitant Treatments ....................................................................41  
11.2.1  Prohibited Treatments  ............................................................................................41  
11.2.2  Permitted Treatments  .............................................................................................41  
11.3  Subj ect Withdrawal from  the Study  ...................................................................42  
Sunovion Pharmaceuticals Inc.  Page 20 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 12 STUDY PROCEDURES  ......................................................................................43  
12.1  Screening Visits (SV1 and SV2)  ..........................................................................43  
12.2  Dose Titration Phase (TV1 to TV9) ....................................................................45  
12.3  Three- Way Balanced Randomized Crossover Assessment Phase:  Period 1, 
Period 2, Period 3 .................................................................................................48  
12.3.1  Double-Blind APL-130277 and Placebo Treatment Periods .................................48  
12.3.2  Open -Label Moxifloxacin Treatment Period  .........................................................50  
12.4  End of Study Visit  ................................................................................................51  
12.5  Duration of Treatment  .........................................................................................51  
12.6  Assessments  ..........................................................................................................52  
12.6.1  Order of Assessments  ............................................................................................52  
12.6.2  Clinical Safety Assessments  ..................................................................................52  
12.6.2.1  Physical Examinations ...........................................................................................52  
12.6.2.2  Vital Signs ..............................................................................................................53  
12.6.2.3  12-Lead ECG .........................................................................................................53  
12.6.2.4  Modified Hoehn and Yahr ......................................................................................54  
12.6.2.5  Mini -Mental State Examination .............................................................................54  
12.6.2.6  Clinical Laboratory Tests  .......................................................................................55  
12.6.2.7  Specimen  Handling Requirements  ..........................................................................55  
12.6.2.8  C-SSRS ...................................................................................................................55  
12.6.2.9  Medical History  .....................................................................................................56  
12.6.3  Efficacy Assessments .............................................................................................56  
12.6.3.1  Confirmation of ‚ÄúOFF‚Äù or ‚ÄúON‚Äù Episodes ..........................................................56  
12.6.3.2  MDS -UPDRS Part III  ............................................................................................58  
12.6.3.3  Pharmacokinetic (PK) Evaluation .........................................................................58  
13 ADVERSE  EVENTS  ............................................................................................59  
13.1.1  Definition  of Adverse Events .................................................................................59  
13.1.2  Definition  of Serious Adverse Events ....................................................................59  
13.1.3  Definition  of Severity  .............................................................................................60  
13.1.4  Definition  of Start  Date,  Stop Date,  and Duration .................................................60  
13.1.5  Action(s) Taken  .....................................................................................................60  
13.1.6  Definition  of Expectedness  ....................................................................................61  
13.1.7  Adverse Events of Special Interest  ........................................................................61  
13.1.8  Definition  of Relationship  to Investigational Drug(s)  ............................................62  
13.1.9  Definition  of Outcome at the Time  of Last Observation ........................................62  
13.1.10  Documentation of Adverse  Events .........................................................................63  
13.1.11  Follow-up of Subjects  With  an Adverse Event.......................................................63  
13.1.12  Special  Procedures  for Manag ing AEs/ SAEs  and Need  for Unblinding ...............63  
13.1.13  Notification  of Serious Adverse Events  .................................................................63  
Sunovion Pharmaceuticals Inc.  Page 21 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 13.1.14  Notification  of Adverse Events of Special Interest  ................................................65  
14 TREATMENTS ....................................................................................................66  
14.1  Treatments  Administered  ....................................................................................66  
14.2  Administration of Study Medication ..................................................................66  
14.3  Storage ..................................................................................................................67  
14.4  Packaging and Labeling  ......................................................................................68  
14.5  Drug  Accountability  .............................................................................................68  
14.6  Method  of Assigning  Subjects  to Treatment  Groups  ........................................69  
14.7  ECG Methodology: Central Laboratory ...........................................................69  
14.8  Randomization .....................................................................................................71  
14.9  Blinding  .................................................................................................................71  
15 STATISTICAL ANALYSES  ..............................................................................73  
15.1  Statistical Analysis Plan  ......................................................................................73  
15.2  Analysis Populations ............................................................................................73  
15.2.1  Safety Analysis Set  ................................................................................................73  
15.2.2  PK Analysis Set  .....................................................................................................73  
15.2.3  Efficacy Analysis Set  .............................................................................................73  
15.2.4  ECG and PK- PD Analysis Sets  .............................................................................73  
15.3  Sample Size Calculation  ......................................................................................73  
15.4  ECG and Conce ntration -QTc Effect Analysis  ..................................................74  
15.4.1  Primary Endpoint ...................................................................................................74  
15.4.2  Secondary Endpoints .............................................................................................74  
15.4.3  Central Tendency Analyses  ...................................................................................74  
15.4.4  Establishment of Assay Sensitivity  ........................................................................75  
15.4.5  Outlier Analyses .....................................................................................................75  
15.4.6  Morphologic Analyses ...........................................................................................76  
15.4.7  Pharmacokinetic- Pharmacodynamic Analyses  ......................................................77  
15.4.8  Safety Analysis  ......................................................................................................77  
15.5  Pharmacokinetic Analysis ...................................................................................78  
15.6  Efficacy Analysis ..................................................................................................79  
16 STUDY CONDUCT  .............................................................................................80  
16.1  Regulations and Guidelines  .................................................................................80  
16.2  Study  Initiation  .....................................................................................................80  
16.3  Study  Documentation ...........................................................................................81  
16.3.1  Investigator‚Äôs Regulatory Documents ....................................................................81  
16.3.2  Case Report Forms  .................................................................................................81  
16.3.3  Source Documents  .................................................................................................82  
16.4  Data  Quality  Assurance .......................................................................................83  
16.4.1  Monitoring the Study .............................................................................................83  
Sunovion Pharmaceuticals Inc.  Page 22 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 16.4.2  Routine Data Collection  .........................................................................................83  
16.4.3  Expedited  Data Collection  .....................................................................................84  
16.4.4  Data Management  ..................................................................................................84  
16.4.5  Study Termination  ..................................................................................................84  
16.4.6  Clinical Site Closure...............................................................................................84  
17 GENERAL  CONSIDERATIONS  .......................................................................86  
17.1  Changes to the Protocol .......................................................................................86  
17.2  Use of Information and Publication ....................................................................86  
17.3  Records  Retention  ................................................................................................86  
17.4  Sample  Retention  ..................................................................................................87  
17.5  Subject  Injury  .......................................................................................................87  
18 REFERENCES  .....................................................................................................88  
19 APPENDICES  ......................................................................................................89  
19.1  APPENDIX I: APOKYN¬Æ Prescribing  Information and APO -go¬Æ Summary 
of Product Characteristics  ..................................................................................89  
19.2  APPENDIX II: Regulations and Guidelines  ......................................................90  
19.2.1  Declaration  of Helsinki ..........................................................................................90  
19.2.2  Approval by an IRB/REB/IEC  ...............................................................................90  
19.2.3  Regulatory Authority/Agency  ................................................................................90  
19.3  APPENDIX III: Modified Hoehn and Yahr Scale  ............................................91  
19.4  APPENDIX IV: Movement Disorder Society - Unified Parkinson‚Äôs Diseas e 
Rating Scale (MDS -UPDRS)  ...............................................................................92  
19.5  APPENDIX V: Columbia Suicide Severity Rating Scale (C -SSRS)  .............125
19.6  APPENDIX VI: United Kingdom  Parkinson‚Äôs Disease Brain Bank Clinical 
Diagnostic Criteria  .............................................................................................132  
 
Sunovion Pharmaceuticals Inc.  Page 23 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 6 LIST  OF ABBREVIATIONS  
5HT3 5-hydroxy tryptophan (serotonin)  
AE adverse event  
AESI  adverse event of special interest  
ALT  alanine aminotransferase  
APO -go¬Æ  apomorphine hydrochloride injection  
APOKYN¬Æ apomorphine hydrochloride injection  
API active pharmaceutical ingredients  
AUC last area under the concentration -time curve from time zero to the last 
measurable plasma concentration -time curve using the linear u p log 
down trapezoidal rule. 
AUC inf area under the concentration -time curve from time zero extrapolated to 
infinity using the linear up log down trapezoidal rule. 
AST  aspartate aminotransferase  
b.i.d.  twice daily  
BLQ  Below the limit of quantification  
BMI  body mass index  
BP blood pressure  
CFR  Code of Federal Regulations  
Cmax maximum observed  plasma concentration  
COMT  Catechol O -methyltransferase  
CR chronic release  
CRA  Clinical Research Associate  
CRF  case report form  
CSA  clinical study agreement  
C-SSRS  Columbia Suicide Severity Rating Scale  
CV%  coefficient of variation  
EAC  enrollment adjudication committee  
ECG  electrocardiogram  
EDC  electronic data capture  
GCP  Good Clinical Practice  
GRAS  Generally Recognized as Safe  
HIV human immunodeficien cy virus  
HR heart rate  
IB Investigator‚Äôs Brochure  
ICF informed consent form  
ICH International Conference on Harmonisation  
IEC Independent Ethics Committee  
Sunovion Pharmaceuticals Inc.  Page 24 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 IND Investigational New Drug  
IRB Institutional Review Board  
ITT intent -to-treat 
IWRS  Interac tive Web Response System  
L-Dopa  L-3,4-dihydroxyphenylalanine  or Levodopa  
LC-MS/MS  liquid chromatograp hy-tandem mass spectrometry  
Œªz terminal -phase rate constant  
MAO -B monoamine oxidase B  
MCH  mean corpuscular hemoglobin  
MCHC  MCH concentration  
MDS -UPDRS  Movement Disorder Society Unified Parkinson‚Äôs Disease Rating Scale  
MedDRA  Medical Dictiona ry for Regulatory Activities  
mITT  modified intent -to-treat 
MMRM  mixed model for repeated measurements  
MRT  mean residence time  
MMSE  Mini -Mental State Examinat ion 
NYHA  New York Heart Association  
OH Orthostatic Hypotension  
PD Parkinson‚Äôs disease  
PK pharmacokinetic  
PKAP  pharmacokinetic analysis plan  
PMAP  pharmacokinetic modeling analysis plan  
QTc Corrected QT interval  
RBC  red blood cell  
REB  Research Ethic s Board  
RR respiratory rate  
SAE  serious adverse event  
s.c. subcutaneous  
SD standard deviation  
SOP Standard Operating Procedure  
Sunovion  Sunovion Pharmaceuticals Inc.  
t¬Ω Terminal -phase half -life 
TdP Torsades de Pointes  
TEAE  treatment emergent adver se events  
Temp  temperature  
t.i.d. three times daily  
Tmax observed time of the maximum concentration  
WBC  white blood cell  
WHO -DD World Health Organization Drug Dictionary  
Sunovion Pharmaceuticals Inc.  Page 25 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 7 INTRODUCTION 
7.1 Background 
Parkinson‚Äôs disease is the second most common neurodegenerative disease after Alzheimer‚Äôs 
disease. PD has a prevalence of approximately 0.5% to 1% among persons 65 to 69 years of age, 
rising to 1% to 3% among persons 80 years of age and older.1 The disease is characterized by 
progressive degeneration of the dopaminergic nigrostriatal system and depletion of dopamine, which results in the core motor symptoms of bradykinesia, rigidity, tremor, and postural instability.
2 During the early stages of the disease, motor symptoms are well controlled with 
L-Dopa plus a dopamine decarboxylase inhibitors, dopamine agonists or MAO -B inh ibitors. 
However, as the disease progresses, PD subjects  develop motor complications which consist of 
dyskinesia and motor fluctuations. Motor fluctuations represent periods of ‚ÄúOFF‚Äù time and include wearing- ‚ÄúOFF‚Äù, delayed ‚ÄúON‚Äù (if with first morning dose termed morning akinesia), 
unexpected ‚ÄúOFF‚Äù or ‚ÄúON‚Äù/ ‚ÄúOFF‚Äù fluctuations. These motor fluctuations can be either 
predictable or unpredictable. The mechanisms by which response fluctuations occur are only 
partially understood but are thought to include presynaptic neuronal degeneration leading to a lack of buffering of released L -Dopa, postsynaptic changes in dopamine receptor sensitivity and 
number, and pharmacokinetic and pharmacodynamic influences of exogenously administered dopaminergic agents.
3,4 Fluctuations in plasma levels of L -Dopa occur due to the short half -life 
of L-Dopa and the unpredictable variability of gastric emptying. In general, approximately 40% 
of subjects  with PD experience mo tor fluctuations and/or dyskinesias after 4 to 6 years of 
L-Dopa therapy, with close to 90% of subjects  experiencing these symptoms after 9 or more 
years of treatment .5  
Predictable motor fluctuations (i.e. wearing -‚ÄúOFF‚Äù) can be treated by increasing the dose or 
frequency of L -Dopa or by adding adjunctive PD medications ( Catechol O -methyltransferase 
[COMT] inhibitors, MAO -B inhibitors, dopamine agonists). However, over time this becomes 
less effective. Treatment of unpredictable motor fluctuations (i.e. del ayed ‚ÄúON‚Äù, sudden ‚ÄúOFF‚Äù, 
‚ÄúON‚Äù/‚ÄùOFF‚Äù fluctuations ) is limited. Some subjects  take oral L -Dopa immediate release as 
needed but this is of limited value as higher doses of L -Dopa can result in dyskinesia and 
perpetuates the development o f further motor compli cations. The only approved treatment for 
acute management of ‚ÄúOFF‚Äù episodes in North America, Europe and Asia is apomorphine 
delivered  subcutaneous ly (s.c.). Although efficacious, s.c. apomorphine has limited use due to its 
parenteral administration and since it may be difficult for a PD patient to deliver. There remains a huge unmet medical need for easy to administer, rapid, safe, effective and reliable rescue medications for the treatment of these ‚ÄúOFF‚Äù episodes in PD subjects . APL -130277, sublingually 
administered apomorphine, provides a more patient -friendly, easy to administer medication for 
the management of both predictable and unpredictable ‚ÄúOFF‚Äù episodes.  
Sunovion Pharmaceuticals Inc.  Page 26 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 Apomorphine is a non- ergot dopamine agonist that binds to D1- like and D2- like receptors. Firs t 
used as a treatment for PD as early as 1951, its clinical use was first reported in 1970 although its 
emetic properties and short half -life made oral use impractical. A later study found that 
combining the drug with 10 mg  domperidone improved results sig nificantly .6-10 
APOKYN¬Æ and APO -go¬Æ (apomorphine hydrochloride injection, see APPENDIX I: APOKYN¬Æ 
Prescribing  Information and APO -go¬Æ Summary of Product Characteristics ) are prescription 
medicine s that reverses ‚ÄúOFF‚Äù episodes (end-of- dose wearing -‚ÄúOFF‚Äù and unpredictable ‚ÄúON‚Äù-
‚ÄúOFF‚Äù episodes) associated with advancing PD. APOKYN¬Æ, which are indicated for the acute, 
intermittent treatment of hypomobility, ‚ÄúOFF‚Äù episodes associated with advanced PD, has been 
studied as an adjunct to other PD medications. Therapeutic use in PD is effective because of the 
drug's strong dopaminergic action. When administered subcutaneously, apomorphine is the most effective dopamine agonist. Within 3 -20 minutes of injection, apomorphine demonstrates a 
magn itude of effect (ability to convert the patient with PD to the ‚ÄúON‚Äù state) that is comparable 
to L-Dopa. The effects of a single s.c. injection last for 60 minutes. Apomorphine can be used in 
combination with L -Dopa. L -Dopa dosing may need to be readjusted (decreased) to reduce dopa -
induced dyskinesias periods .
6-10 
Subcutaneous injection of apomorphine was developed to avoid first -pass metabolism as 
apomorphine is almost completely metabolized when delivered orally (between 1- 2% of the total 
dose enters the  bloodstream following oral administration ). The total daily dose can range up to 
20-25 mg /daily. Domperidone, a peripheral dopamine antagonist , may be administered to avoid 
emesis, bradycardia and hypotension caused by apomorphine 's peripheral dopaminergi c action. 
Subjects  on chronic apomorphine treatment may be able to discontinue domperidone 
co-administration after about 2  months without recurrence of the dopaminergic adverse effects of 
apomorphine. Domperidone is not available in the US, where trimethobenzamide is used.  
There is a small dose related prolongation of QTc interval with single doses of APOKYN¬Æ/APO-
go¬Æ greater than 6  mg ( see APPENDIX I: APOKYN¬Æ Prescribing  Information and APO -go¬Æ 
Summary of Product Characteristics ). This study will evaluate the QT interval prolongation 
potential of APL -130277. 
7.2 Drug Substance  
The active ingredient is apomorphine hydrochloride hemihydrate (C 17H17NO 2‚Ä¢HCl  ‚Ä¢¬ΩH 2O(salt)). 
Apomorphine is synthesized from morphine, but it is not a narcotic, nor is it a controlled substance. Apomorphine hydrochloride appears as white or greyish- white glistening crystals or 
white powder. The R- enantiomer is used clinically.  
The drug substance, apomorphine hydrochloride hemihydrate , is manufactured by Sanofi -
Avent is. Apomorphine hydrochloride is manufactured from morphine monohydrate in the 
presence of orthophosphoric acid, ethyl acetate and hydrochloric acid. Purification is performed 
Sunovion Pharmaceuticals Inc.  Page 27 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 in the presence of water, sodium chloride, sodium sulfite, ethyl acetate and sil ica gel.  
A summary of physico -chemical data are provided below:  
Active Pharmaceutical  
Ingredients ( API) Common 
Name Apomorphine Hydrochloride Hemihydrate  
Production Site  Manufacture r of Active Pharmaceutical Ingredient 
for Clinical Batches:  
Sanofi Aventis (Aramon Site)  
SANOFI CHIMI E 
Route d‚ÄôAvignon 
30390 Aramon France  
IUPAC nomenclature  4H-Dibenzo [de, g] quinoline -10, 11 -diol, 5, 6, 6a, 
7-tetrahydro -6-methyl hydrochloride, hemihydrate 
Synonyms, common names  Apomorphine hydrochloride, SR94013A, 6a,bet a-
aporphine-10,11-diol hydrochloride 
CAS number  41372 -20-7 
Formula  C17H17NO 2‚Ä¢HCl‚Ä¢1/2H2O 
Molecular weight  312.79 g/mol  
Specific Rotation  -60.5o to -63.0o 
pKa pKa: 7.0, 8.9  
pH 4.3 
Water solubility  Sparingly soluble in water and alcohol; slightly 
soluble in chloroform  
7.3 Drug  Product  (APL -130277 Sublingual Film)  
The product under development, APL -130277, is a soluble thin film for sublingual 
administration. APL -130277 is designed to deliver apomorphine systemically through absorption 
from the oral cavity  mucosa , thus bypassing the extensive first pass metabolism associated with 
gastrointestinal absorption of the compound. The product is intended to be an alternative to the injectable form of apomorphine hydrochloride, which is marketed in North America as 
APOKYN
¬Æ and in most of Europe and Asia as APO- go¬Æ. 
APL -130277 is manufactured for clinical studies as a bilayer thin film with one layer containing 
the active ingredient, apomorphine hydrochloride, and the other layer containing a buffer , 
pyridoxine . Dosage units of 10, 15, 20, 25, and 30 mg  are achieved from a single formulation by 
cutting different sized rectangular thin films from sheets of bulk film  as shown in the table 
below. Identifying marks are printed in white ink on the buffer (pyridoxine) side of the 
Sunovion Pharmaceuticals Inc.  Page 28 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 sublingual thin film.  
APL -130277 Dose  
(mg)  Length 
(mm)  Width (mm)  Area 
(mm2) Identifying 
Mark  
10 22 8.8 193.6  C1 
15 22 13.2 290.4  C2 
20 22 17.6 387.2  C3 
25 22 22 484.0  C4 
30 22 26.4 580.8  C5 
 
To administer the 35 mg dose, study staff will administer the 20 mg sublingual thin film under 
the tongue  first, and then after 3 minutes has elapsed, immediately administer the 15  mg 
sublingual thin film for another 3 minutes ( total dosing time should be 6 minutes).  
To administer the 40 mg dose, study st aff will administer the 20  mg sublingual thin film under 
the tongue  first, and then after 3 minutes has elapsed, subjects will be instructed to consume 
approximately 1  teaspoon of water immediately prior to dosing the second 20 mg dose, and staff 
will ensu re the sublingual space is free of excess water . The second 20 mg sublingual thin film 
will be administered under the tongue for another 3 minutes (total dosing time should be 
6 minutes) . 
To adm inister the 50  mg dose, st udy staff will administer the 25  mg sublingual thin film under 
the tongue  first, and then after 3 minutes has elapsed, subjects will be instructed to consume 
approximately 1  teaspoon of water immediately prior to dosing the second 25 mg dose, and staff 
will ensure the sublingual space is fr ee of excess water . The second 25 mg sublingual thin film 
will be administered under the tongue for another 3  minutes (total dosing time should be 
6 minutes) . 
To administer the 60 mg  dose, s tudy staff will administer the 30  mg sublingual thin film under 
the tongue  first, and then after 3 minutes has elapsed, subjects will be instructed to consume 
approximately 1 teaspoon of water immediately prior to dosing the second 30 mg dose, and staff 
will ensure the sublingual space is free of excess water . The second  30 mg sublingual thin film 
will be administered under the tongue for another 3  minutes (total dosing time should be 
6 minutes) . 
The APL -130277 finished drug product will be manufactured at ARx, LLC facilities at: 
400 Seaks Run Road Glen Rock, PA 17327, US A. 
The formulations for each of the dosage strengths have exactly the same proportions of active 
pharmaceutical ingredient and inactive excipients.  
The formulation consists of pharmaceutically acceptable cellulosic film formers along with glycerin as a plasticizer; and flavor, sweetener and colo ur additives for patient 
Sunovion Pharmaceuticals Inc.  Page 29 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 acceptability.  Other excipients include sodium hydroxide to modify pH and sodium metabisulfite 
as an  antioxidant/preservative. The formulation also includes pyridoxine HCL as a buffer 
component. The excipients used in formulating APL -130277 sublingual thin films, are 
compendial (USP, NF or FCC) items and/or are Generally Recognized as Safe (GRAS) and/or 
have precedent for use in pharmaceutical products approved in the US. 
7.4 Clinical Experience 
This is the twelfth planned  in-man study for APL -130277. Previous studies CTH -101, CTH -102, 
CTH -103, CTH -104, CTH -106, CTH -107 and CTH -200 were performed in healthy volunteers in 
Malaysia, all at Info  Kinetics. The first study completed in a PD patient population, CTH -105, 
was conducted at 4 sites in North America.  CTH -203, CTH -300 and CTH -301, evaluating 
APL -130277 in a PD patient population, are being conducted and CTH -302 is  planned for later 
this year.  
The healthy volunteer studies are summarized in considerable detail in the Investigator ‚Äôs 
Brochure  (IB). Adverse events were those expected to be seen with apomorphine, with the most 
common AEs being somnolence , dizziness and nausea. No dose limiting side effects were 
encountered  and no subjects discontinued APL -130277 treatment due to an AE.  
The healthy volunteer studies confirmed the method of administration, allowed further 
refinement of the formulation and confirmed PK comparability of APL -130277 to s.c. 
apomorphine. The CTH -103 and CTH -104 PK study results demonstrated dose proportionality 
of the doses of APL -130277 tested (10  mg, 15 mg, 25 mg) and that the 25 mg dose is sustained 
over an extended period of time (162 minutes) above the minimal efficacious plasma concentration of apomorphine (approximat ely 3  ng/m L), believed to be a level demonstrating 
symptomatic relief of ‚ÄúOFF‚Äù symptoms. The T
max for the 25 mg dose of APL -130277 was 
approximately 40 minutes, which was similar for the 10  mg and 15 mg doses of 
APL -130277. The rapid uptake of apomorphine in the APL -130277 sublingual thin film is 
comparable to that described in the s.c. apomorphine label s (i.e. , between 10 and 60 minutes).  
The PD subjects dosed in CTH -105 (19 subjects) displayed similar side effects to that seen in 
healthy volunteers;  the most common AEs (seen in 2 or more subjects ) were dizziness, 
somnolence, nausea, yawning, headache and hyperhidrosis. Most of these AEs were mild to 
moderate in severity. There was no dose -response relationship seen with the most common AEs 
and no subjects  discontinued due to an AE . Local irritation of the oral mucosa was monitored in 
the study and none was noted. 
The CTH -105 study demonstrated that APL -130277 provided rapid, clinically meaningful 
improvement in MDS -UPDRS Part III scores for PD subjects  in the ‚ÄúOFF‚Äù state and converted 
most subjects from the ‚ÄúOFF‚Äù state to the ‚ÄúON‚Äù state . Much of the benefit was sustained through 
90 minutes. A range of doses were utilized but over half of the subjects responded to the two 
Sunovion Pharmaceuticals Inc.  Page 30 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 lowest doses (10 and 15 mg). 
The CT H-106 study results demonstrated that the orientation of the thin film does not have a 
meaningful impact on the bioavailability of apomorphine. 
In CTH -107 and CTH -200, similar AEs were seen as in the previous healthy volunteer studies, 
and study analysis is ongoing.  
7.5 Summary of Potential Risks and Benefits  
APL -130277 
Given that APL -130277 uses the same active pharmaceutical ingredient ( API) as APOKYN¬Æ and 
APO- go¬Æ, and the pharmacokinetic profile is comparable between the sublingual thin film and 
the s.c. injection, the risks associated with the drug will be the same as those seen in the 
APOKYN¬Æ and APO -go¬Æ Product Inserts (see  APPENDIX I: APOKYN¬Æ Prescribing  
Information and APO -go¬Æ Summary of Product Characteristics ), except for the significant 
injection site reactions. It is assumed that the bioavailability of APL -130277 will be consistent in 
CTH -201 with that found in previous experience with APL -130277 compared with APOKYN¬Æ 
and APO- go¬Æ. 
The buffer contained in the inactive layer of  APL -130277 is designed to mitigate potential 
irritation of the oral mucosa seen in other buccal formulations of apomorphine as well as assist in maintaining a stable pH and optimal absorption kinetics. A preclinical hamster study demonstrated no evidence of microscopic or macroscopic irritation. No local irritation was noted 
in the CTH -105 study . In other ongoing clinical studies of APL -130277, non- serious AE reports 
of irritation of the oral mucosa have been received. Local irritation will be closely monitored 
throughout study participation. The goal of this development program, however, is to formulate a medication that provides the PD patient with an easier delivery system. We hypothesize that an 
orally available formulation will be easier to use, allow quicker control over predicted ‚ÄúOFF‚Äù 
periods, be more readily accessible to the patient when unpredicted ‚ÄúOFF‚Äù episodes occur during activities of daily living, and potentially be used by the milder PD patient when ‚ÄúOFF‚Äù episodes begin during the advanceme nt of the disease.  
Moxifloxacin  
Moxifloxacin is an antibiotic belonging to the fluoroquinolones family and will be used as a reference product in this study. 
Changes in cardiac electrophysiology have been observed following exposure to moxifloxacin, 
in the form of QT prolongation and is therefore contraindicated in patients with: 
‚Ä¢ Congenital or documented acquired QT prolongation; 
‚Ä¢ Electrolyte disturbances, particularly in uncorrected hypokalaemia; 
Sunovion Pharmaceuticals Inc.  Page 31 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 ‚Ä¢ Clinically relevant bradycardia; 
‚Ä¢ Clinically relevant heart failure with reduced left -ventricular ejection fraction ; 
‚Ä¢ Previous history of symptomatic arrhythmias . 
The risk of cardiac abnormalities may increase with increased dose. There is a rare chance that 
patients may experience a severe, sudden allergic reaction  (an anaphylactic reaction/shock) with 
the following symptoms: tightness in the chest, feeling dizzy, feeling sick or faint, or experience dizziness on standing. Moxifloxacin may cause inflammation of the liver, diarrhea (during or after taking this type o f antibiotic), and may occasionally cause pain and inflammation of 
tendons. Quinolone antibiotics may make the patient's  skin become more sen sitive to sunlight or 
UV light.  
7.6 Rationale 
This multi- center, Phase 2 study is designed to evaluate the QT interval  prolongation potential of 
10 mg  to 60 mg  doses of APL -130277 compared to placebo and the positive control, 400 mg  
moxifloxacin in subjects  with PD who experience motor fluctuations (‚ÄúOFF‚Äù episodes).  
 
Sunovion Pharmaceuticals Inc.  Page 32 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 8 ETHICS  
This study will be conducted in compliance with  the principles established by the World Medical 
Assembly in the Declaration of Helsinki - Ethical Principles for Medical Research Involving 
Human Subjects  and all applicable amendments , the ICH Principles of Good Clinical Practice 
(GCP) (including archiving of essential study documents), and applicable regulatory 
requirements and guidelines. 
A properly constituted, valid Institutional Review Board (IRB) or Research Ethics Board (REB) 
or Independent Ethics Committee (IEC) must review and approve the protocol, each 
Investigator‚Äôs I nformed Consent Form (ICF) , and related subject information before the start of 
the study, and any subject recruitment material(s) before they are provided to subjects . During 
the Clinical Trial, any amendment or modification to the  protocol should be submitted to the 
IRB/REB/IEC. The IRB/REB/IEC should also be informed of any event likely to affect the 
safety of subjects or the continued conduct of the study, in particular any changes in safety. All 
updates to the IB will be sent to  the IRB/REB/IEC.  
It is the responsibility of each Investigator to ensure that written informed consent is obtained 
from the subject  before any study activity or procedure is undertaken. 
Sunovion Pharmaceuticals Inc.  Page 33 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 9 OBJECTIVES  AND STUDY ENDPOINTS  
9.1 Objectives  
The primary objective is to  evaluate the effect of APL -130277 compared to placebo on QT c 
intervals in subjects  with Parkinson‚Äôs disease (PD) complicated by motor fluctuations. 
The secondary objectives include the evaluation of safety and pharmacokinetics of APL -130277 
and the comparison of efficacy of the highest tolerated dose level and the lowest APL -130277 
dose resulting in a full ‚ÄúON‚Äù during the Dose Titration Phase. 
9.2 Study Endpoints  
9.2.1 Primary Endpoint  
1) Time -matched change from baseline in QTc, placebo -adjusted and corrected for HR based 
on the Fridericia correction method (QTcF) method (‚àÜ‚àÜQTcF) . Assay sensitivity will be 
demonstrated by inclusion of a positive control, moxifloxacin. 
9.2.2 Secondary Endpoints  
1) Pharmacokinetics of apomorphine and apomorphine metabolites; 
2) Evaluation of safety and tolerability of APL -130277 as measured by adverse events, 
physical examination including assessment of oropharyngeal adverse events, 12- lead 
ECGs, vital signs including orthostatic hypotension (OH), clinical laboratory tests, and 
C-SSRS assessments; 
3) ECG assessments including QTc with Bazett correction (QTcB), heart rate, PR interval, 
QRS interval, uncorrected QT interval, ECG morphology and presence of cardiac 
arrhythmias such as ventricular tachycardia or Torsade de Pointes  (TdP);  
4) MDS -UPDRS Part III change from pre -dose to 30, 60, 90 minutes after dosing during the 
Titration Phase at the highest tolerated APL -130277 dose level and the lowest 
APL -130277 dose resulting in a full ‚ÄúON‚Äù ; 
5) Time to ‚ÄúON‚Äù during T itration Phase  at the highest tolerated APL -130277 dose level and 
the lowest APL -130277 dose resulting in a full ‚Äú ON‚Äù; 
6) Duration of ‚ÄúON‚Äù during T itration Phase  at the highest tolerated APL -130277 dose level 
and the lowest APL -130277 dose resulting in a full ‚ÄúON‚Äù. 
Sunovion Pharmaceuticals Inc.  Page 34 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 10 STUDY DESIGN  
This is a multi- center, phase 2, randomized, double -blind, placebo controlled, 3-period 
crossover, positive control, QT -evaluation study of APL -130277 in subjects  with PD 
complicated by motor f luctuations (‚ÄúOFF‚Äù episodes). 
10.1 General Overview  
This study will commence with initial Screening Visits, followed by an open- label Dose 
Titration Phase in which individual responses to single doses of APL -130277 are evaluated in 
order to determine the dose for the Randomized Assessment P hase. APL -130277 and placebo 
will be  double-blinded and randomized in a balanced three -way crossover Williams design with 
open- label moxifloxacin treatment (Period  1, Period 2 and Period 3).11 
10.1.1  Screening Visits  
Before any study procedures are performed on any subject , informed consent must be obtained at 
an initial Sc reening Visit (SV1). Subjects  recruited to participate in the study, and who have 
provided full consent to participate, will be asked to attend a second Screening Visit (SV2), 
having taken their last dose of L -Dopa and any other adjunctive PD medication no later than 
midnight the evening prior to the visit. Their normal morning dose of L -Dopa ( without 
adjunctive PD medication)  will be administered in the clinic following confirmation of an ‚ÄúOFF‚Äù 
episode by the Investigator  and subject, to ensure that they e xperience an ‚ÄúON‚Äù response. 
Eligibility criteria will be assessed  by the Investigator and approved by the Enrollment 
Authorization Committee (EAC)  prior to  enrollment.  
Subjects  will be asked to return to the clinic the morning of Titration Visit 1 (TV1) to start the 
Dose Titration Phase of the study. 
If needed, the site will arrange subject transfers. Alternatively, subjects may be monitored in the 
clinic overnight to facilitate ‚ÄúOFF‚Äù evaluation the following morning if such facilities exist and the subject  consents. These occurrences will not be considered a SAE. 
10.1.2  Dose Titration Phase  
Depending on the Investigator's decision, subjects will be asked to arrive at the clinic : 
‚Ä¢ after their usual morning dose of PD medications; but before taking their next dose of  
medication ; OR  
‚Ä¢ after withholding their normal morning dose of L -dopa (ie, in the practically defined 
"OFF" state with no anti-parkinsonian medication after midnight the night prior). 
During the Dose Titration Phase of the study, subjects will start with a  dose of 10 mg  
APL -130277 and increase in 5 mg  increments up to 40 mg  and then in 10 mg  increments for the 
50 mg  and 60 mg  dose levels  until the subject reaches a full ‚ÄúON‚Äù state. Once a full ‚ÄúON‚Äù state 
Sunovion Pharmaceuticals Inc.  Page 35 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 is achieved, dosing will continue for 2 additional vi sits to a maximum dose of 6 0 mg  (i.e., if a 
subject  experiences the first full ‚ÄúON‚Äù at 1 0 mg , dosing will continue up until a dose of 20 mg ). 
For those subjects who do not achieve a full "ON" response, titration should continue until the 
maximum tolerated dose of APL-130277 is determined. 
Note:  For subjects who have previously participated in the CTH -300 or CTH -301 study, the 
subject will begin titration at the effective dose used in the respective previous study. Similarly dose titration of these subjects will increase in 5 mg  increments up to 40 mg and then in 10 mg 
increments for the 50  mg and 60 mg dose levels until the subject reaches a full ‚ÄúON‚Äù state. Once 
a full ‚ÄúON‚Äù state is achieved, dosing will continue for 2 additional visits to a maximum dose of  
60 mg (i.e., if a subject  experiences the first full ‚ÄúON‚Äù at 35 mg , dosing will continue up until a 
dose of 50 mg ). 
At Titration Visit 1 (TV1), once the subject's ‚ÄúOFF‚Äù state has been confirm ed by both the 
Investigator and subject, the subject will be treated with 10 mg APL -130277. Subjects who 
tolerate the 10  mg APL -130277 will restart their normal PD medications and will be asked to 
return to the clinic the next business day for Titration Visit 2 (TV2), to assess the next highest 
dose (i.e., 15 mg) in a manner identical to that of Titration Visit 1 (TV1).   
Doses of APL -130277 will increase in 5 mg  increments up to 40 mg  and then in 10 mg  
increments for the 5 0 mg  and 60 mg  dose levels until a full ‚ÄúON‚Äù state is achieved , then dosing 
will continue for 2 additional visits  to a maximum dose of 60 mg . This will sequentially be 
20 mg  (TV3), 25 mg  (TV4), 30 mg  (TV5), 35 mg  (TV6), 40 mg  (TV7), 50 mg  (TV8) and 6 0 mg  
(TV9).  
For Titration Visit 3 (TV3), Titration Visit 4 (TV4), Titration Visit 5 (TV5)  and Titration Visit 6 
(TV6) subjects should be dosed with the next highest dose of study medication within 4 hours of 
the dose, as long as the subject  achieves another ‚ÄúOFF‚Äù that day . TV3 should be paired with TV4 
(20 mg  and 25 mg  can be dosed on the same day); TV4 should  be paired with TV5 (25 mg  and 
30 mg  can be dosed on the same day) , TV5 should be paired with TV6 (30 mg  and 35 mg  can be 
dosed on the same day)  and TV6 should be paired with TV7 (35 mg  and 4 0 mg  can be dosed on 
the same day).  
Should the subject be unabl e to tolerate either  of the two additional dose levels after reaching a 
full ‚ÄúON‚Äù state, in the Investigator‚Äôs opinion, due to adverse events commonly associated with 
apomorphine (e.g., orthostatic hypotension, nausea, vomiting, etc.), subjects will be randomized 
to the previous dose. 
Dosing days in the Dose Titration Phase should be scheduled on consecutive business days and a 
maximum of 2  days between visits may be permitted with Medical Monitor approval. All visits 
in the Dose Titration Phase must be completed within 14 days . 
Safety and efficacy assessments will be performed at each visit  according to the protocol. 
Sunovion Pharmaceuticals Inc.  Page 36 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 10.1.3  Three-W ay Balanced Randomized Crossover  Assessment Phase : Period 1, 
Period  2, Period 3 
Subjects who successfully complete the Dose Titration Phase of the study, and are approved by 
the Sponsor to proceed to randomization, will be asked to return to the clinic for Period 1 Dosing Visit 1 (P1V1). This visit will occur between 2 and 7 days after the final visit in the Dose Titration Phase of the st udy. Depending on the Investigator's decision, subjects  will be asked to 
arrive at the clinic : 
‚Ä¢ after their usual morning dose of PD medications; but before taking their next dose of 
medication ; OR  
‚Ä¢ after withholding their normal morning dose of L -dopa (ie, in the practically defined 
"OFF" state with no anti-parkinsonian medication after midnight the night prior). 
Subjects will be randomized in equal numbers to six possible sequences of each of the three 
treatments being studied:  
1. Treatment A: APL -130277 at the dose determined in the Dose Titration Phase, 
2. Treatment B: Matched placebo  APL -130277, 
3. Treatment C: A single 40 0 mg  dose of moxifloxacin. 
Following confirmation by both the Investigator and subject that the subject is in the ‚ÄúOFF‚Äù state, the sub ject will be dosed according to the subject's random treatment assignment. 
APL -130277 and placebo APL -130277 will be administered in a double -blind fashion and 
moxifloxacin will be administered open -label in a three -way balanced crossover. All subjects 
will be exposed to all three treatments. The six possible treatment sequences are: 1) ABC; 2) 
ACB; 3) BCA; 4) BAC; 5) CAB; and 6) CBA. 
Subjects will return to clinic 3 days after Period 1 and will be dosed for Period 2 with one of the 
other two treatments.  
Subjects will return to clinic 3 days after Period 2 and will be dosed for Period 3 with the third 
and last treatment.  
At the Period 1 Dosing Visit 1 (P1V1), three (3) sets of triplicate 12-L ead ECGs will be obtained 
using a continuous 12- lead Holter monito r over approximately 1- hour (prior to dosing) as the 
baseline assessment for analyses defined in Section 15.4.3. 
10.1.4  Enrollment Adjudication Committee (EAC) 
The Investigator must obtain approval from the EAC and Sponsor prior to e nrolling any subject 
into the study . The EAC will determine the subject ‚Äôs appropriateness for inclusion in the study, 
independent of the entry criteria . The EAC will consult with the Medical Monitor, and the 
Investigator as appropriate, to address and resolve any o utstanding questions or issues. 
Sunovion Pharmaceuticals Inc.  Page 37 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 The EAC review should be completed within 48 hours of submitting a request, and the 
Investigator will b e informed of the decision. Following EAC /Sponsor approval, the final 
determination of eligibility for enrollment in the study will be made by the Investigator, who will then submit a request via the IWRS for enrollment into the Dose Titration Phase of the study . In 
case of refusal, the decision will be accompanied by a rationale. For additional details, please 
refer to the Enrollment and Randomization Adjudication Process, which is contained in a 
separate document.  
A dedicated charter will be developed in order to address the mode of operations of the EAC to ensure the integrity of the study will be protected. The communication from the EAC, 
documenting review and approval of the subject , will serve as EAC documentation for inclusion 
into the study and must be stored in the site study file.  
Sunovion Pharmaceuticals Inc.  Page 38 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 11 PATIENT  POPULATION  
11.1 Selection  of Study  Population 
A screening log of potential study candidates and an enrollment log of enrolled subjects  must be  
maintained at each study site.  
The study will require forty -two (42) subjects to complete the 3 -period, single dose crossover 
phase. Recruitment will continue until the required number of subjects completes the study. 
11.1.1  Inclusion  Criteria   
Subject s who meet each of the following criteria will be eligible for participation in the study:  
1) Male or female ‚â•  18 years of age. 
2) Clinical diagnosis of Idiopathic PD, consistent with UK Brain Bank Crit eria (excluding 
the ‚Äúmore than one affected relative‚Äù criterion).  
3) Clinically meaningful response to Levodopa (L -Dopa). Subjects with or without 
well-defined ‚ÄúOFF‚Äù episodes, as determined by the Investigator, will be allowed . 
4) Receiving stable doses of L -Dopa/carbidopa (immediate or sustained release) 
administered at least 3 times per day OR Rytary‚Ñ¢ administered 3 times per day, for at 
least 4 weeks before the initial Screening Vi sit (SV1). Subjects receiving 
L-Dopa/carbidopa 3 times a day must also be on sta ble treatment with adjunctive PD 
medication regimens. These regimens must be maintained at a stable dose for at least 
4 weeks prior to the initial Screening Visit (SV1) with the exception that MAO -B 
inhibitors must be maintained at a stable level for at le ast 8 weeks prior to the initial 
Screening Visit (SV1) . 
5) No planned medication change(s) or surgical intervention anticipated during the course of study.  
6) The subject must be able to have a drug withdrawal induced ‚ÄúOFF‚Äù episode. 
7) Stage III or less on the modi fied Hoehn and Yahr scale in the ‚ÄúON‚Äù state.  
8) Mini‚ÄìMental State Examination (MMSE) score > 21. 
9) If female and of childbearing potential, must agree to use one of the following methods of birth control throughout the study and until at least 30 days after final drug administration: 
‚Ä¢ Oral contraceptive;  
‚Ä¢ Contraceptive patch;  
‚Ä¢ Barrier (diaphragm, sponge or condom) plus spermicidal preparations; 
Sunovion Pharmaceuticals Inc.  Page 39 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 ‚Ä¢ Intrauterine contraceptive system;  
‚Ä¢ Levonorgestrel implant; 
‚Ä¢ Medroxyprogesterone acetate contraceptive injection;  
‚Ä¢ Complete a bstinence from sexual intercourse;  
‚Ä¢ Hormonal vaginal contraceptive ring; or 
‚Ä¢ Surgical sterilization or partner sterile (must have documented proof). 
10) Male subjects must be either surgically sterile, agree to be sexually abstinent or use a 
barrier method of bi rth control (e.g., condom) from first study drug administration until at 
least 30 days after final drug administration. 
11) Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study-related procedures to complete the s tudy. 
12) Able to understand the consent form, and to provide written informed consent. 
13) Must be approved as a satisfactory candidate by the Enrollment Authorization Committee 
(EAC) and the Sponsor. 
11.1.2  Exclusion  Criteria   
Subject s will be excluded from participation in the study for any of the following reasons: 
1) Atypical or secondary parkinsonism. 
2) Nausea associated with the use of dopamine agonist s that requires treatment with an anti-
emetic.  
3) Previous treatment with any of the following: a neurosurgical procedure f or PD; 
continuous subcutaneous (s.c.) apomorphine infusion; or Duodopa/Duopa. 
4) Treatment with any form of s.c. apomorphine within 7 days prior to the initial Screening Visit (SV1). Subject s that stopped s.c. apomorphine for any reason other than systemic 
safety concerns or lack of efficacy may be considered.  
5) Contraindications to moxifloxacin or APOKYN
¬Æ, or hypersensitivity to apomorphine 
hydrochloride or any macrolide antibiotic or any of the ingredients of APOKYN¬Æ (notably 
sodium metabisulfite) . 
6) Female who  is pregnant or lactating.  
7) Participation in a clinical trial within 30  days prior to the initial Screening Visit (SV1 ), 
with the exception of clinical studies related to APL -130277. 
8) Receipt of any investigational (i.e., unapproved) medication within 30 day s prior to the 
initial Screening Visit (SV1 ), with the exception of APL-130277. 
Sunovion Pharmaceuticals Inc.  Page 40 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 9) Any selective 5HT 3 antagonists (i.e., ondansetron, granisetron, dolasetron, palonosetron, 
alosetron), dopamine antagonists (including Tigan [t rimethobenzamide] and domperidone, 
but excluding quetiapine or clozapine) or dopamine depleting agents within 30 days prior 
to initial Screening Visit (SV1).  
10) Drug or alcohol dependency in the past 12 months. 
11) Subject has a history of malignancy within 5 years prior to SV1, except for adequa tely 
treated basal cell or squamous cell skin cancer or in situ cervical cancer. Pituitary tumo rs 
of any duration are excluded . 
12) Documented abnormalities with ECGs including, arrhythmias, clinically meaningful 
interval irregularities, structural heart abnor malities, myocardial infarction, presence or 
history of a pacemaker, or any abnormality of the ECG, that in the opinion of the Investigator, would interfere with the ability to measure the QT interval, or correct the QT interval for heart rate.  
13) Male subjec ts with a screening corrected QT interval using Fridericia‚Äôs formula (QTcF)  of 
‚â• 450 ms; female subjects  with a screening QT interval ‚â• 470 ms.  Eligibility will be based 
on the core laboratory ECG interpretation report.  
14) HR at screening < 45 bpm or > 100 bpm. 
15) QRS duration at screening > 120 ms . 
16) PR interval at screening > 200 ms . 
17) Subje cts with a history of cataplexy, unexplained syncope or seizures . 
18) Family history of sudden cardiac death . 
19) Heart failure (NYHA Class II or greater) and/or a myocardial infarction.  
20) Current use of any concomitant mediations that prolong the QT/QTc interval . Refer to 
https://crediblemeds.org  for listing . 
21) History of additional risk factors for TdP (i.e., heart failure, hypokalemia, family history of Long QT Syndrome) . 
22) Clinically significant medical, surgical, or laboratory abnormality in the opinion of the Inves tigator.  
23) Subject has a positive screening laboratory test  result for h uman immunodeficiency virus 
(HIV) . 
24) Subject has a positive screening laboratory test  result for  hepatitis B surface antigen  or 
hepatitis C antibodies  and has liver function test results a t screening above the ULN  for 
the reference laboratory.  
Sunovion Pharmaceuticals Inc.  Page 41 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 25) Major psychiatric disorder including, but not limited to, dementia, bipolar disorder, 
psychosis (including Parkinson‚Äôs disease psychosis), or any disorder that, in the opinion of 
the Investigator, req uires ongoing treatment that would make study participation unsafe or 
make treatment compliance difficult.  
26) History of clinically significant impulse control disorder(s).  
27) Dementia that precludes providing informed consent or would interfere with participati on 
in the study. 
28) Current suicidal ideation within one year prior to the second Screening Visit (SV2) as evidenced by answering ‚Äúyes‚Äù to Questions 4 or 5 on the suicidal ideation portion of the Columbia- Suicide Severity Rating Scale (C -SSRS) or atte mpted suicide within the last 
5 years.  
29) Donation of blood or plasma in the 30 days prior to first dosing. 
11.2 Prior  and Concomitant Treatments  
11.2.1  Prohibited Treatments  
The following concomitant treatments will not be allowed during the course of this study:  
‚Ä¢ Any form of s. c. apomorphine from 7 days prior to the initial Screening Visi t (SV1) until 
study completion. 
‚Ä¢ Any selective 5HT
3 antagonist ( i.e., ondansetron, granisetron, dolasetron, palonosetron, 
alosetron) from 30 days prior to the initial Screening Visit (SV1) until study completion.  
‚Ä¢ Dopamine antagonists (including Tigan [t rimethobenzamide] and domperidone, but 
excluding quetiapine or clozapine) or dopamine depleting drugs.  
‚Ä¢ Deep brain stimulation or other neurosurgical procedure for the treatment of PD , 
continuous s.c. apomorphine infusion, or Duodopa/Duopa. 
‚Ä¢ Any medication that can prolong QT . Refer to https://crediblemeds.org  for listing . 
11.2.2  Permitted Treatments  
The following concomitant treatments will be allowed during the course of the study:  
‚Ä¢ Stable doses of an L -Dopa formulation with or without other stable adjunctive PD 
therapies (from at least 4  weeks prior to the initial Screening Visit (SV1), with no 
planned medication changes during the study). 
‚Ä¢ Any other medication other than those identified in Section 11.2.1 are allowed, provided 
they are stable, with no planned medication changes scheduled during the study. Other therapies should only be administered as necessary for the treatment of the subject , at the 
Sunovion Pharmaceuticals Inc.  Page 42 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 discretion  of the Investigator. All concomitant medications must be recorded in the 
appropriate Case Report Form (CRF) for the subject. 
11.3 Subject Withdrawal from  the Study  
Subjects  may be withdrawn from participating in this study for the following:  
1) If QT/QTc is >  500 ms and is an increase from screening of > 60 ms (to be confirmed by 
triplicate ECG ). If a subject experiences an adverse event suggestive of torsade de pointes 
(TdP) the immediate management of TdP will be according to standard medical care as 
directed by  the Investigator/ primary care physician ; 
2) In order to protect their safety and/or well- being;  
3) If they  are unwilling or unable to comply with required study procedures; 
4) If they withdraw their consent to participate in the study;  
5) If the study is prematurely terminated by the Sponsor or Regulatory Authorities; 
6) If they no longer meet the inclusion/exclusion criteria within the study.  
Subjects  will be advised that they are free to withdraw from the study at any time, for any reason, 
and without prejudice. Every reasonable and appropriate effort should be made by the 
Investigator to keep subjects  in the study. However, subjects  must be withdrawn from the study 
if the subject withdraws his or her consent to participate. In the event of subject withdrawal, the 
Inves tigator should attempt to determine the reason for the subject‚Äôs  withdrawal.  
The reason for discontinuation and the date of withdrawal from the study will be recorded in the appropriate CRF. The Investigator should make at least 3 documented attempts to contact a 
subject who is lost to follow -up, with at least 1 attempt made by a certified letter. Documentation 
of contact attempts must be made in the subject ‚Äôs record.  
Neither subjects withdrawing from the study nor those removed by the Investigator or Spons or 
will be replaced. Subjects  who are withdrawn from this study may not re- enter the study at a later 
date. The screening  number for a withdrawn subject will not be reassigned to another subject . 
If a subject is removed or withdraws from the study, the procedures outlined in the EOS Visit 
will be performed, where possible. 
Sunovion Pharmaceuticals Inc.  Page 43 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 12 STUDY PROCEDURES  
This study will consist of the following:  
1) Screening Visits (SV1 and SV2 ) 
2) Dose Titration Phase 
a. Titration Visit 1 (TV1)  
b. Titration Visit 2 (TV2)  
c. Titration Visit 3 (TV3)  
d. Titration Visit 4 (TV4)  
e. Titration Visit 5 (TV5)  
f. Titration Visit 6 (TV6)  
g. Titration Visit 7 (TV7)  
h. Titration Visit 8 (TV8)  
i. Titration Visit 9 (TV9)  
3) Three-Way Balanced Randomized Crossover Assessment Phase 
a. Period 1 Dosing Visit (P1V1) 
b. Period 2 Dosing Visit (P2V2) 
c. Period 3 Dosing Visit ( P3V3 ) 
4) End of Study Visit (EOS) 
12.1 Screening Visits (SV1 and SV2)   
Subject s must sign an ICF before any screening -related procedures are performed  at an initial 
Screening Visit (SV1) . Following receipt of subject consent, the subject will be asked to return to 
the clinic for the second Screening Visit (SV2). All s creening assessments must be performed 
within 14 days before Titration Visit 1 (TV1).  
If required by the Investigator, and following receipt of subject consent, the Inves tigator may 
review the subject ‚Äôs medical history, BMI, height, weight, vital signs, ECG s and perform a 
complete physical examination at SV1 to determine if the subject may be eligible for study 
participation. If these assessments are done at SV1, the remaining procedures outlined below for 
SV2, including the assessment of L-Dopa responsiveness, will only be performed. 
The following procedures will be performed by study staff at SV2 : 
‚Ä¢ Reconfirm consent. 
Sunovion Pharmaceuticals Inc.  Page 44 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 ‚Ä¢ Review inclusion/exclusion criteria.  
‚Ä¢ Record demographics and detailed medical history, including review of medications 
taken within 6 months prior to the initial Screening Visit (SV1), current treatment 
regimens, drug, alcohol and smoking history. 
‚Ä¢ Perform a complete physical examination, including an oropharyngeal examination. The 
oropharyngeal cavity examination should include a visual inspection of the inside of each 
cheek, the inside of the  upper and lower lip, the surface of the tongue, and under the 
tongue. 
‚Ä¢ Measure height and weight; calculate BMI.  
‚Ä¢ Obtain a 12-lead ECG in triplicate using a resting ECG device for eligibility . Triplicate 
ECG should be completed within 5 minutes. ECGs will be centrally reviewed by the ECG laboratory and the result provided for eligibility. 
‚Ä¢ Record vital signs (BP, HR, RR and Temp), after the subject has been in a supine 
position for 5 minutes. Subject BP to be measured both supine and standing (within 3 
minutes of standing). 
‚Ä¢ Collect blood and urine sample  for clinical laboratory tests (hematology, chemistry, 
urinalysis and serology). Serum pregnancy test for females of child -bearing potential 
only.  
‚Ä¢ Assess suicidal ideation using C -SSRS (see APPENDIX V: Columbia Suicide Severity 
Rating Scale (C -SSRS) ). The ‚ÄúScreening‚Äù scale should be used at this  visit.  
‚Ä¢ Perform a MMSE.  
‚Ä¢ Assess subject using the Modified Hoehn and Yahr scale (see APPENDIX III : Modified 
Hoehn and Yahr Scale ). 
‚Ä¢ Assess subject motor function using MDS -UPDRS Part III at t = 0 (just prior to L -Dopa 
administration) , 30, 60 and 90 minutes after L -Dopa administration (see APPENDIX IV: 
Movement Disorder Society - Unified Parkinson‚Äôs Disease Rating Scale 
(MDS -UPDRS ). These assessments will exclude the ‚ÄúDyskines ia Impact on Part III 
Ratings‚Äù and the Hoehn and Yahr staging. 
‚Ä¢ Perform subject training in order to distinguish ‚ÄúOFF‚Äô versus ‚ÄúON‚Äù episodes (see 
Section  12.6.3.1).  
‚Ä¢ Investigator confirmation of ‚ÄúOFF‚Äù or ‚ÄúON‚Äù . The subject must be in an ‚ÄúOFF‚Äù state prior 
to dosing to ensure they experience an ‚ÄúON‚Äù response. 
‚Ä¢ Subject confirmation of ‚ÄúOFF‚Äù or ‚ÄúON‚Äù. 
Sunovion Pharmaceuticals Inc.  Page 45 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 ‚Ä¢ Confirm L -Dopa responsiveness. Subjects  will take their normal dose of L -Dopa without 
their normal adjunctive PD medicatio n. 
‚Ä¢ Record any AEs/SAEs that  have occurred after  the informed consent was obtained. 
‚Ä¢ Record any new concomitant medications and/or changes to current concomitant 
medications being used by the subject since the last visit.  
‚Ä¢ Subject inclusion into the study to be approved by the EAC.  
The Investigator will review all information obtained from the screening procedures. If the 
subject is not eligible, the subject will be a screening failure and will not attend any other visits. 
Subjects  who fulfill all entry criteria will be found eligible to participate in the trial and an 
appointment for Titration Visit 1 (TV1)  will be made.  
Eligible subjects  will be asked to return to the clinic the morning of Titration Visit 1 (TV1) to 
start the Dose Titration Phase of the study. 
12.2 Dose Titration Phase (TV1 to TV9) 
Depending on the Investigator's decision, subjects will be asked to arrive at the clinic : 
‚Ä¢ after their usual morning dose of PD medications; but before taking their next dose of 
medication ; OR  
‚Ä¢ after withholding their normal morning dose of L -dopa (ie, in the practically defined 
"OFF" state with no anti-parkinsonian medication after midnight the night prior). 
Once the subject's ‚ÄúOFF‚Äù state has been confirm ed by both the Investigator and subject, the 
subject will be treated with 1 0 mg  APL -130277 (TV1).  Subjects who tolerate  the 1 0 mg  
APL -130277 will restart their normal PD medication and will be asked to return to the clinic the 
next business day for Titration Visit 2 (TV2) to assess the next highest dose in a manner identica l 
to that of TV1. 
During the Dose Titration Phase of the study, subject s will start with 1 0 mg  and increase in 5 mg  
increments up to 40 mg  and in 10 mg  increments for the 5 0 mg  and 60 mg  dose levels  until the 
subject  reaches a full ‚ÄúON‚Äù state. Once a full  ‚ÄúON‚Äù state is achieved, dosing will continue for 
2 additional visits to a maximum dose of 60 mg  (e.g., if a subject  experiences the first full ‚ÄúON‚Äù 
at 10 mg , dosing will continue up until a dose of 20 mg ). Dosing days in the Dose Titration 
Phase should be  scheduled the next business  day after the previous visit and must be completed 
within 14 days . 
‚Ä¢ Titration Visit 1 (TV1) ‚Äì 10 mg  APL -130277; 
‚Ä¢ Titration Visit 2 (TV2) ‚Äì 15 mg  APL -130277; 
‚Ä¢ Titration Visit 3 (TV3) ‚Äì 20 mg  APL -130277; 
Sunovion Pharmaceuticals Inc.  Page 46 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 ‚Ä¢ Titration Visit 4 (TV4) ‚Äì 25 mg  APL -130277; 
‚Ä¢ Titration Visit 5 (TV5) ‚Äì 30 mg  APL -130277; 
‚Ä¢ Titration Visit 6 (TV6) ‚Äì 35 mg  APL -130277 (20 mg  sublingual thin film under the 
tongue for 3 minutes before placing the second 15 mg  sublingual thin film, sequentially  
for another 3 minutes [total dosing time should be 6 minutes] ); 
‚Ä¢ Titration Visit 7 (TV7) - 40 mg  APL -130277 (20 mg  sublingual thin film under the 
tongue for 3 minutes before placing the second 2 0 mg  sublingual thin film, sequentially  
for another 3 minutes [total dosing time should be 6 minutes] ); 
‚Ä¢ Titration Visit 8 (TV8) - 50 mg  APL -130277 (25 mg  sublingual thin film under the 
tongue for 3 minutes before placing the second 2 5 mg  sublingual thin film, sequentially  
for another 3 minutes [ total dosing time should be 6 minutes] ); 
‚Ä¢ Titration  Visit 9 (TV9) - 60 mg  APL -130277 (30 mg  sublingual thin film under the 
tongue for 3 minutes before placing the second 3 0 mg  sublingual thin film, sequentially  
for another 3 minutes [total dosing time should be 6 minutes] ). 
For Titration Visit 3 (TV3), Titration Visit 4 (TV4), Titration Visit 5 (TV5) and Titration Visit 6 
(TV6) only, subjects can be dosed with the next highest dose of study medication within 4 hours 
of the initial dose, as long as the subject achieve s another ‚ÄúOFF‚Äù state that day.  
‚Ä¢ TV3 should  be paired with TV4 (20 mg  and 25 mg  can be dosed on the same day);  
‚Ä¢ TV4 should be paired with TV5 (25 mg  and 30 mg  can be dosed on the same day)  
‚Ä¢ TV5 should be paired with TV6 (30 mg  and 35 mg  can be dosed on the same day). 
‚Ä¢ TV6 should be paired with TV7 (3 5 mg  and 40 mg  can be dosed on the same day). 
After reaching a full ‚ÄúON‚Äù state, the subject will continue with the next two T itration Visits . 
Should the subject be unable to tolerate one of the two additional dose levels after reaching a full 
‚ÄúON‚Äù state , in the Investigator‚Äôs opinion, due to adverse events commonly associated with 
apomorphine ( e.g., orthostatic hypotension, nausea, vomiting, etc.), subjects will be randomized 
to the previous dose.  
Study staff will perform the  following  procedures  at each  Titration Visit: 
‚Ä¢ Reconfirm consent. 
‚Ä¢ Review restriction criteria.  
‚Ä¢ Perform an abbreviated physical examination, including oropharyngeal examination at 
t = 0 (just prior to dosing ) and 120 minutes after dosing at TV1 to TV 9. The 
oropharyngeal cavity examination should include a visual inspection of the inside of each 
cheek, the inside of the upper and lower lip, the surface of the tongue, and under the 
Sunovion Pharmaceuticals Inc.  Page 47 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 tongue. 
‚Ä¢ Single 12- lead ECG will be obtained using a resting ECG device at t = 0 (just prior to 
dosing) and 45 minutes after dosing  as a safety evaluation ; assessment by the 
Investigator/ECG qualified person to be completed at the visit. 
‚Ä¢ Record vital signs (BP, HR, RR and Temp) at t  = 0 minutes (just prior to dosing), 15, 45 
and 60 minutes after dosing. Blood pressure to be measured both supine and standing 
(measured within 3 minutes of standing). 
‚Ä¢ Assess subject motor function using MDS -UPDRS Part III at t =  0 (just prior to dosing) , 
30, 60 and 90 minutes after dosing (see APPENDIX IV: Movement Disorder Society - 
Unified Parkinson‚Äôs Disease Rating Scale (MDS -UPDRS) ). These assessments will 
exclude the ‚ÄúDyskinesia Impact on Part III Ratings‚Äù and the Hoehn and Yahr staging. 
‚Ä¢ Investigator confirmation of ‚ÄúOFF‚Äù or ‚ÄúON‚Äù. The subject must be in an ‚ÄúOFF‚Äù state prior 
to dosing in order to proceed with dosing . Investigator will assess ‚ÄúOFF‚Äù/‚ÄùON‚Äù state as 
part of the MDS- UPDRS Part III assessments.  
‚Ä¢ Subject confirmation of ‚ÄúOFF‚Äù or ‚ÄúON‚Äù . The subject must be in an ‚ÄúOFF‚Äù state prior to 
dosing in order to proceed with dosing. 
‚Ä¢ When subject is in the ‚ÄúOFF‚Äù state, dose with APL-130277. 
‚Ä¢ Subject  will report the time when they turned to a full ‚ÄúON‚Äù (if applicable) and report the 
time when they turned ‚ÄúOFF‚Äù following dosing (if it occurs within 90 minutes of dosing). 
‚Ä¢ Record any AEs/SAEs that have occurred since the last visit.  
‚Ä¢ Record any new concomitant medications and/or changes to current concomitant 
medications being used by the subject since the last visit.  
‚Ä¢ Assess suicidal ideation using C -SSRS (see APPENDIX V: Columbia Suicide Severity 
Rating Scale (C -SSRS) ). The ‚ÄúSince Last Visit‚Äù scale should be used at this visit.  
‚Ä¢ Subject inclusion into the Crossover Phase to be approved by Sponsor prior to 
Randomization. 
If in the opinion of the Investigator the subject  can no longer tolerate the ‚ÄúOFF‚Äù state at any 
point during the visit, the subject  may receive rescue L -Dopa ( ¬± other adjunctive PD medication) 
at a dosage considered appropriate by the Investigator to achieve a full ‚ÄúON‚Äù state. Where 
possible, administration of rescue L -Dopa should be delayed until after the 60 minute efficacy 
assessments are complete.  
If the subject  receives rescue L -Dopa ( ¬± other adjunctive PD medication) as described above, 
subjects  can return to the clinic on another day to resume the titration with the next highest dose. 
Sunovion Pharmaceuticals Inc.  Page 48 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 12.3 Three-Way Balanced Randomized Crossover Assessment Phase :  Period 1, Period 2, 
Period 3  
Subjects  who successfully completed the Dose Titration Phase will be asked to return to the 
clinic for Period 1 Dosing Visit  1 (P1V1). This visit will occur between 2 and 7 days after the 
final visit in the Dose Titration Phase of the study . Depending on the Investigator's decision, 
subjects  will be asked to arrive at the clinic : 
‚Ä¢ after their usual morning dose of PD medications; but before taking their next dose of 
medication ; OR  
‚Ä¢ after withholding their normal morning dose of L -dopa (ie, in the practically defined 
"OFF" state with no anti-parkinsonian medication after midnight the night prior).  
Following confirmation by both the Investigator and subject that the subject is in the ‚ÄúOFF‚Äù 
state, the subject will be randomized using the Williams design . Subjects will be randomized in 
equal numbers to six possible sequences of each of t he three treatments being studied:  
1. Treatment A: APL -130277 at the dose determined in the Dose Titration Phase, 
2. Treatment B: Matched placebo  APL -130277, 
3. Treatment C: A single 40 0 mg  dose of moxifloxacin. 
APL -130277 and placebo will be administered  in a double -blind fashion and moxifloxacin will 
be administered open- label in a three- way balanced crossover. All subjects will be exposed to all 
three treatments. The six possible treatment sequences are: 1) ABC; 2) ACB; 3) BCA; 4) BAC; 5) CAB; and 6) CB A. In Period 1, regardless of the randomized treatment assignment , the 
baseline ECG will be obtained over approximately 1- hour (prior to dosing)  using a Holter 
monitor device . Three (3) se ts of triplicate 12 -lead ECGs  will be used as the baseline assessmen t 
for analyses as defined in Section 15.4.3. Triplicate 12 -lead ECGs will also be obtained at t = 15, 
30, 45, 60 minutes after dosing and at 2, 3, 4, 8, 12, 24 hours after dosing. 
Subjects  will return to clinic 3 days after Per iod 1 and will be dosed for Period 2 with one of the 
other two treatments.  
Subjects will return to clinic 3 days after Period 2  and will be dosed for Period 3 with the third 
and last treatment.  
12.3.1  Double -Blind APL -130277 and Placebo Treatment Periods  
The following
 procedures will take place at these visits  except where explicitly noted:  
‚Ä¢ Reconfirm consent. 
‚Ä¢ Review restriction criteria.  
‚Ä¢ Perform an abbreviated physical examination, including oropharyngeal examination at 
Sunovion Pharmaceuticals Inc.  Page 49 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 t = 0 (just prior to dosing) and 120 minutes  after dosing. The oropharyngeal cavity 
examination should include a visual inspection of the inside of each cheek, the inside of 
the upper and lower lip, the surface of the tongue, and under the tongue. 
‚Ä¢ Measure body weight.  
‚Ä¢ Triplicate 12 -lead ECG will be obtained using a Holter monitor device at t  = 0 (just prior 
to dosing), 15, 30, 45, 60  minutes after dosing and at 2, 3, 4, 8, 12, 24 hours after dosing.  
If the treatment is administered in Pe riod 1, t = 0 will be omitted  and replaced by the 
baseline ECG ba seline assessment described  above in Section 12.3. 
‚Ä¢ A single 12- lead ECG will be obtained using a resting ECG device 60  minutes after 
dosing as a safety evaluation; assessment by the Investigator /ECG qualified pe rson to be 
completed at the visit. 
‚Ä¢ Record vital signs (BP, HR, RR and Temp) at t  = 0 minutes (just prior to dosing), and at 
15, 45 and 60 minutes after dosing. Blood pressure to be measured both supine and standing (measured within 3 minutes of standing). 
‚Ä¢ Collection and processing of blood samples for PK assessment will occur at the following 
time points: t = 0 (just prior to dosing) , 30, 45, 60  minutes after dosing and at 2, 4 hours 
after dosing . 
‚Ä¢ Investigator confirmation of ‚ÄúOFF‚Äù or ‚ÄúON‚Äù. The subject mus t be in an ‚ÄúOFF‚Äù state prior 
to dosing in order to proceed with dosing. 
‚Ä¢ Subject confirmation of ‚ÄúOFF‚Äù or ‚ÄúON‚Äù. The subject must be in an ‚ÄúOFF‚Äù state prior to dosing in order to proceed with dosing. 
‚Ä¢ When subject is in the ‚ÄúOFF‚Äù state, proceed with dosing according to the randomization 
scheme.  
‚Ä¢ Record any AEs/SAEs that have occurred since the last visit.  
‚Ä¢ Record any new concomitant medications and/or changes to current concomitant medications being used by the subject since the last visit.  
‚Ä¢ Assess suicidal ideat ion using C -SSRS (see APPENDIX V : Columbia Suicide Severity 
Rating Scale (C -SSRS) ). The ‚ÄúSince Last Visit‚Äù scale should be used at this visit.  
If in the opinion of the Investigator the subject  can no longer tolerat e the ‚ÄúOFF‚Äù state at any 
point during the visit, the subject  may receive rescue L -Dopa ( ¬± other adjunctive PD medication) 
at a dosage considered appropriate by the Investigator to achieve a full ‚ÄúON‚Äù state. Where 
possible, administration of rescue L- Dopa s hould be delayed until 120 minutes after dosing . 
Sunovion Pharmaceuticals Inc.  Page 50 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 12.3.2  Open -Label Moxifloxacin Treatment Period  
The following procedures  will be conducted at this visit except where explicitly noted : 
‚Ä¢ Reconfirm consent. 
‚Ä¢ Review restriction criteria.  
‚Ä¢ Perform an abbreviated physical examination, including oropharyngeal examination at 
t = 0 (just prior to dosing) and 120 minutes after dosing. The oropharyngeal cavity 
examination should include a visual inspection of the inside of each cheek, the inside of 
the upper and lower lip, the surface of the tongue, and under the tongue. 
‚Ä¢ Measure body weight.  
‚Ä¢ Triplicate 12 -lead ECG will be obtained using a Holter monitor device at t = 0 (just prior 
to dosing), 15, 30, 45, 60  minutes after dosing and at 2, 3, 4, 8, 12, 24 hours after dosing.  
If the treatment is administered in Period 1, t = 0 will be omitted and replaced by the 
baseline ECG baseline assessment described above in Section 12.3. 
‚Ä¢ A single 12- lead ECG will be obtained using a resting ECG  device 60  minutes after 
dosing as a safety evaluation; assessment by the Investigator /ECG qualified person to be 
completed at the visit.  
‚Ä¢ Record vital signs (BP, HR, RR and Temp) at t = 0 minutes (just prior to dosing), 15, 45 
and 60 minutes after dosing. Blood pressure to be measured both supine and standing 
(measured within 3 minutes of standing). 
‚Ä¢ Collection and processing of blood samples for PK assessment will occur at the following 
time points: t = 0 (just prior to dosing) , 30, 60 minutes after dosing and at 2, 3, 4, 6, 
8 hours after dosing.  
‚Ä¢ Investigator confirmation of ‚ÄúOFF‚Äù or ‚ÄúON‚Äù. The subject must be in an ‚ÄúOFF‚Äù state prior to dosing in order to proceed with dosing. 
‚Ä¢ Subject confirmation of ‚ÄúOFF‚Äù or ‚ÄúON‚Äù. The subject must be in an ‚ÄúOFF‚Äù state prior to dosing in order to proceed with dosing. 
‚Ä¢ When subject is in the ‚ÄúOFF‚Äù state, dose with 400 mg  moxifloxacin.  
‚Ä¢ Record any AEs/SAEs that have occurred since the last visit.  
‚Ä¢ Record any new concomitant medications and/or changes to current concomitant medications being used by the subject since the last visit.  
‚Ä¢ Assess suicidal ideation using C -SSRS (see APPENDIX V: Columbia Suicide Severity 
Rating Scale (C -SSRS) ). The ‚ÄúSince Last Visit‚Äù scale should be used at this visit. 
Sunovion Pharmaceuticals Inc.  Page 51 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 If in the opinion of the Investigator the subject  can no longer tolerate the ‚ÄúOFF‚Äù state at any 
point during the visit, the subject  may receive rescue L -Dopa ( ¬± other adjunctive PD medication) 
at a dosage considered appropriate by the Investigator to achieve  a full ‚ÄúON‚Äù state. Where 
possible, administration of rescue L-Dopa should be delayed until 120 minutes after dosing . 
12.4 End of Study Visit  
Approximately 7 days  following the completion of the study  (after P3V3), subjects  will be asked 
to return to the clinic  for a final safety assessment visit. The following  procedures will take place 
at this visit:  
‚Ä¢ Reconfirm consent. 
‚Ä¢ Perform a complete physical examination, including an oropharyngeal examination. The 
oropharyngeal cavity examination should include a visual inspection of the inside of each 
cheek, the inside of the upper and lower lip, the surface of the tongue, and under the tongue. 
‚Ä¢ Measure body weight.  
‚Ä¢ Triplicate 12 -lead ECG will be obtained using a resting  ECG  device.  Triplicate ECG 
should be completed within 5 minutes ; assessment by the Investigator /ECG qualified 
person to be completed at the visit.  
‚Ä¢ Record vital signs (BP, HR, RR and Temp), after the subject has been in a supine 
position for 5 minutes. Subject BP to be measured both supine and standing (within 
3 minutes of standing). 
‚Ä¢ Collect blood and urine sample for clinical laboratory tests (hematology, chemistry, 
urinalysis). Serum pregnancy test for females o f child -bearing potential only. 
‚Ä¢ Assess suicidal ideation using C -SSRS (see APPENDIX V : Columbia Suicide Severity 
Rating Scale (C -SSRS) ). The ‚ÄúSince Last Visit‚Äù scale should be used at this visit.  
‚Ä¢ Record any AEs/SAEs that have occurred since the last visit.  
‚Ä¢ Record any new concomitant medications and/or changes  to current concomitant 
medications being used by the subject since the last visit.  
12.5 Duration of Treatment  
Subject  participation in this study from Screening until final study completion is anticipated to be 
a maximum of 46  days.  
Sunovion Pharmaceuticals Inc.  Page 52 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 12.6 Assessments  
12.6.1  Order of Asses sments  
The following summarizes the suggested sequence of asses sments prior to dosing during SV2, 
Dose Titration Phase and Periods 1, 2, and 3 of the study: 
ECG ‚Äì PK ‚Äì Vitals  ‚Äì Efficacy   
The following summarizes the suggested sequence of assessments after dosing during Dose 
Titration Phase and Periods 1, 2, and 3 of the study: 
MDS -UPDRS Part III - Subject ‚ÄúOFF‚Äù/‚ÄùON‚Äù status ‚Äì ECG  ‚Äì PK ‚Äì Vitals   
In the event the completion of the MDS- UPDRS Part III at a previous timepoint conflicts with 
other assessments that  are scheduled, priority should be given to completing the MDS- UPDRS 
Part III first before conduc ting the remaining assessments.  
12.6.2  Clinical Safety Assessments  
12.6.2.1 Physical Examinations 
Complete physical examination s at all scheduled timepoints must include the  following: head -
eyes-ears-nose and throat; respiratory system; cardiovascular system; gastrointestinal system, 
including the oral cavity  (and oropharyngeal cavity examination ); musculoskeletal system; 
central and peripheral nervous system; and skin; t o be done at the second  Screening Visit (SV2)  
and End of Study (EOS) Visit. 
Abbreviated physical exam inations at all scheduled timepoints must include head -eyes-ears-nose 
and throat; heart, lungs; abdomen; oropharyngeal cavity examination; and skin; t o be done at 
t = 0 (just prior to dosing) and 120 minutes after dosing at visits TV1 to TV 9, Period 1, Period 2, 
and Period 3. 
All physical examinations performed in this study, whether complete or abbreviated, will include 
an oropharyngeal cavity examination by the  Investigator (or designate trained to perform this 
examination) and will include a visual inspection of the inside of  each cheek, the inside of the 
upper and lower lip, the surface of the tongue, and under the tongue. Each location within the 
oropharyngeal examination will be scored and graded as follows: 
‚Ä¢ Finding 
o None 
o Focal reddening  
o Multiple foci of reddening 
o Edema  
o Ulceration  
Sunovion Pharmaceuticals Inc.  Page 53 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 ‚Ä¢ Grade  
o Mild  
o Moderate  
o Severe  
All abnormal findings at baseline will be recorded on the Medical History/Concomitant 
Diagnoses page (or  equivalent) of the CRF. New abnormal findings or a worsening of baseline 
conditions detected at follow-up physical examinations will be recorded as AEs on the CRF. 
The Investigator (or designate) should evaluate each finding against AE criteria and comple te the 
AE CRF, as appropriate. Photographs for reference may be taken by the Investigator (or 
designate) provided the subject provides consent to do so. 
12.6.2.2 Vital Signs  
Vital signs ( HR, RR, BP and body temperature ) will be measured at various timepoints after the 
subject has been in a supine position for 5 minutes. Vital signs will be measured at t = 0 (just 
prior to dosing), 15, 45, 60 minutes after dosing at all scheduled study visits.  Vital signs (BP 
only) will also be measured within three minutes of standi ng at all timepoints . The same arm 
should be used during each assessment of BP and HR. If the subject is unable to stand due to 
orthostatic symptoms such as light- headedness, dizziness, or changes in sensorium upon 
standing, every attempt should be made to obtain BP and HR in the sitting position. Study personnel will carefully monitor subjects  for signs of OH; defined as:  
‚Ä¢ a systolic  BP decrease of ‚â•  20 mmHg within three minutes of standing up from a supine 
position; and/or 
‚Ä¢ a diastolic BP decrease of ‚â•  10 mmHg within three minutes of standing up from a supine 
position. 
12.6.2.3 12-Lead ECG  
12-lead ECG s will be performed as outlined in the prot ocol using two modalities, a continuous 
Holter monitor and a resting ECG device. Detailed i nstructions will be provided to study staff 
and subjects. 
12-lead Holter M onitor:   At the Period 1 Dosing Visit 1 (P1V1) , three ( 3) sets of triplicate 
12-lead ECG s will be obtained over approximately 1-hour (prior to dosing) as the baseline 
assessment for analyses  defined in Section 15.4.3 . Triplicate 12 -lead ECG s will also be obtained 
at t = 15, 30, 45, 60 minutes after dosing and at 2, 3, 4, 8, 12, 24 hours after dosing . In Period  2 
and Period 3, triplicate 12 -lead ECG will be obtained at t  = 0, 15, 30, 45, 60 minutes and at 2, 3, 
4, 8, 12, 24 hours after dosing . At each ECG extraction time points the subject must have 
rested in the supine position for 10 minutes prior to the nominal timepoint and 10  minutes 
Sunovion Pharmaceuticals Inc.  Page 54 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 after. 
ECGs obtained using the continuous Holter monitor will be sent directly to the central core ECG 
laboratory contracted by the Sponsor and/or its designate. The Holter monitor results will not be 
provided to the site. 
Resting ECG Device:   At Screening Visit 2 (SV2)  a triplicate 12 -lead ECG will be obtained . 
Triplicate ECG should be completed with 5 minutes. The screening ECG will be centrally 
reviewed by the ECG Laboratory and the result provided for eligibility. 
At each Titration Visit, a single  12-lead ECG will be performed  at t = 0 (just prior to dosing) and 
45 minutes after dosing . In Period 1, Period  2 and Period 3, a single ECG  will be performed at 
t = 60 minutes after dosing . At the End of Study Visit (EOS), a triplicate 12 -lead ECG will be 
obtained. 
ECGs obtained using a resting ECG device will be used as a safety evaluation and assessed  by 
the Investigator/ECG qualified person at each visit.  
The following parameters will b e reported in the CRF based on the safety ECGs:  
‚Ä¢ Heart rate  
‚Ä¢ PR interval  
‚Ä¢ QRS interval  
‚Ä¢ RR interval  
‚Ä¢ QT interval  
‚Ä¢ QTc Interval (Fridericia‚Äôs correction)  
‚Ä¢ QTc Interval (Bazett‚Äôs correction)  
All safety ECGs should be assessed by the Investigator and deemed ‚ÄúNormal‚Äù, ‚ÄúAbnormal, not 
clinically significant‚Äù or ‚ÄúAbnormal, clinically significant‚Äù. Abnormal readings that, in the 
opinion of the Investigator are deemed clinically significant should be reported as AEs on the 
appropriate CRF page.  
12.6.2.4 Modified Hoehn and Yahr  
The Modified Hoehn and Yahr scale will be administered at the second Screening Visit (SV2) to 
verify subjects meet the eligibility criteria for this study. This will be conducted in the ‚ÄúON‚Äù 
state.  
12.6.2.5 Mini -Mental State Examination 
Mini- Mental State Examination (M MSE) is used to evaluate a person‚Äôs cognitive and mental 
function and will be administered at the second Screening Visit (SV2) to verify subjects meet the 
Sunovion Pharmaceuticals Inc.  Page 55 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 eligibility criteria for this study.  
12.6.2.6 Clinical Laboratory Tests  
The following  clinical  laboratory  test samples  will be collected where documented:  
Hematology:  hemoglobin, hematocrit,  red blood cell  (RBC)  count, RBC indices, 
mean  corpuscular hemoglobin (MCH),  MCH concentration 
(MCHC),  platelet count (or estimate),  white blood cell ( WBC ) 
count including diff erential . 
Serum Chemistry:  albumin, total bilirubin,  total protein,  alkaline  phosphatase,  
chloride, alanine aminotransferase (ALT),  aspartate 
aminotransferase (AST),  blood urea,  creatinine, glucose,  sodium, 
potassium, uric acid, globulin, vitamin B6. 
Serum pregnancy test will be performed on all females of child -
bearing potential only. 
Urinalysis:  pH, specific gravity, blood, glucose, protein, ketones .  
Serology (at the 
Screening Visit only):  Human immunodeficiency virus (HIV), Hepatitis B surface antigen, 
Hepatitis C antibodies . 
12.6.2.7 Specimen  Handling  Requirements  
The transmission of infectious agents may occur through contact with contaminated needles and blood or blood products. Consequently, appropriate blood and body fluid precautions should be employed by all personnel involved in the drawing of blood and the handling of specimens in 
both the clinic and laboratory settings. 
In addition to appropriate handling of subject samples, specific regulations exist regarding the 
shipment of biologic/etiologic samp les. Procedures and regulations for the packaging and 
shipping of infectious samples may be  outlined in the study Laboratory Manual. It is the 
responsibility of the Investigator to ensure all study samples that are to be transported to another 
location are appropriately packed and shipped according to the applicable regulations. 
Blood and urine samples for hematology, serum chemistry, urinalysis, and serology  will be sent 
to a central  laboratory for analyses.  Please see the Laboratory Manual for details.  
12.6.2.8 C-SSRS 
Formal assessments of subject  suicidal ideation and behavior will be assessed at the second 
Screening Visit (SV2)  and all following visits through to the End of Study (EOS). A final 
assessment will be performed at the time of termination, regardless if it is scheduled (i.e., at 
EOS) or an early termination/withdrawal.  
Sunovion Pharmaceuticals Inc.  Page 56 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 At SV2 the C -SSRS ‚ÄòScreening‚Äô assessment tool will be used. Subjects who answer ‚ÄòYes‚Äô to 
Questions 4 and 5 at this Visit should be excluded from participation in the study. All subsequent  
evaluations will utilize the C -SSRS ‚ÄòSince Last Visit‚Äô assessment . 
12.6.2.9 Medical History  
At the Screening Visit (SV2), the Investigator (or designate) will review the subject ‚Äôs medical 
history in order to ascertain the subject ‚Äôs eligibility. The medical history  should assess the 
subject ‚Äôs current PD medications, including medication name, dose, number of tablets per dose 
(if applicable), dosage units and frequency per day. 
The medical history assessment will include a detailed assessment of the subjects  PD histo ry, 
including, but not limited to: 
‚Ä¢ Year of Diagnosis;  
‚Ä¢ Presence of a rest tremor at the time of diagnosis;  
‚Ä¢ Year when motor fluctuations began; 
‚Ä¢ Type of ‚ÄúOFF‚Äù episodes experienced (e.g., morning akinesia, wearing -‚ÄúOFF ‚Äù, 
delayed ‚ÄúON‚Äù, dose failure, sudden ‚ÄúOFF ‚Äù); 
‚Ä¢ Number of ‚ÄúOFF‚Äù episodes per day; 
‚Ä¢ Typical length of ‚ÄúOFF‚Äù episodes . 
‚Ä¢ PD medications previously or currently taken, including: 
o Dopamine agonists; 
o MAO-B inhibitors; 
o COMT inhibitors; 
o Amantadine;  
o Anti-cholinergics.  
12.6.3  Efficacy Assessments  
12.6.3.1 Confirmation of ‚ÄúOFF‚Äù or ‚ÄúON‚Äù Episodes 
‚ÄúOFF‚Äù and ‚ÄúON‚Äù Training of Subjects at SV2  
At S creening Visit  2 (SV2), subjects  will present to the clinic having taken their last dose of 
L-Dopa and any other adjunctive PD medication no later than midnight the evening prior to the 
visit. Their normal morning dose of L -Dopa ( without adjunctive PD medication) will be 
administered in the clinic. Prior to administration of their L -Dopa dose, subject s will be 
examined by the Investigator in order to verify that they are in the ‚ÄúOFF‚Äù state . If they are in the 
‚ÄúOFF‚Äù state, the Investigator will educate the subject  that this is an ‚ÄúOFF‚Äù period or ‚ÄúOFF‚Äù 
Sunovion Pharmaceuticals Inc.  Page 57 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 episode. The Investigator should clearly explain to the subject that this ‚ÄúOFF‚Äù time is when their 
medication has worn off, and does not provide benefits in terms of mobility, slowness and 
stiffness.   
Subject s will then take their next scheduled dose of L -Dopa. Once the Investigator determines 
that the subjec t is experiencing an ‚ÄúON‚Äù state, they should educate the subjec t that this is an 
‚ÄúON‚Äù state.  The Investigator should clearly explain to the subjec t that an ‚ÄúON‚Äù episode is the 
period of time where their medication is providing benefit with regard to mobility, slowness and stiffness, and they feel they can perform normal daily activities.  Once the  subjec t has 
demonstrated understanding of the ‚ÄúOFF‚Äù and ‚ÄúON‚Äù state, the training is complete. Successful 
completion and understanding of this training should be noted in the appropriate CRF.  
Any subject  who cannot differentiate between an ‚ÄúON‚Äù and ‚ÄúOFF‚Äù state will be deemed a screen 
failure.  
Definitions of Full ‚ÄúON‚Äù and ‚ÄúOFF‚Äù 
The following definitions will be used in this study: 
‚ÄúOFF‚Äù ‚Äì defined as:  
‚Ä¢ A period of time when medication has worn off and is no longer providing benefit with 
regard to mobility, slowness, and stiffness; 
‚Ä¢ Confirmed by the Investigator using their clinical judgement as ‚ÄúOFF‚Äù.  
‚Ä¢ Confirmed by the subjec t as ‚ÄúOFF‚Äù.  
Full ‚ÄúON‚Äù as assessed by the subject  ‚Äì defined as:  
‚Ä¢ A period of time where medication is providing benefit with regard to mobility, stiffness and slowness and where a subjec t feels he/she can perform normal daily activities.  
‚Ä¢ A response comparable to or better than their normal response to PD medications prior to 
enrolling in the study. 
Full ‚ÄúON‚Äù as assessed by the Investigator ‚Äì defined as: 
‚Ä¢ Based on clinical judgment , it is the period of time  where the Investigator feels the 
medication is providing benefit with regard to mobility, stiffness and slowness and the 
subject  has adequate motor function to allow them to perform their norm al daily 
activities.  
Clinical confirmation of the ‚ÄúOFF‚Äù state must occur prior to dosing a subject  with study 
medication (or their standard L -Dopa dose at the second Screening Visit (SV2)). The same 
assessor should be utilized for each subject  throughout the study. 
Subject s must confirm they are in an ‚ÄúOFF‚Äù state prior to dosing with study medication (or their 
Sunovion Pharmaceuticals Inc.  Page 58 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 standard L -Dopa dose at the second Screening Visit (SV2)).  
The Investigator will assess ‚ÄúOFF‚Äù/‚Äù ON‚Äù state as part of the MDS -UPDRS Part III assessme nts.  
At each Dose Titration, the subject  will report the time when they turned to full ‚ÄúON‚Äù  (if 
applicable) and will  report  the time when they turned ‚ÄúOFF‚Äù following dosing (if it occurs within 
90 minutes of dosing). The timing of this should begin when t he subject is dosed with the study 
medication , APL -130277, and recorded with a suitable timing device. These times are to  be 
documented on the appropriate form of the CRF. 
12.6.3.2 MDS -UPDRS Part III  
The Motor Function section (Part III) of the MDS -UPDRS will be ad ministered at all visits 
where it is indicated.  
Administration will be performed at t = 0 (just prior to dosing) , 30, 60 and 90 minutes after 
dosing at the second Screening Visit (SV2)  and during the Dose Titration Phase.  
These assessments will exclude the ‚ÄúDyskinesia Impact on Part III Ratings‚Äù and the Hoehn and 
Yahr staging. The modified Hoehn and Yahr will be used during the Screening Visit ( SV2). 
The MDS -UPDRS can only be performed by the Principal Investigator or Sub- Investigator who 
has been trained  to perform this evaluation. In specific cases , another appropriately experienced 
and certified study staff member can perform the assessment if approved by the Sponsor. 
12.6.3.3 Pharmacokinetic  (PK) Evaluation  
Blood draws for PK analyses  on APL -130277 and placebo treatment  days will occur at t = 0 (just 
prior to dosing) , 30, 45, 60 minutes after dosing and at 2, 4 hours after dosing. On the 
moxifloxacin treatment day , blood draws will occur at t  = 0 (just prior to dosing), 30, 60 minutes 
after dosing and at 2, 3, 4, 6, 8 hours after dosing. Sampling should occur as close as possible to 
the target time.  
Instructions specific to PK draws will be outlined in the PK lab manual . 
 
 
Sunovion Pharmaceuticals Inc.  Page 59 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 13 ADVERSE  EVENTS  
Adverse events  will be recorded  from  the time of signing  of the ICF by the subject through to 
30 days after  study completion or earlier , if warranted  by a subject discontinuation. 
13.1.1  Definition  of Adverse Events  
An AE is any untoward medical occurrence in a subject  (or patient)  or clinical investigation 
subject (or patient) administered a pharmaceutical product that does not necessarily have a causal 
relationship with the product. An AE can therefore be any unfavorable and unintended sign 
(including a new, clinically important abnormal laboratory finding), symptom, or disease, temporally associated with the product, whether or not related to the product. 
Pre-existing  diseases  or conditions  will not be considered  AEs unless there is an increase in the 
frequency or severity, or a change in the quality, of the disease or condition. 
13.1.2  Definition  of Serious  Adverse Events  
An SAE  is any untoward  medical  occurrence that at any dose: 
‚Ä¢ Results  in death;  
‚Ä¢ Is life threatening; 
‚Ä¢ Requires  in-subject hospitalization  (being admitted)  or prolongation of existing  
hospitalization;  
‚Ä¢ Results  in permanent  (persi stent)  disability/incapacity;  
‚Ä¢ Is a congenital  anomaly;  
‚Ä¢ Is an important medical  event. 
Medical and scientific judgment should be exercised in deciding whether it is appropriate to consider other situations serious, such as important medical events  that may not be 
immediately life -threatening or result in death or hospitalization but may jeopardize the subject  
(or patient)  or may require intervention to prevent another of the outcomes listed in the definition 
above. 
Examples of such events are intensive treat ment in an emergency room or at home for allergic 
bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, or development of drug dependency or drug abuse. 
An elective hospital admission to treat a condition present before exposure to the investigational 
drug, or a hospital admission for a diagnostic evaluation of an AE, does not  qualify the condition 
or event as an SAE.  
A spontaneous abortion or congenital anomaly  in an infant  born to a mother  who was exposed  to 
Sunovion Pharmaceuticals Inc.  Page 60 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 the investigatio nal drug during  pregnancy is an SAE.  Because the effect of APL -130277 or 
apomorphine on human male reproduction has not been determined, a ll pregnancies ( in the 
subject or the subject's partner) will be documented on the Pregnancy Reporting Form with 
expressed consent. 
Due to the nature of subjects  being enrolled in this study, and the given study objectives, 
subjects  who are hospitalized  for their titration and Period  1, 2 and 3  visit ‚ÄúOFF‚Äù  episodes  
will not  be considered a SAE.  
13.1.3  Definition  of Severity  
The clinical  ‚Äúseverity‚Äù of an AE will be classified  as: 
Mild:  Causes no limitation of usual activities . 
Moderate:  Causes some limitation of usual activities . 
Severe:  Prevents or severely limits usual activities . 
 
13.1.4  Definition  of Start  Date,  Stop  Date,  and Duration  
Start  Date: The date at which  the AE is first noted. 
Stop Date: The date at  which  the AE is known to be resolved. If it is not known to 
have stopped, then indicate  ‚Äúongoing‚Äù . 
Duration : A time in days,  hours or minutes  (this is optional). 
 13.1.5  Action(s ) Taken  
Actions taken may consist of: 
None: No actions  taken.  
Discontinued Investigational
 
Drug:  Investigational drug was permanently  discontinued  because 
of the AE. 
Change Investigational Drug:  Investigational  drug was given  at a lower dose, at a longer  
interval between  doses, or was temporarily  withheld  
because of the AE. 
Sunovion Pharmaceuticals Inc.  Page 61 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 Treatment:  Specified medication  (to be listed  on the concomitant  
medication  chart)  was used as a countermeasure.  
Others:  Other  actions,  such as an operative procedure, were  
required  because of the AE.  
 
13.1.6  Definition  of Expectedness  
An expected AE is an AE for which the nature or severity  is consistent with the known AE 
profile of the product. For an investigational  drug, the known information  is contained  in the IB. 
For a marketed  product,  the known information  is contained  in the current  package insert  for the 
product. 
An unexpected  AE is an AE for which the specificity  or severity  is not consistent with the 
current IB.  For example, hepatic necrosis  would be unexpected  (greater  severity ) if the IB only 
listed  elevated  hepatic enzymes  or hepatitis. Likewise,  cerebral  thromboembolism and cerebral  
vasculitis  would be unexpected  (greater  specificity) if the IB only listed  cerebral  vascular  
accidents.  
Furthermore, reports that  add significant  information on specificity or severity of a known, 
already documented adverse reaction  constitute  unexpected events. Examples would be (a) acute 
renal failure as an expected  adverse reaction with a subsequent new occurrence of interstitial 
nephritis and ( b) hepatitis with a first  occurrence of fulminate hepatitis.  
13.1.7  Adverse Events of Special Interest  
Adverse events of special interest (AESI) for APL -130277 pertaining to irritation of the oral 
mucosa require immediate reporting (see Section  13.1.14) no matter if the event is serious or 
non-serious. These AESIs include, but are not limited to: 
‚Ä¢ Stomatitis  
‚Ä¢ Oral Ulcers  
Note: Per their discretion, Investigators may use other terminology and/or descriptors pertaining 
to irritation of the  oral mucosa.  
Other AESIs for APL -130277 should be immediately reported only if they meet the serious 
criteria or lead to the discontinuation of the subject from the study. These AESIs include: 
‚Ä¢ Changes in QT. 
‚Ä¢ Orthostatic Hypotension. 
Sunovion Pharmaceuticals Inc.  Page 62 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 13.1.8  Definition  of Relation ship to Investigational Drug(s)  
The categories  for classifying  the Investigator‚Äôs  opinion regarding  the relationship of an AE to 
investigational drug(s) are listed below: 
Certain:  An AE occurring  in a plausible time  relationship  to 
investigational drug  administration  and which  cannot be 
explained  by a concurrent disease or other drugs  or events.  
The response to  withdrawal  of the drug  (dechallenge) is 
clinically  reasonable.  
Probable (likely): An AE with a reasonable time  sequence to  administration  of 
the investigational drug  and which  is unlikely to be attributed  
to concurrent disease or other drugs  or events.  The response to  
withdrawal  of the drug  (dechallenge) is clinically  reasonable.  
Possible: An AE with a reasonable time  sequence to  administration  of 
the investigational drug,  but which could also be explained  by 
concurrent disease or other drugs  or events.  Information  on 
drug withdrawal  may  be lacking or unclear.  
Unlikely: An AE, including laboratory  test abnormality, with a temporal  
relationship  to in vestigational  drug administration  that makes a 
causal  relationship improbable and  in which  other drugs, 
events, or underlying disease provide plausible explanations. 
Not related:  An AE with  sufficient  evidence to accept  that there is no 
causal  relationship to  investigational drug  administration  (e.g.,  
no temporal  relationship  to drug administration,  because the  
drug was administered  after onset of event;  investigation  
shows that  the drug  was not administered; another cause was  
proven; etc.).  
13.1.9  Definit ion of Outcome  at the Time  of Last  Observation 
The outcome at the time of last observation will be classified  as: 
‚Ä¢ Resolved; 
‚Ä¢ Resolved  with sequelae;  
‚Ä¢ Ongoing;  
‚Ä¢ Death;  
Sunovion Pharmaceuticals Inc.  Page 63 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 ‚Ä¢ Unknown. 
Death should only be selected as an outcome when the AE resulted in death. If more than 1 AE is 
possibly related to the subject ‚Äôs death, the outcome of death should be indicated for the AE 
attributed as the cause of death in the death certificate or summary . 
13.1.10  Documentation  of Adverse Events  
The Investigator will monitor and/or ask about or evaluate AEs using non -leading questions at 
each visit or evaluation. The occurrence of all AEs will be documented in the CRF with the following information, where appropriate: 
‚Ä¢ AE name or term;  
‚Ä¢ When  the AE  first occurred  (start  date);  
‚Ä¢ When  the AE stopped (stop  date),  or an indication  of ‚Äúongoing‚Äù; 
‚Ä¢ How long the AE persisted  (optional); 
‚Ä¢ Severity  of the AE; 
‚Ä¢ Seriousness; 
‚Ä¢ Actions  taken;  
‚Ä¢ Outcome;  
‚Ä¢ Investigator opinion regarding  the relationship  of AE to the investigational  drug(s).  
13.1.11  Follow -up of Subjects  With  an Advers e Event  
Any AE will be followed to a satisfactory resolution, until it becomes stable, or until it can be explained by another known cause(s) (i.e., concurrent condition or medication) and clinical judgment indicates that further evaluation is not warrante d. All findings relevant to the final 
outcome of an AE must be reported in the subject ‚Äôs medical record . 
13.1.12  Special  Procedures  for Managing  AEs/ SAEs  and Need  for
 Unblinding 
If AEs occur  in a subject which are not tolerable, or for which continued administration of 
investigational drug is not reasonable  in view of the potential benefit to subject, the Investigator  
must decide whether to stop investigational treatment and/or treat the subject . Subject 
withdrawal should be avoided, if possible. If discontinuation of treatment occurs, every attempt 
should be made to restart study drug if medically appropriate, whatever the duration of discontinuation. 
13.1.13  Notification  of Serious  Adverse  Events  
The Investigator must  report all SAEs  and pregnancies promptly to Sunovion or its designee, by 
completing the SAE form and submit by email (or fax) within  24 hours of first
 becoming aware of 
Sunovion Pharmaceuticals Inc.  Page 64 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 the event. Email: sunovionsafety@druginfo.com or Fax: 1-855-278-6344. 
The Investigator will be able to contact  the study medical monitors. The North American 
Medical Monitor is Dr. Poonam Hundal  (mobile: +1 (919) 592- 1802 or email: 
Poonam.Hundal@incresearch.com ) and the European Union Medical Monitor  is 
Dr. Souad- Amel Kechairi (mobile: +33  (0) 6 13 56 67 03 or email: 
Souad- Amel.Kechairi@incresearch.com ). 
If a SAE is reported via telephone, the  Investigator must  follow  up the initial telephone 
notification by completing the SAE form and submit by email (or fax).  
At the time of the first notification of an SAE, the clinical  site should provide the following  
information to the contact  person, if available:  
‚Ä¢ Subject ‚Äôs study number and initials; 
‚Ä¢ Subject ‚Äôs date of birth ; 
‚Ä¢ Subject ‚Äôs gender; 
‚Ä¢ Date of first dose of investigational drug(s); 
‚Ä¢ Date of last dose of investigational drug(s), if applicable; 
‚Ä¢ AE term ; 
‚Ä¢ Time and date of occurrence of the event ; 
‚Ä¢ A brief description of the event, outcome to date, and any actions taken; 
‚Ä¢ The seriousness criteria(on) that were met ; 
‚Ä¢ Concomitant medication at onset of the event; 
‚Ä¢ Relevant medical history information ; 
‚Ä¢ Relevant laboratory test findings; 
‚Ä¢ Investigator‚Äôs opinion of the relationship to investigational drug(s); 
‚Ä¢ Whether and when the Investigator was unblinded as to the subject ‚Äôs treatment 
assignment . 
Any missing or additional relevant  information  concerning  the S AE should be provided in a 
written  follow-up report.  
The Sponsor  or designee  will promptly notify all clinical sites  and Investigators of a SAE that is 
determined to be expedited to the Regulatory Authorities  in accordance with  applicable law (s) 
and regulation(s ). These SAEs must be promptly reported to the Institutional Review Board 
(IRB) , Research Ethics Board  (REB),  or Independent Ethics Committee (IEC) by the 
Sunovion Pharmaceuticals Inc.  Page 65 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 Investigator or the appropriate person at the clinical site  if required per IRB/ REB/ IEC guidelines . 
13.1.14  Notification  of Adverse Events of Special Interest  
All AESIs pertaining to irritation of the oral mucosa  (Section  13.1.7) must be reported 
immediately to  the Sponsor  regardless of seriousness  or presumed relationship to study drug . All 
AESIs pertaining to irritation of the oral mucosa  are considered immediately reportable events 
and must be reported within 1 business day  of the Investigator or study center staff becoming 
aware of the event . 
Similarly, any AESI related to: 
‚Ä¢ Changes i n QT 
‚Ä¢ Orthostatic Hypotension  
that meet the serious criteria or leads to the discontinuation of the subject from the study 
(Section  13.1.7), regardless of presumed relationship to study drug, must be reported to the 
Sponsor within 1 business day of the Investigator or study center staff becoming aware of the 
event .  
AESI s that require immediate reporting should be submitted via Email: 
sunovionsafety@druginfo.com or by Fax: 1 -855-278-6344. 
 
 
Sunovion Pharmaceuticals Inc.  Page 66 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 14 TREATMENTS  
14.1 Treatments  Administered  
APL-130277 is a near square bilayer film containing apomorphine hydrochloride. APL -130277 
is intended for fast sublingual absorption for use in rescue therapy for acute intermittent ‚ÄúOFF‚Äù 
episodes experienced by PD subjects. APL -130277 bilayer is composed of 2 layers laminated 
together: a first layer is composed of cellulose -ether based film, containing drug substance, 
stabilizers and plasticizers; a second layer contains a pH -modifier (pyridoxine hydrochloride) 
contained within a similar cellulosic film bas e, flavor agents and a permeation enhancer . Buffer 
layer will be on the side of the sublingual film that has an alphanumeric printing. 
APL -130277 sublingual thin films will be provided in 5 strengths: 1 0 mg , 15 mg , 20 mg , 25 mg  
and 30 mg . Two sublingual thin films will be administered sequentially to form the 3 5 mg  dose , 
40 mg  dose , 50 mg  dose and 60 mg  dose (as described below ). In this study, placebo sublingual 
thin films will be prepared, which will be identical in appearance, size and colour, but contain no 
active ingredient (i.e., apomorphine).  Moxifloxacin  400 mg  tablets will be provided to the site for oral administration.  
14.2 Administration of Study Medication 
During all phases of this study; subjects  will be dosed by study staff.  
Dose Administration for APL -130277 and Placebo: 
Before dosing, the study staff will read out to subject s:  
‚ÄúThe product is a film . It will be placed against the bottom of the tongue . After the dose is placed 
in the mouth, close your mouth naturally. Let your tongue take a natural position. Do not move 
the tongue around to try to taste the drug or change its position. Just let it slowly dissolve in place. It will disso lve in 3 to 4 minutes. During that time try not to swallow saliva or the film. 
When the film is dissolved, raise  your hand to let the clinical staff know. We will ask that you 
open your mouth to show us.‚Äù 
Subjects will be instructed to consume a glass of water immediately prior to dosing, and staff 
will ensure the sublingual space is free of excess water.  
Using glo ved hands, or a single -use plastic disposable tweezers, staff will place the product 
beneath the tongue, with the drug side facing up and placed against  the bottom of the tongue 
(i.e., the side of the film that does not have  an alphanumeric printing), and ask subjects to close 
their mouth naturally. Subjects  should not swallow the medication and should also try not to 
swallow their saliva for at least 3 minutes. If, upon inspection at the 3 minute mark, the film is 
not completely dissolved, subjects  should be instructed to close their mouth and hold the study 
medication under their tongue for another minute (i.e., maximum of 4 minutes in total).  
Sunovion Pharmaceuticals Inc.  Page 67 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 If the subject feels the film has fully dissolved prior to the 3 minute mark, they should indicate 
this to staff by raising their hand, who will then verify. If upon inspection, the film is not 
completely dissolved, subjects  should be instructed to close their mouth again and hold the study 
medication under their tongue. Staff may verify at regular intervals, as appropriate, for a duration 
maximum of 4  minutes in total.  
To administer the 3 5 mg  dose, study staff will administer the 20 mg  sublingual thin film under 
the tongue  first, and then after 3 minutes has elapsed, immediately administer the 1 5 mg  
sublingual thin film for another 3 minutes (total dosing time should be 6 minutes) . 
To administer  the 4 0 mg  dose, study staff will administer the  20 mg  sublingual thin film under 
the tongue  first, and then after 3 minutes has elapsed, subjects will be instructed to consume 
approximately 1  teaspoon of water immediately prior to dosing the second 20 mg dose, and staff 
will ensure the sublingual space is free of excess water . The second 20 mg  sublingual thin film 
will be administered under the tongue for another 3  minutes (total dosing time should be 
6 minutes) . 
To adm inister the 5 0 mg  dose, st udy staff will administer the 2 5 mg  sublingual thin film under 
the tongue  first, and then after 3 minutes has elapsed, subjects will be instructed to consume 
approximately 1 teaspoon of water immediately prior to dosing the second 2 5 mg dose, and staff 
will ensure the sublingual space is free of excess water . The second 25 mg sublingual thin film 
will be administered under the tongue for another 3  minutes (total dosing time should be 
6 minutes) . 
To administer the 6 0 mg  dose, s tudy staff will administer the 3 0 mg  sublingual thin film under 
the tongue  first, and then after 3 minutes has elapsed, subjects will be instructed to consume 
approximately 1  teaspoon of water immediately prior to d osing the second 30 mg dose, and staff 
will ensure the sublingual space is free of excess water . The second 30 mg sublingual thin film 
will be administered under the tongue for another 3  minutes (total dosing time should be 
6 minutes) . 
Dose Administration for Moxifloxacin: 
A single dose of 400 mg  of moxifloxacin tablet will be administered orally to the subjects by 
study staff . The tablet should be swallowed whole with plenty of water; do not crush or chew the 
tablet.  
14.3 Storage 
The Investigator is responsible  for ensuring the proper storage of study medication according to 
procedures agreed in advance. Each Investigator is  required to keep investigational drug product 
in a locked cabinet or other secure storage contained with limited access to personnel. Temperature logs must be maintained for the storage room.  
Sunovion Pharmaceuticals Inc.  Page 68 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 APL -130277/Placebo : Unit dose pouches must be stored at controlled room temperature: 68-
77¬∞F (20-25¬∞C).  
Moxifloxacin: Tablets must be stored  at controlled room temperature 59-86oF (15-30¬∞C). Avoid 
freezing.  Store in the original package to protect from moisture. 
The Investigator must maintain accurate and adequate records including expiry dates, lot 
number, and quantities received, individual usage, etc. At the end of the study, t he Investigator 
must also return unused supplies to the Sponsor giving an account of usage in a trial whether or 
not the trial is completed or terminated. At the time of return to the Sponsor, the Investigator must verify that all unused or partially used drug supplies have been returned and that no 
remaining supplies are in the Investigator's possession. Certificates of delivery and returns must be signed and filed in the clinical site file . 
14.4 Packaging and Labeling  
Investigational drug product will be administered in the clinic.  
APL -130277 and Placebo:   
Each package of investigational drug product and matched placebo APL -130277 will be labeled 
with study specific information meeting all the applicable regulatory requirements, including specifying the dose of APL -130277. 
Individua l sublingual thin films of APL -130277 and matched placebo APL -130277 will be 
supplied packed in individual unit dose pouches. 
Moxifloxacin 400 mg  Tablets: 
Moxifloxacin film- coated tablets will be packaged according to the market authorization holder 
and l abeled with study specific information meeting all the applicable regulatory requirements .  
14.5 Drug  Accountability  
Drug  supplies, which will be provided by Sunovion or a CRO appointed by Sunovion, must be 
kept in a secure, limited access storage area.  
The Investigator, pharmacist, and/or investigational drug storage manager must maintain records of the product‚Äôs delivery to the trial site, the inventory at the site, the use by each subject , and the 
return to Sunovion of unused product(s). These records will include dates, quantities, batch/serial 
numbers, expiry dates, and the unique code numbers assigned to the investigational product(s) and trial subjects . The Investigator, pharmacist, and/or investigational drug storage manager will 
maintain records that doc ument adequately that the subjects  were provided the doses specified by 
the clinical trial protocol and reconcile all investigational product(s) received from Sunovion. At 
the time of return to Sunovion, the Investigator or site designate must verify that all unused or 
partially used drug supplies have been returned by the clinical trial subject and that no remaining 
Sunovion Pharmaceuticals Inc.  Page 69 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 supplies are in the Investigator‚Äôs possession. 
Note: If any of the investigational drug is not dispensed; is lost, stolen, spilled, unusable; or 
arrives at the clinical site in a damaged container, this information must be documented and 
reported to Sunovion and appropriate regulatory agencies as required. The investigational drug 
will only be administered to subjects  participating in this study . Only authorized clinical site 
personnel may supply or administer the investigational drug. 
14.6 Method  of Assigning  Subjects  to Treatment  Groups  
In the Dose Titration Phase, all s ubjects  will be assigned open -label APL -130277 treatment using 
an IWRS system . 
In the Three- Way Balanced Randomized Crossover Assessment Phase (Period 1, Period 2, 
Period  3) s ubjects will be randomized  using the Williams Design such that subjects are 
randomized in equal numbers to six possible sequences of each of the three treatments  being 
studied: 
1) APL -130277 at the dose determined  in the Dose Titration Phase,  
2) Matched placebo  APL -130277, 
3) A single 400 mg  dose of moxifloxacin. 
APL -130277 and placebo will be administered in a double -blind fashion and moxifloxacin will 
be admi nistered open- label in a three -way balanced crossover. The strength  of APL -130277 or 
placebo  (i.e., 10 mg , 15 mg, 20 mg , 25 mg , 30 mg , 35 mg , 40 mg , 50 mg , 60 mg) to be given will 
be determined based on safety/tolerability during the Dos e Titration Phase o f the study.  
14.7 ECG  Methodology: Central Laboratory 
ECGs obtained digitally using a continuous 12- lead Holter device will undergo central review . 
ECGs to be used in the analysis will be selected /extracted  at predetermined time points and will 
be read central ly using a high -resolution manual on- screen caliper semiautomatic method with 
annotations. Triplicate (3) 12 -lead ECGs at each timepoint specified will be downloaded from 
the continuous recording approximately one minute apart. The digital ECGs will underg o a 
treatment -blinded high- resolution measurement of the cardiac intervals and morphological 
assessment by a central cardiologist also blinded to the study treatment.  
Digital ECGs will be processed via the central core laboratory‚Äôs  validated data managemen t 
system, EXPERT. Interval duration measurements will be collected using computer assisted 
caliper placements on three consecutive beats . Trained analysts will review all ECGs for correct 
lead and beat placement and adjudicate the pre- placed algorithm calipers as necessary using a 
proprietary validated electronic caliper system applied on a computer screen (manual adjudication methodology). A cardiologist will then verify the interval durations and perform the 
Sunovion Pharmaceuticals Inc.  Page 70 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 morphology analysis . The ECG interval duration measurements will be performed in Lead II and 
when Lead II is not analyzable in Lead V5, when Lead V5 is not analyzable in Lead V2, 
followed by the most appropriate lead, if necessary. 
On-screen measurements of the RR, PR, QRS, and QT interval durations will be performed and 
heart rate, QTcF and QTcB will be derived by the following process: Interval measurements will be obtained by the following method:  
‚Ä¢ Three (3) R -R    mean R -R Interval is reported  
‚Ä¢ Three (3) PR    mean PR Interval is reported  
‚Ä¢ Three (3) Q RS   mean QRS Width is reported  
‚Ä¢ Three (3) QT    mean QT Interval is reported  
The following calculations will be made from the interval measurements: 
Three (3) QTcF measurements ‚ÄîQTc correction by the Fridericia‚Äôs formula  
‚Ä¢ QTcF1 = QT1/3‚àöRR1 
‚Ä¢ QTcF2 = QT2/3‚àöRR2 
‚Ä¢ QTcF3 = QT3/3‚àöRR3 
‚Ä¢ Mean QTcF = (QTcF1 + QTcF2 + QTcF3)/3  
Three (3) QTcB measurements - QTc correction by the Bazett‚Äôs formula  
‚Ä¢ QTcB1 = QT1/ ‚àöRR1 
‚Ä¢ QTcB2 = QT2/ ‚àöRR2 
‚Ä¢ QTcB3 = QT3/ ‚àöRR3 
‚Ä¢ Mean QTcB = (QTcB1 + QTcB2 + QTcB3)/3  
Three (3) Heart Rate measurements  
‚Ä¢ HR1 = 60 / RR1  
‚Ä¢ HR2 = 60 / RR2  
‚Ä¢ HR3 = 60 / RR3  
‚Ä¢ Mean HR = (HR1 + HR2 + HR3)/3  
Each fiducial point (onset of P wave, onset of Q wave, offset of S wave, and offset of T wave) 
will be marked . The original ECG waveform and such annotations will be saved separately in 
XML format for independent review. 
Sunovion Pharmaceuticals Inc.  Page 71 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 14.8 Randomization  
At Screening, the IWRS will assign a unique subject  identification number to the subject  known 
as the Screening Number. This number will be associated with the subject  throughout the study. 
Every subject  that signs an ICF must be entered into the IWRS regardless of eligibility in order 
to obtain a Screening Number. This 7- digit number will consist of a 4 -digit site ID followed by a 
3-digit number assigned sequentially wi thin each site starting at 001.  
Follow ing Sponsor approval  (additional details are available in the Enrollment a nd 
Randomization Adjudication Process, which is contained in a separate document) , subjects  will 
be randomized centrally at a study level after the Dose Titration Phase has been completed ( prior 
to Period 1 Dosing Visit 1) to one of the six  randomization sequences using the Williams design : 
1. APL -130277 ‚Äì P lacebo ‚Äì Moxifloxacin  
2. APL -130277 ‚Äì Moxifloxacin ‚Äì P lacebo  
3. Placebo ‚Äì Moxifloxacin ‚Äì APL -130277 
4. Placebo ‚Äì APL -130277 ‚Äì Moxifloxacin  
5. Moxifloxacin ‚Äì Placebo ‚Äì APL -130277 
6. Mox ifloxacin ‚Äì APL -130277 ‚Äì Placebo  
No stratification factors will be used. The randomization scheme will be designed by the study 
statistician. Once designed, an independent randomization expert will execute the randomiz ation 
in the IWRS. The 5- digit randomization number is used to identify the treatment sequence 
(APL -130277, placebo , moxifloxacin ) of the kits that will be assigned to the subject  during the 
Period  1, Period  2 and Period 3 of the Crossover Phase.  
A randomization number can only be assigned to one subject and cannot be reused once assigned.  
14.9 Blinding  
This study will be open -label during the Dose Titration Phase and for m oxifloxacin dosing 
during the Crossover Assessment Phase.  
APL -130277 and Placebo  Dosing V isits will be double -blinded. 
An IWRS will allocate treatment for Period 1 , Period 2 and Period 3 Dosing Visits based on a 
pre-specified randomization list, generated by the IWRS provider.  
For blinded Dosing Visits active and placebo study medication will be provided to each site 
participating in the study. For each dose, study medication and placebo packaging will be identical in size, shape, color and appearance. Investigators will not have access to the 
randomization (treatment) code except in case of a SAE. In this case, the code may be broken 
Sunovion Pharmaceuticals Inc.  Page 72 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 only in exceptional circumstances when knowledge of the study medication is essential for 
treating the subject. Subjects and study staff members will be blinded to treatment assignments 
until the completion of the study.  
A list of treatment kit numbers for each treatment sequence is generated centrally by the vendor 
selected by the Sponsor to perform this function, and the treatment kits are prepared in 
accordance with this list. Numbers will not be reused regardless of the status of the use of the corresponding study drug. 
Sunovion Pharmaceuticals Inc.  Page 73 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 15 STATISTICAL  ANALYSES  
15.1 Statistical  Analysis Plan 
Full statistical considerations  and complete analysis of data collected in this study will be 
specified in a formal Statistical Analysis Plan (SAP) . This section of the protocol prospectively 
outlines the analysis methods. The final SAP will be finalized prior to locking the database  and 
prior to unblinding any study data. The SAP will serve as a compl ement to the study protocol 
and supersedes it in case of differences. In case of major differences between the study protocol 
and SAP (e.g. changes in the analysis related to the primary endpoint), a protocol amendment 
will be considered.  
15.2 Analysis Populations 
15.2.1  Safety Analysis Set  
All subjects  who receive  at least one dose of study medication will be included in the safety 
analysis set. The safety analysis set will be used for the analysis of the safety endpoints and the 
subjects  will be grouped according to the treatment that they received.  
15.2.2  PK Analysis S et 
The PK analysis set includes all subjects  with at least one PK evaluation and will be used for the 
analysis of the PK data.  
15.2.3  Efficacy Analysis Set  
The efficacy analysis set includes subjects who have efficacy assessments at the lowest or 
highest dose lev el resulting in a full ‚ÄúON‚Äù . The efficacy analysis set will be used for the analysis 
of the efficacy data collected during the Dose Titration Phase.  
15.2.4  ECG and PK -PD Analysis  Sets 
The analysis populations for the ECG and pharmacokinetic -pharmacodynamic (PK -PD) analyses 
(Evaluable Population) will be comprised of all subjects who are randomized, receive at least one dose of study medication, and have at least one evaluable pre- dose ECG and one evaluable 
on-treatment post- dose ECG within the same Treatment Perio d. Additionally, for the PK -PD 
analysis (placebo corrected change in QTc vs . plasma concentration), a time -matched plasma 
concentration would also be necessary. 
15.3 Sample Size Calculation  
The study is powered to detect a mean difference in the change in QTcF between APL -130277 
and placebo  (‚àÜ‚àÜQTcF ) of 7  ms, assuming that the true difference between APL -130277 and 
placebo can be up to 3 ms, adding up to the predefined threshold of 10 ms. The standard 
deviation of  ‚àÜ‚àÜQTcF  is assumed to be 14 ms.
12 Assuming a one-s ided significance level of 0.05, 
Sunovion Pharmaceuticals Inc.  Page 74 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 42 subjects are required for the 3x3 cross -over phase to achieve approximately 80% power. 
15.4 ECG and Concentration- QTc Effect Analysis  
15.4.1  Primary E ndpoint  
The primary endpoint for this trial will be the time -matched change from  baseline in QTc, 
placebo -adjusted and corrected for HR based on the Fridericia correction method (QTcF) method 
(‚àÜ‚àÜQTcF).  
15.4.2  Secondary E ndpoints  
Secondary endpoints will include: 
‚Ä¢ QTc with Bazett correction (QTcB) ; 
‚Ä¢ Heart rate; 
‚Ä¢ PR interval ; 
‚Ä¢ QRS interval ; 
‚Ä¢ Uncorr ected QT interval ; 
‚Ä¢ ECG morphology. 
15.4.3  Central Tendency Analyses  
The primary analysis for the QT/QTc data in this study is based on the time -matched analysis for 
each treatment group. This time -matched analysis will be based upon the endpoint ‚Äúchange from 
baseline in the QTc F interval, placebo-adjusted ‚Äì ŒîŒî QTc.‚Äù Baseline is defined as the mean of 
the 9  ECGs (3 sets of triplicate ECGs) recorded at baseline (P1V1). Note that the measurements 
from the three ECGs collected at a time point are averaged to produce a single value for each 
ECG interval for that time point . These baseline and Day  1 post -dose ECG data, for each 
Treatment Period, will then be subjected to a mixed effects model (using the SAS Procedure PROC MIXED) with the following covariates: time (categorical), treatment, time by treatment interacti on, region, gender, and the baseline value of the parameter . Since this is a crossover 
design, period and sequence terms will necessarily also be included in the model . Subject will be 
included as a random effect . Gender  and region effects will be investig ated as specified below . 
Should a significant treatment by gender /region  interaction be observed, it will also be included 
in the model . The estimate s of the ŒîŒîQTc at each time point and its confidence intervals (CI) 
will be performed using a LSMEAN statement within PROC MIXED and a diff option. For this 
analysis a 90% two -sided confidence interval will be calculated. Hypotheses will be based upon 
the Intersection -Union test. Since the Intersection -Union test can be applied here, no multiple 
endpoint adjust ment is needed . Based on the ICH E14 guidance, the hypothesis will be evaluated 
by observing if any of the time points have a two -sided 90% upper confidence bound (i.e. one -
Sunovion Pharmaceuticals Inc.  Page 75 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 sided 95%) which is equal to, or exceeds, 10 ms.  
The upper limit of the two -sided 90% CI on treatment will be compared to the 10 ms bound only 
for APL -130277 versus placebo. If the upper limit of the two- sided 90% CI for APL -130277 
versus placebo falls below 10 ms, it will be concluded that  APL -130277 does not prolong the 
QTc interval to  a clinically significant degree.  
The 7 time points to be evaluated for the primary analysis include 15, 30, 45 60 minutes and 2, 3, 
and 4 hours post -dose. If only 1 or 2 of the 7 timepoints for APL -130277 just exceeded 10  ms, a 
determination of whether this is a false positive response relied on all of the study findings with 
special emphasis on the PK -PD model described below. 
The analysis also will be presented in a graphical manner: for each comparison of interest all CI‚Äôs (corresponding to the number of post -baseline time points) will be presented superimposed 
in one graph showing moxifloxacin and APL-130277, all of which have been placebo -adjusted . 
A similar analysis will be conducted for QTcB . 
15.4.4  Establishment  of Assay Sensitivity 
To establish assay sens itivity, there should be at least one time point where the lower confidence 
bound of the mean difference of moxifloxacin and placebo is greater than 5 ms . The same model 
as described for the time- matched analyses will be used for this analysis.  
The hypothe sis of assay sensitivity will be rejected if the lower limit of the one -sided 
(Bonferroni corrected) 95% confidence interval is never above 5 ms . However, detecting the 
positive control‚Äôs effect will establish the ability of the study to detect such an eff ect of the study 
drug. 
For purposes of determining assay sensitivity, 4 time points (i.e., hours 1, 2, 3, and 4) will be 
utilized for calculating the one -sided 95% (i.e. two- sided 90%) confidence limits . In this case, 
since the alternative hypothesis is that at least one of the time points is greater than or equal to 5 ms, a multiplicity adjustment is necessary . Therefore, the confidence intervals will be 
calculated using Bonferroni adjustment, specifically an adjusted alpha error level of 0.05/4 = 0.0125. Note that although only these time points will be used to assess assay 
sensitivity, the calculated upper and lower confidence bounds (Bonferroni -corrected) for the 
entire moxifloxacin profile will be displayed.  
15.4.5  Outlier Analyses  
An outlier or categorical an alysis supplements the central tendency analysis by determining if 
there were subjects who had an exaggerated effect on any ECG interval that would not be revealed in a mean change from baseline central tendency analysis. Each subject would be considered having an outlier value based on the most extreme value across all of the time points.  
The following criteria (‚Äústudy endpoints‚Äù) are defined for this analysis: 
Sunovion Pharmaceuticals Inc.  Page 76 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 ‚Ä¢ Heart rate: A value for a subject is considered to be an outlier at a pre -determined post -
dose time point if the heart rate measurement at that time point is <  50 bpm and the 
measure is at least a 25% decrease from the subject‚Äôs baseline mean heart rate (i.e., a 
bradycardic event) or if the heart rate measurement at the pre- determined post -dose time  
point is >  100 bpm and the measure is at least a 25% increase from the baseline mean 
heart rate (i.e., a tachycardic event).  
‚Ä¢ PR interval: A value for a subject is considered to be an outlier at a pre -determined post -
dose time point if the PR interval at that follow -up time point is >  200 ms and it is at least 
a 25% increase from the subject‚Äôs baseline mean PR interval.  
‚Ä¢ QRS interval: A value for a subject is considered to be an outlier at a pre -determined 
post- dose time point if the QRS interval at that f ollow- up time point is >  100 ms and it is 
at least a 25% increase from the subject‚Äôs baseline mean QRS interval.  
‚Ä¢ QT interval: A value for a subject is considered to be an outlier at a pre -determined post -
dose time point if the QT interval at that follow -up time point is >  500 ms and the 
subject‚Äôs baseline mean QT interval is ‚â§ 500 ms.  
‚Ä¢ QTcF: A value for a subject is considered to be an outlier at a pre -determined post -dose 
time point if the QTcF interval at that follow -up time point is >  500 ms and the subject‚Äôs 
baseline mean QTcF interval is ‚â§ 500 ms . Outlier values will also be presented if the 
QTcF interval at a pre -determined post -dose time point is >  480 ms when the subject‚Äôs 
baseline mean QTcF interval is ‚â§ 480 ms and when a pre -determined post -dose ti me 
point is >  450 ms when the subject‚Äôs baseline mean QTcF interval is ‚â§ 450 ms . In 
addition, the proportion of subjects with changes from baseline in >  30-60 ms and 
> 60 ms will be reported . 
‚Ä¢ QTcB: A value for a subject is considered to be an outlier at a pre-determined post -dose 
time point if the QTcB interval at that follow -up time point is >  500 ms and the subject‚Äôs 
baseline mean QTcB interval is ‚â§ 500 ms . Outlier values will also be presented if the 
QTcB interval at a pre- determined post -dose time point  is > 480 ms when the subject‚Äôs 
baseline mean QTcB interval is ‚â§ 480 ms and when a pre -determined post -dose time 
point is >  450 ms when the subject‚Äôs baseline mean QTcB interval is ‚â§ 450 ms . In 
addition, the proportion of subjects with changes from baseline in >  30-60 ms and 
> 60 ms will be reported.  
15.4.6  Morphologic  Analyses  
Morphological analyses will be performed with regard to the ECG waveform interpretation as defined by the central ECG laboratory‚Äôs cardiologist. Changes from baseline to on- treatment will 
be evaluated.  
Sunovion Pharmaceuticals Inc.  Page 77 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 All findings will be presented in the ECG listings . New onset findings will be presented as the 
percentage of subjects meeting the ‚Äúnew‚Äù criteria within each Treatment Period (‚Äúnew‚Äù means 
not present on any baseline ECG and becomes present on at  least one on -treatment ECG) for the 
following variables: 
‚Ä¢ Second degree heart block;  
‚Ä¢ Third degree heart block; 
‚Ä¢ Atrial fibrillation or atrial flutter ; 
‚Ä¢ Complete right bundle branch block;  
‚Ä¢ Complete left bundle branch block;  
‚Ä¢ ST segment change (elevation and  depression separately) ;  
‚Ä¢ T wave abnormalities (negative T waves only) ; 
‚Ä¢ Myocardial infarction pattern; and  
‚Ä¢ Any new abnormal U waves.  
15.4.7  Pharmacokinetic-Pharmacodynamic Analyses 
A concentration- QTc analysis will be conducted to evaluate the relationship between the 
placebo -corrected (placebo -adjusted) change from baseline in QTc intervals (QTcF and QTcB 
and plasma concentrations of APL -130277). The analysis will be done as a separate standalone 
analysis and a detailed PK modeling analysis plan (PMAP) will be generated to describe the planned evaluation. 
15.4.8  Safety Analysis 
Disposition  
The number of subjects  who failed the screening will be summarized along with the reason for 
exclusion. The premature discontinuation will be summarized by study phase and treatment 
group/dose level along with the reason for the discontinuation. 
Adverse events  
The adverse event data will be summarized for the overall APL -130277 treatment and further 
classified by the dose level at the time of the onset of the event. In addition, the adverse events starting during the placebo and moxifloxacin treatment will be summarized. Adverse events will be tabulated by treatment group and dose level according to the Medical Dictionary for Regulatory Activities (MedDRA). Treatment- emergent adverse events (TEAEs) will be 
summarized by body system and preferred term. Descriptive statistics will be used to compare the overall incidence of TEAEs between the treatment groups. 
Sunovion Pharmaceuticals Inc.  Page 78 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 Safety laboratory variables 
The changes in safety laboratory variables from Screen ing to the end of the study will be 
summarized with descriptive statistics or listed only.  
Vital signs  
The vital signs, including orthostatic blood pressure will be summarized with descriptive 
statistics as changes from pre-dose to post dose time point s by treatment group/dose level. 
Oral irritation  
The data on oral irritation will be summarized with descriptive statistics.  
The full details of the safety analysis will be provided in the SAP. 
15.5 Pharmacokinetic  Analysis  
The stand -alone non-compartmental PK analysis of the plasma PK concentration data will be 
described in details in a separate PK analysis plan (PKAP).  
Apomorphine levels and metabolites (norapomorphine and apomorphine sulphate) will be 
measured in plasma using a validated liquid chromatography -tandem mass spectrometry 
(LC-MS/MS) method . 
Pharmacokinetic parameters will be derived using noncompartmental methods employing a 
validated installation of Phoenix WinNonlin¬Æ version 6.3 or higher (Pharsight, St Louis, MO) 
software.  
The following PK paramete rs will be estimated or calculated using plasma apomorphine, 
norapomorphine and apomorphine sulphate concentration- time data. Other PK parameter may be 
calculated as appropriate. Actual elapsed time from dosing will be used to determine all 
individual PK parameters . 
Cmax Maximum drug concentration in plasma, determined directly from the 
concentration -time profile . 
Tmax Time of C max in plasma, determined directly from the concentration -time 
profile . 
AUC 0-t Area under the plasma concentration vs. time curve  from time of dosing to 
last measurable concentration, calculated using the linear up, log down 
trapezoidal rule.  
AUC inf AUC extrapolated to infinity (AUC last + last quantifiable concentration/ Œªz), 
calculated using the linear -up/log-down trapezoidal rule. 
Œªz The terminal phase rate constant; estimated by linear regression through the 
Sunovion Pharmaceuticals Inc.  Page 79 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 terminal phase of the log concentration -time profile, using at least 3 data 
points. 
t¬Ω The terminal phase half -life calculated as:  
zŒª) 2ln(t¬Ω=  
CL/F  Plasma clearance, calculated as Dose/AUC inf after single dose ( apomorphine only). 
MRT  Mean residence time calculated using the following equation: MRT = 
AUMC inf/AUC inf. AUMC inf is the area under the first moment curve.  
M/P Ratio  Metabolite to Parent exposure ratio (C max and AUC) . 
 
Linear and semi -log plots of the concentration- time data for apomorphine and metabolites will 
be presented by subject and treatment.  Plasma apomorphine and metabolites (norapomorphine and apomorphine sulphate) 
concentrations will be summarized using descriptive statistics (including N, mean, standard deviation (SD), coefficient of variation (CV%), median, minimum, and maximum) . 
Concentrations below the limit of quantitation (BLQ) will be treated as zero for the computation of descriptive statistics and for construction of mean concentration- time profiles.  
Actual elapsed time from dosing will be used to determine all individual PK parameters . Plasma 
PK parameters will be tabulated by dose level, and summary statistics that are presented will include the arithmetic and geometric mean, geometric CV%, SD of the arithmetic mean, median, minimum, maximum, and N.  
15.6 Efficacy Analysis  
The main  efficacy endpoint of this study is the change in MDS -UPDRS Part III at 30 minutes. 
The MDS -UPDRS Part III will  be analyzed using a Mixed Model for Repeated Measures with 
data from the lowest dose level resulting in a full ‚ÄúON‚Äù and at the highest tolerated dose level 
during the Titration Phase as response variables. The baseline (SV2) value will be included as a covariate and the day (1 = assessment at the lowest dose level resulting in a full ‚ÄúON‚Äù, 
2 = assessment at the highest tolerated dose level) and dose level (1 0 mg , 15 mg , 20 mg , 25 mg , 
30 mg , 35 mg , 40 mg , 50 mg , 60 mg ) as fixed factors in the model. Separat e models will be used 
for each time point (30, 60 and 90 minutes).  
The other efficacy endpoints will be analyzed with similar principles. These analyses will be 
defined in the SAP. 
Sunovion Pharmaceuticals Inc.  Page 80 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 16 STUDY CONDUCT  
Steps  to assure  the accuracy  and reliability  of data include  the selection of qualified Investigators 
and appropriate clinical  site, review of protocol procedures with the Investigator and associated 
personnel prior to the study, periodic monitoring visits, and meticulous data management. 
16.1 Regulations and Guidelines  
By signing this study protocol, the Investigator agrees to conduct this study in accordance with 
all laws, regulations and guidelines of the pertinent regulatory authorities, including and in accordance with the April 1996 ICH Guidance for Industry E6 GCP  and in agreement with the 
Declaration of Helsinki (including all applicable amendments). While delegation of certain aspects of the study to Sub- Investigators and study coordinators is appropriate, the Principal 
Investigator (PI) will remain personally ac countable for closely overseeing the study and for 
ensuring compliance with the protocol and all applicable regulations and guidelines. The PI is responsible for maintaining a list of all persons that have been delegated study -related 
responsibilities (e.g ., Sub- Investigators and study coordinators) and their specific study related 
duties. 
Investigators should ensure that all persons who have been delegated study -related 
responsibilities are adequately qualified and informed about the protocol, investigational drugs, 
and their specific duties within the context of the study. Investigators are responsible for providing Sunovion with documentation of the qualifications, GCP training, and research 
experience for themselves and their staff as required by Sunovion and the relevant governing 
authorities.  
See APPENDIX II: Regulations  and Guidelines  for additional information . 
16.2 Study  Initiation  
Clinical study staff may not screen or enroll subjects  into the study until receiving  notification 
from Sunovion or its designee that the study can be initiated at the clinical site. The clinical site 
will not be authorized for study initiation until:  
‚Ä¢ The Sponsor has received the appropriate Regulatory Authority/Agency approval for the 
protocol and ICF; 
‚Ä¢ The clinical site has received the appropriate IRB/REB/IEC approval for the protocol and 
the IRB/REB/IEC -approved ICF;  
‚Ä¢ The clinical site has a Clinical Trial Agreement in place;  
‚Ä¢ The clinical site personnel, including the Investigator, have participated in a study initiation meeting . 
Sunovion Pharmaceuticals Inc.  Page 81 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 16.3 Study  Documentation 
16.3.1  Investigator‚Äôs Regulatory Documents  
The regulatory documents listed below must be received from the Investigator and reviewed and 
approved by Sunovion or its designee before the clinical site c an initiate the study and before 
Sunovion will authorize shipment of investigational drug to the clinical site. Copies of the 
Investigator‚Äôs regulatory documents must be retained at the clinical site in a secure location. Additional documents, including a copy of the protocol and applicable amendment(s), the APL -130277 IB, copies of regulatory references, copies of IRB/REB/IEC correspondence, and 
investigational drug accountability records must be retained as part of the Investigator‚Äôs regulatory documents. It is the Investigator‚Äôs responsibility to ensure that copies of all required 
regulatory documents are organized, current, and available for inspection. 
Documents  Required  for Regulatory Packet:  
Confidentiality Agreement  Signed Clinical Trial Agreement  
Final Protocol  PI CV 
Final Protocol Amendments (if any)  PI Medical License  
Protocol Signature Pages  Sub-Investigator CV  
Protocol Amendment Signature Pages  
(if any)  Sub-Investigator License  
APL -130277 IB  IRB Approvals  
Signed  Financial  Disclosure  IRB Me mbership List / Assurance Statement  
Regulatory Agency Approval  Approved Informed Consent Template(s)  
 
Additional documentation requirements may be communicated by Sunovion staff (or it‚Äôs 
designate) . 
16.3.2  Case  Report  Forms  
As part of the responsibilities assumed by participating in the study, the Investigator agrees to 
maintain accurate CRFs and source documentation as part of the case histories for all subjects 
who sign an ICF. 
The vendor selected to perform CRF design will be responsible for drafting CRFs for the study, 
which Sunovion will review and approve before implementation. An electronic CRF may be 
used instead of paper CRFs, and the term CRF is synonymous for both types of CRFs. 
Sunovion Pharmaceuticals Inc.  Page 82 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 CRFs are considered confidential documents and should be handled and stored accordingly. 
Sunovion or its designee will provide the necessary training on the use of the specific CRF 
system used during the study to ensure that the information is captured accurately and appropriately. 
In order to ensure data accuracy, CRF data for individual subject visits should be completed as 
soon as possible following the visit in accordance with the site Clinical Trial Agreement in place . 
CRFs will be reviewed by the Clinical Research Associate (CRA) during monitoring visits. The 
CRA will ver ify data recorded with source documents. 
A copy of all the CRFs will be sent securely to Sunovion at the end of the study. 
If the study is managed using an Electronic Data Capture (EDC) system, the Investigator agrees to maintain accurate CRFs/EDC modules and source documentation as part of the case histories 
for all subjects  who sign an ICF.  
CRFs/EDC modules are considered confidential documents and should be handled and stored accordingly. Sunovion or its designee will provide the necessary training on th e use of the 
specific EDC system used during the study to ensure that the information is captured accurately and appropriately. 
In order to ensure data accuracy, EDC module data for individual subject  visits should be 
completed as soon as possible following the visit and in accordance with the site Clinical Trial 
Agreement in place. EDC data will be reviewed by the CRA during monitoring visits. The CRA 
will verify data recorded with source documents.  
All corrections or changes requested to the study data must be made as soon as possible by the study site, and verified by the Investigator. When all incorrect and/or inconsistent data has been accounted for, EDC data will be considered complete. 
The site is expected to notify the Study Medical Monitor before breaking the study blind, unless 
it is in the subject ‚Äôs best interest if the blind is broken immediately. All corrections or changes 
made to any study data must be appropriately tracked in an audit trail. When all incorrect and/or inconsistent data has been accounted for, CRFs will be considered complete. 
16.3.3  Source Documents  
All information recorded in the CRF must be supported by corresponding source documentation. 
Examples of acceptable source documentation include but are not limited to hospital records, clinic and office charts, laboratory notes, and recorded data from automated instruments, 
memoranda, and pharmacy dispensing records. If available, source documents for at least the 2 years prior to screening will be reviewed by the CRA to verify the subject ‚Äôs eligibility for the 
study.  
Original versions of the laboratory reports and ECG tracings will be retained at the clinical site 
Sunovion Pharmaceuticals Inc.  Page 83 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 with the subject‚Äôs  source documents . 
16.4 Data  Quality  Assurance 
Sunovion and its designees will perform quality control and assurance  checks on all clinical 
studies that it sponsors. Sunovion, or its designee, will be responsible for additional data quality 
assurance related to the clinical data being generated, entered and maintained as part of this 
clinical study . 
16.4.1  Monitoring the Study  
Clinical monitors will conduct site visits to the study facilities to monitor the study. The Investigator agrees to allow these monitors and other authorized Sunovion personnel access. T he 
clinical site will be monitored by Sunovion and/or it‚Äôs designate to ensure compliance with the 
protocol, GCP, and applicable regulations and guidelines. As representatives of Sunovion, CRAs 
are responsible for following the study protocol closely and notifying project management of any noted deviations. The assigned CRA (s) will visit the Investigator and clinical site at periodic 
intervals and maintain periodic communication. The CRA(s) will maintain current knowledge of the study through observation, review of study records and source documentation, and discussion of th e conduct of the study with the Investigator and staff. While on site, the CRA(s) will review 
regulatory documents, compare entries in the source documents, and review investigational drug accountability records. The CRA will ask for clarification and/or correction of any noted inconsistencies.  
By signing the protocol, the Investigator agrees to meet with the CRA during clinical site visits, to ensure that study staff is available to the CRA(s) as needed, to provide the CRA(s) access to all study documentation and medical records , to the clinical supplies dispensing and storage area, 
and agrees to assist the monitors in their activities, if requested. The Investigator also agrees to allow inspectors from regulatory agencies to review records and to assist the inspectors in their duties, if requested. 
16.4.2  Routine  Data  Collection  
CRFs will be reviewed by the CRA during monitoring visits. The CRA will verify data with 
source documents. If the CRA‚Äôs comparison of the original CRF data with source documents reveals data discrepancies or omissions that require study staff to make corrections, corrections will be made. After the CRF data have been monitored and all corrections have been made, the Investigator must appropriately document within the data system his/her agreement with the data contained therein. If corrections are required subsequent to the Investigator‚Äôs signature, the Investigator must document his/her agreement with the CRF data to confirm the accuracy of the changed data. A copy of all CRF data will be retained at the clinical site. If corrections are required after all data have been electronically transferred, corrections that have been made must be verified in writing by the Investigator, and new data provided to Sunovion. 
Sunovion Pharmaceuticals Inc.  Page 84 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 Should an EDC system be implemented, the CRA will verify data with source documents. If the 
CRA‚Äôs comparison of the original EDC module data with source documents reveals data discrepancies or omissions that require study staff to make corrections, the corrections will be made as outl ined in the Study Monitoring Plan. After  the EDC module data have been monitored 
and all corrections have been made, the Investigator must appropriately document within the data system his/her agreement with the data contained therein. If corrections are r equired subsequent 
to the Investigator‚Äôs signature, the Investigator must document his/her agreement with the EDC module data to confirm the accuracy of the changed data. A copy of all EDC module data will be retained at the clinical site. If corrections are required after all data have been electronically transferred, the corrections must be made as instructed in site training . 
16.4.3  Expedited Data  Collection  
Monitoring of selected CRF data may occur following the CRF submission, using data from the data system and source documents as necessary. Any post submission/transfer corrections of 
CRF data must be verified in writing by the Investigator, and new data provided to Sunovion. 
16.4.4  Data  Management  
A vendor contracted by Sunovion will provide the data management sys tem and data 
management services for the study. An EDC system may be implemented.  
Clinical site personnel will be responsible for providing  resolutions to all data queries.
 The 
Investigator will be required  to review  and document data to  ensure the  accurac y of the corrected  
and/or clarified  data. If an EDC system is implemented, this documentation will be electronic.  
Query  forms  or documentation must be generated and filed by the site. 
16.4.5  Study  Termination  
The study may be terminated at Sunovion‚Äôs discretion a t any time for any reason. If Sunovion 
discovers conditions that warrant early termination of the study, the Investigator will be notified 
by Sunovion or its designee. Examples of conditions that may warrant premature termination of 
the study include, but are not limited to the following:  
‚Ä¢ The discovery of an unexpected, serious, or unacceptable risk to the subjects enrolled in 
the study; and 
‚Ä¢ The decision on the part of Sunovion to suspend or discontinue testing, evaluation, or 
development of the investigational product. 
16.4.6  Clinical Site Closure  
On termination of the study, all screening and ongoing study related procedures conducted at the clinical site  will be closed. Sunovion may terminate participation of the clinical site at any time. 
Examples of conditions  that may warrant premature termination of a clinical site include, but are 
not limited to the following:  
Sunovion Pharmaceuticals Inc.  Page 85 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 ‚Ä¢ Noncompliance with the protocol and/or applicable regulations and guidelines; 
‚Ä¢ Inadequate subject enrollment; 
‚Ä¢ Administrative reasons . 
Sunovion Pharmaceuticals Inc.  Page 86 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 17 GENERAL  CONSIDERATIONS  
17.1 Changes to the Protocol 
This protocol cannot be altered or changed except through a formal protocol amendment, which 
requires the written approval of Sunovion. The protocol amendment must be signed by the 
Investigator and approved by the IRB /REB /IEC  before it may be implemented. Protocol 
amendments will be filed with the appropriate regulatory agency(s) having jurisdiction over the conduct of the study. 
17.2 Use of Information and Publication  
All information concerning APL -130277, Sunovion‚Äôs operations, patent applications, formulas, 
manufacturing processes, basic scientific data, and formulation information supplied by 
Sunovion to the Investigator and not previously published, is considered confidential and 
remains the sole property of Sunovion. The CRFs also remain the property of Sunovion. The 
Investigator agrees to use this information for purposes of study execution through finalization. 
The information developed in this study will be used by Sunovion in connection with the 
continued development of APL -130277 and thus may be disclosed as required to other clinical 
investigators or government regulatory agencies. Publication or other public presentation of APL -130277 data resulting from this study requires 
prior review and written approval of Sunovion, which will not be unreasonably withheld. 
Abstracts, manuscripts, and presentation materials should be provided to Sunovion for review at 
least 30 days prior to the relevant submission deadline. After publication of the results of the multi- center study or 24 months after the clinical study 
report has been finalized, whichever comes first, the Sponsor acknowledges the Investigator's 
rights to publish results from this study. Any such scientific paper, presentation, communication, or other information concerning the study described in this protocol must be submitted to the Sponsor for review prior to submission for publication/presentation. 
17.3 Records  Retention  
The Investigator shall retain and preserve 1 copy of all data generated in the course of the study, 
speci fically including but not limited to those defined by GCP as essential, for the longer of: (1) 
2 years after the last marketing authorization for the investigational drug has been approved or 
Sunovion has discontinued its research with respect to such drug ; or (2) such longer period as 
required by applicable global regulatory requirements. At the end of such period, the Investigator shall notify Sunovion in writing of its intent to destroy all such material. Sunovion shall have 
30 days to respond to the Investigator‚Äôs notice, and Sunovion shall have a further opportunity to 
retain such materials at Sunovion‚Äôs expense. 
Sunovion Pharmaceuticals Inc.  Page 87 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 17.4 Sample  Retention  
Samples may  be used for purposes related  to this research.  The samples  will be stored  until the 
study team  has determined  that specimens are no longer  needed  and the decision  has been  made  
that there are no samples  to be re-assayed.  In addition, identifiable  samples  can be destroyed  at 
any time at the request  of the subject . 
17.5 Subject  Injury  
In general, specific to provisions in t he clinical trial agreement, if a subject is injured as a direct 
result of a test artic le and the site, its staff and I nvestigators have followed the protocol and all 
documentation supporting the proper running of the trial, Sunovion will pay for reasonabl e and 
necessary medical treatment for the injury. If laws or regulations of the locality in which the 
study is taking place require additional payment of expenses, Sunovion shall comply with such 
laws or regulations. Where applicable, Sunovion has taken specific national insurance. 
Sunovion Pharmaceuticals Inc.  Page 88 
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 18 REFERENCES  
1) Tanner CM, Goldman SM. Epidemiology of Parkinson's disease. Neurol Clin. 
1996;14:317-35. 
2) Hornykiewicz O. Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway:  the view of an eyewitness. Neurodegener Dis. 
2008;5:114‚Äì7. 
3) Mouradian MM, Heuser IJ, Baronti F, et al. Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol. 1989;25(5):523-6. 
4) Stocchi F, Vacca L, Ruggieri S, et al. Intermittent vs. continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol. 2005;62(6):905-10. 
5) Ahlskog JE, Muenter MD. Frequency of levodopa- related dyskinesias and motor 
fluctuations as estimated from the cumulative lite rature. Mov Disord . 2001;16(3):448-58. 
6) APOMORPHINE treatment for morphine addiction. Br J Addict Alcohol Other Drugs . 
1949;46(2):93- 101. 
7) Cotzias GC, Papavasiliou PS, Fehling C, Kaufman B, Mena I. Similarities between neurologic effects of L -dipa and of apomorphine. N Engl J Med. 1970;282(1):31-3. 
8) Corsini GU, Del Zompo M, Gessa GL, Mangoni A. Therapeutic efficacy of 
apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease.  Lancet. 1979;1(8123):954-6. 
9) Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman- Tancredi A. 
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002;303(2):791-804. 
10) Schwab  RS, Amador LV, Lettvin  JY. Apomorphine in Parkinson's disease. Trans Am 
Neurol Assoc.  1951;56: 251‚Äì3. 
11) Wang BS, Wang XJ, Gong, LK. The Construction of a Williams Design and Randomization in a Cross- Over  Clinical Trials Using SAS. J Stat Softw. 2009;29(1):1 -10. 
12) Mendzelevski B, Sprenger CR, Spiegelstein O, Rabinovich- Guilatt L. Cardiac safety of 
rasagiline, a selective monoamine oxidase type B inhibitor for the treatment of Parkinson's disease: a thorough QT/QTc study. Int J Clin Pharmacol Ther. 2014 Mar;52(3):192-201. 
 
Sunovion Pharmaceuticals Inc.   
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 19 APPENDICES  
19.1 APPENDIX I: APOKYN¬Æ Prescribing  Information and APO -go¬Æ Summary of 
Product Characteristics  
https://www.apokyn.com/sites/all/themes/apokyn/content/resources/Apokyn_PI.pdf  
 
https://www.medicines.org.uk/emc/medicine/12941  
  
  
Sunovion Pharmaceuticals Inc.   
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 19.2 APPENDIX II: Regulations and Guidelines  
19.2.1  Declaration  of Helsinki  
The Policy  of the World  Medical  Association  is available at URL:  https://www.wma.net/policies -
post/wma -declaration -of-helsinki- ethical -principles- for-medical -research -involving-human-
subjects/  
19.2.2  Approval  by an IRB/REB/IEC  
This protocol must be reviewed and approved by a valid IRB /REB /IEC  prior to initiation of the 
study. Written notification of approval is to be submitted by the Investigator to Sunovion 
monitor prior to shipment of investigational drug supplies, and will include the date of the 
committee's approval and the chairperson's signature. This written approval will consist of a completed Institutional Review Board Approval form or Research Ethics Board Approval
 form,  
or written  documentation from  the IRB or REB  containing  the same inform ation. 
Until written approval by the IRB /REB /IEC  has been received by the Investigator, no subject 
may undergo any procedure solely for determining eligibility for this study.  
Protocol amendments must also be reviewed and approved by the IRB /REB /IEC . Written 
approval from the IRB /REB /IEC , or a designee, must be received by Sunovion, before 
implementation. This written approval will consist of a completed approval form , or written  
documentation from  the IRB/REB/IEC  containing  the same information.  
19.2.3  Regulatory  Authority/Agency  
For Investigational New Drug (IND) studies, the minimum standards of study conduct and 
requirements for informed consent are defined in the applicable regulations of the country in which the study is conducted. 
This protocol must be reviewed and approved by the country specific Regulatory 
Authority/Agency prior to initiation of the study . The Sponsor or authorized delegate will be 
responsible for the submission.  
 
  
Sunovion Pharmaceuticals Inc.   
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 19.3 APPENDIX III: Modified Hoehn and Yahr Scale  
Modified Hoehn & Yahr 
0: Asymp tomatic.  
1:  Unilateral involvement only.  
1.5:  Unilateral and axial involvement  
2:  Bilateral involvement without impairment of balance.  
2.5:  Mild bilateral disease with recovery on pull test.  
3:  Mild to moderate involvement; some postural instability b ut physically independent; 
needs assistance to recover from pull test.  
4:  Severe disability; still able to walk or stand unassisted.  
5:  Wheelchair bound or bedridden unless aided. 
 
  
Sunovion Pharmaceuticals Inc.   
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 19.4 APPENDIX IV: Movement Disorder Society - Unified Parkinson‚Äôs Disease Ra ting 
Scale (MDS -UPDRS)  
MDS-UPDRS Permissions  
 
Permission is required to use the MDS-developed Rating Scales (with the exception of 
pers
onal/individual use). Reproduction, translation, modification, sale, or distribution of any 
portion of the MDS Rating Scales is strictly prohibited. MDS Rating Scales may not be 
incorporated into clinical trials, training or certification programs or materials, software programs, 
or otherwise except through use of the Permissions Request Form  and payment of applicable 
fees. 
 
 
Continue to p. 2 to view the MDS-UPDRS  
 
____
____________________________________________________________________ 
 
Page 1   
                   MDS-UPDRS 
 
  
The Movement Disorder Society (MDS)-sponsored new version of the UPDRS is founded on the critique 
that was formulated by the Task Force for Rating Scales in Parkinson‚Äôs disease ( Mov Disord 2003;18:738-750).   
Thereafter, the MDS recruited a Chairperson to orga nize a program to provide the Movement Disorder 
community with a new version of the UPDRS that would maintain the overall format of the original UPDRS, but 
address issues identified in the critique as weakness es and ambiguities. The Chairperson identified 
subcommittees with chairs and members. Each part was written by the appropriate sub committee members 
and then reviewed and ratified 
by the entire gr oup. These members are listed below.  
 
 
The MDS- UPDRS has four parts:  Part I (non-mo tor experience s of daily living), Part II (motor 
experiences of daily living, Part III (motor examination) and Pa
rt IV (mot or complications).  Part I has two 
components: IA concerns a number of behaviors that ar e assessed by the investigator  with all pertinent 
information from patients and caregive
rs, and IB is co mpleted by the patient with or without the aid of the 
caregiver, but independen
tly of the investigator.  These sections can, however, be reviewed by the rater to 
ensure that all questions are answered clearly and the rater can help ex plain any perceived ambiguities. Part II
is designed to be a self-administered questionnaire like Part IB, but can be reviewed by the 
investigator to ensure completeness and clarity. Of note, the official versio ns of Part IA, Part IB and Pa rt II of
the MDS-UPDRS do not have separate on or off ratings.  However, for individual  programs or protocols the same
questions can be used separately for on and off. Part III has instructions for the rater to give or  demonstrate
to the patient; it is completed by the rater.  Part IV has instructions for th e rater and also instructions to be read
to the patient. This part integrates patient-derived information with the rater‚Äôs clinical observations and judgments 
and is completed by the rater.  
 
The authors of this new version are: 
 Chairperson:  Christopher G. Goetz 
Part I:  Werner Poewe (chair), Bruno Dubois, Anette Schrag 
Part II:  Matthew B. Stern (chair),  Anthony E. Lang, Peter A. LeWitt 
Part III:  Stanley Fahn (chair), Joseph Jankovic, C. Warren Olanow 
Part IV:  Pablo Martinez-Martin (chair), A ndrew Lees, Olivier Rascol, Bob van Hilten 
Development Standards: Glenn T. Stebbins (c hair), Robert Holloway, David Nyenhuis 
Appendices:  Cristina Sampaio (chair),  Richard Dodel, Jaime Kulisevsky 
Statistical Testing:  Barbara Tilley (chair), Sue Leurgans, Jean Teresi,  
Consultant:  Stephanie Shaftman, Nancy LaPelle 
 Contact person:  Christopher G. Goetz, MD 
Rush University Medical Center 1725 W. Harrison Street, Suite 755 
Chicago, IL USA 60612 
 
Telephone 312-942-8016 
Email: cgoetz@rush.edu  
 
 July 1, 2008
July 1, 2008 
July 1, 2008 
Page 2  Part I:  Non-Motor Aspects of Ex periences of Daily Living (nM-EDL)   
Overview:  This portion of the scale assesses the non- motor impact of Parkinson's disease (PD) on patients‚Äô 
experiences of daily living. There are 13 questions.  Part 1A  is administered by the rater (six questions) and focuses 
on complex behaviors.  Part 1B is a component of the self-administered Patient Questionnaire that covers seven 
questions on non-motor experiences of daily living.  
  
Part 1A:  In administering Part IA, the examiner should use the following guidelines: 
 
1.   Mark at the top of the form t he primary data source as patient, caregi ver, or patient and caregiver in equal 
proportion.     
2.   The response to each item should refer to a period encompassing the prior week including the day on which the 
information is collected.  
3.    All items must have an integer rating (no half points, no missing scores).  In the event that an item does not 
apply or cannot be rated (e.g., amputee who cannot walk), the item is marked UR for Unable to Rate. 
4.  The answers should reflect the usual level of function and words such as ‚Äúusually‚Äù, ‚Äúgenerally‚Äù, ‚Äúmost of the time‚Äù 
can be used with patients. 
5.  Each question has a text for you to read (Instruction s to patients/caregiver).  After that statement, you can 
elaborate and probe based on the target symptoms outlined in the Instructions to examiner.  You should NOT 
READ the RATING OPTIONS to the patient/caregiver, because these are written in medical terminology.  From 
the interview and probing, you will use your medica l judgment to arrive at the best response.  
6.  Patients may have co-morbidities and other medical condi tions that can affect their function.  You and the patient 
must rate the problem as it exists and do not attempt to  separate elements due to Parkinson‚Äôs disease from other 
conditions.   
EXAMPLE OF NAVIGATING THROUGH TH E RESPONSE OPTIONS FOR PART 1A  
 Suggested strategies for obtaini ng the most accurate answer: 
After reading the instructions to the patient, you will need to  probe the entire domain under discussion to determine 
Normal vs. problematic:  If your questions do not identify any problem in this domain, record 0 and move on to the 
next question.   
If your questions identify a problem in this domain, you sh ould work next with a reference anchor at the mid-range 
(option 2 or Mild) to find out if the patient functions at this  level, better or worse.  You will not be reading the choices of  
responses to the patient  as the responses use clinical terminology.  You will be asking enough probing questions to 
determine the response that should be coded.  
Work up and down the options with the patient to identify  the most accurate response, giving a final check by 
excluding the options above and below the selected response. 
Is this item normal for you? 
Consider mild (2) as a reference point 
and then compare with slight (1). 
Consider moderate (3) to see if this 
answer fits better. 
Consider severe (4) to see if this 
answer fits better. 
‚ÄòYes, severe is closest.‚Äô ‚ÄòNo, I have problems.‚Äô 
If mild is closer than slight. Mark (0) Normal. 
Confirm and mark (1) Slight. 
Confirm and mark (2) Mild. 
Confirm and mark (3) Moderate. 
Confirm and mark (4) Severe. If moderate is closer than mild. ‚ÄòYes‚Äô. 
‚ÄòYes, slight is closest‚Äô. 
‚ÄòNo, moderate is too severe‚Äô. 
‚ÄòNo, severe is too severe‚Äô. 
July 1, 2008
Page 3  
July 1, 2008                   MDS UPDRS 
Part I: Non-Motor Aspects of Expe riences of Daily Living (nM-EDL) 
 
Part 1A: Complex behaviors: [completed by rater]  
Primary source of information: 
  
 
  Patient    
 Caregiver    
 Patient and Caregiver in Equal Proportion  
 
To be read to the patient: I am going to ask you six questi ons about behaviors that you may or may not experience.  
Some questions concern common problems and some concern uncommon ones.  If you have a problem in one of the areas, please choose the best response that describes  how you have felt MOST OF THE TIME during the PAST 
WEEK. If you are not bothered by a problem, you can simply respond NO.  I am trying to be thorough, so I may ask 
questions that have nothing to do with you.  
SCORE 
 
 

  
1.1  COGNITIVE IMPAIRMENT   
Instructions to examiner: Consider all types of altered level of cognitive function including cognitive slowing, 
impaired reasoning, memory loss, defic its in attention and orientation. Rate their impact on activities of 
daily living as perceived by t he patient and/or caregiver. 
 Instructions to patients [and caregiver]: Over the past week have you had problems remembering things, 
following conversations, paying attention, thinking clea rly, or finding your way around the house or in town? 
[If yes, examiner asks patient or caregi ver to elaborate and probes for information]    
  
0:  Normal:        No cognitive impairment. 
 1:  Slight: Impairment appreciated by patient or ca regiver with no concrete interference with the 
patient‚Äôs ability to carry out normal ac tivities and social interactions. 
 2:  Mild: Clinically evident cognitive dysfun ction, but only minimal interference with the 
patient‚Äôs ability to carry out normal ac tivities and social interactions. 
 3:  Moderate: Cognitive deficits interfere with but  do not preclude the patient‚Äôs ability to carry out 
normal activities and social interactions. 
 4:  Severe: Cognitive dysfunction precludes the pati ent‚Äôs ability to carry out normal   activities and 
social interactions.  
   
___ ___ - ___ ___  - ___ ___ ___ ___     
(mm-dd-yyyy)     
Assessment Date  
____ ____ ____ 
 
Site ID  
____ ____ ____ ____ ____ ____ ____ ____ 
 
                 Patient Name or Subject ID 
  
____ ____ ____ 
 
Investigator‚Äôs Initials 
Page 4   
1.2  HALLUCINATIO NS AND PSYCHOSIS 
 
Instructions to examiner:  Consider both illusions (misinterp retations of real stimuli) and 
hallucinations (spontaneous false sensations). Consider all major sensory domains (visual, 
auditory, tactile, olfactory and gustatory). Determine presence of unformed (for example sense of presence or fleeting false impressions) as well as formed (fully developed and detailed) 
sensations. Rate the patients insight into hallucinations and identify delusions and psychotic 
thinking.   Instructions to patients [and caregiver]:
 Over the past week have you seen, heard, smelled or felt 
things that were not really there? [If yes, examiner asks patient or caregiver to elaborate and 
probes for information]   
0:  Normal:        No hallucinations or psychotic behaviour. 
 
1:  Slight: Illusions or non-formed halluci nations, but patient recognizes them without 
loss of insight. 
 2:  Mild: Formed hallucinations independent of environmental stimuli. No loss of 
insight. 
 3:  Moderate:    Formed hallucinations with loss of insight.  
4:  Severe:        Pati ent has delusions or paranoia. 
 
 SCORE 
 
 

 
 
1.3  DEPRESSED MOOD  
Instructions to examiner
: Consider low mood, sadness, hopeles sness, feelings of emptiness or 
loss of enjoyment. Determine their presence and duration over the past week and rate their interference with the patient‚Äôs ability to carry out  daily routines and engage in social interactions. 
 Instruction to the patient (and caregiver)
: Over the past week have you felt low, sad, hopeless or 
unable to enjoy things? If yes, was this feeling for longer than one day at a time? Did it make it difficult for you carry out your usual activities or to be with people? If yes, examiner asks patient or 
caregiver to elaborate and probes for information]   
 
0:  Normal:       No depressed mood.  
1:  Slight: Episodes of depressed mood that are not sustained for more than one day 
at a time. No interference with patient ‚Äôs ability to carry out normal activities 
and social interactions. 
 
2:  Mild:  Depressed mood that is sustaine d over days, but without interference with 
normal activities and social interactions.  
 
3:  Moderate: Depressed mood that interferes  with, but does not preclude, the patient‚Äôs 
ability to carry out normal activi ties and social interactions. 
 
4:  Severe: Depressed mood precludes patient‚Äôs  ability to carry out normal activities and   
social interactions.  
 
 
 
July 1, 2008
Page 5   
1.4  ANXIOUS MOOD  
Instructions to examiner:
 Determine nervous, tense, worried or an xious feelings (including panic attacks) 
over the past week and rate their duration and interf erence with the patient‚Äôs ability to carry out daily 
routines and engage in social interactions.   Instructions to patients [and caregiver]: 
Over the past week have you felt nervous, worried or tense? If 
yes, was this feeling for longer than one day at a time? Did it make it difficult for you to follow your usual 
activities or to be with other people ? [If yes, examiner asks patient or caregiver to elaborate and probes 
for information.]   
 
0:  Normal: No anxious feelings.  1:  Slight: Anxious feelings present but not sustained for more than one day at a time. No 
interference with patient‚Äôs ability to carry out  normal activities and social interactions. 
 2:  Mild: Anxious feelings are sustained over more than one day at a time, but without 
interference with patient‚Äôs ability to carry out  normal activities and social interactions. 
 3:  Moderate:  Anxious feelings interfere with, but do not preclude, the patient‚Äôs ability to carry out 
normal activities and social interactions. 
 4:  Severe:  Anxious feelings pr eclude patient‚Äôs ability to carry out normal activities and social 
interactions.  
 SCORE 
 
 

 
 
1.5  APATHY  
Instructions to examiner:
 Consider level of spontaneous activity , assertiveness, motivation and initiative 
and rate the impact of reduced levels on performance of  daily routines and social interactions. Here the 
examiner should attempt to distinguish between apathy  and similar symptoms that are best explained by 
depression. 
 
Instructions to patients (and caregiver): Over the past week, have you felt indifferent to doing activities 
or being with people? If yes, examiner asks patient or caregiver to elaborate and probes for information.]  
 
0:  Normal:  No apathy. 
 
1:  Slight: Apathy appreciated by patient and/or caregiver, but  no interference with daily 
activities and social interactions. 
 2:  Mild:  Apathy interferes with is olated activities and social interactions. 
 
3:  Moderate:   Apathy interferes with most activities and social interactions. 
 4:  Severe: Passive and withdrawn,  complete loss of initiative. 
 
July 1, 2008 
Page 6   
1.6  FEATURES OF DOPAMINE DYSREGULATION SYNDROME   
Instructions to examiner
: Consider involvement in a variety of  activities including atypical or 
excessive gambling (e.g. casinos or lottery tickets), atypical or excessive sexual drive or 
interests (e.g., unusual interest in pornography , masturbation, sexual demands on partner), 
other repetitive activities (e.g. hobbies, dismant ling objects, sorting or organizing), or taking 
extra non-prescribed medication for non-physical reasons (i.e., addictive behavior). Rate the 
impact of such abnormal activities/behaviors on the patient‚Äôs personal life and on his family and 
social relations (including need to borrow money or  other financial difficult ies like withdrawal of 
credit cards, major family conflicts, lost time fr om work, or missed meals or sleep because of the 
activity).  
Instructions to patients [and caregiver] :  Over the past week, have you had unusually strong 
urges that are hard to control?  Do you feel driven to do or think about something and find it 
hard to stop?  [Give patient examples such as gambling, cleaning, using the computer, taking extra medicine, obsessing about food or se x, all depending on the patients.   
 
0:  Normal:        No problems present.  
 
1:  Slight:  Problems are present but usually do not cause any difficulties for the patient or 
family/caregiver.  
 2:  Mild:  Problems are present and usually caus e a few difficulties in the patient‚Äôs personal 
and family life.  
 3:  Moderate: Problems are present and usually cause a lot of difficulties in the patient‚Äôs personal 
and family life.  
 4:  Severe:  Problems are present and preclu de the patient‚Äôs ability to carry out normal 
activities or social interactions or to maintain previous standards in personal and 
family life. 
 SCORE 
 
  

 
 
The remaining questions in Part I (Non-motor Experienc es of Daily Living) [Sleep, Daytime Sleepiness, Pain and 
Other Sensation, Urinary Problems, Constipation Proble ms, Lightheadedness on Standing, and Fatigue] are in the 
Patient Questionnaire along with all questions in Part II [Motor Experiences of Daily Living].   
July 1, 2008 
Page 7  
Instructions:   
 
This questionnaire will ask you about y our experiences of daily living.  
 There are 20 questions.  We are trying to be thorough, and some of these questions may 
therefore not apply to you now or ever.  If you do not have the prob lem, simply mark 0 for NO.  
 Please read each one carefully and read all answers before selecting the one that best applies to you.   We are interested in your average or usual f unction over the past week including today.  
Some patients can do things better at one time of the day than at other s.  However, only one 
answer is allowed for each question, so please ma rk the answer that best  describes what you 
can do most of the time
. 
 You may have other medical condi tions besides Parkinson‚Äôs disease.  Do not worry about 
separating Parkinson‚Äôs disease from other conditions.  Just  answer the question with your 
best response.     Use only 0, 1, 2, 3, 4 for answers, not hing else.  Do not leave any blanks.  
 Your doctor or nurse can review  the questions with you, but th is questionnaire is for patients 
to complete, either alone or with their caregivers.     
 
 Who is filling out this questionnaire (check the best answer): 

  Patient         
  Caregiver        
  Patient and Caregiver in Equal Proportion  Patient Questionnaire:   
July 1, 2008
Page 8 Part I: Non-Motor Aspects of Expe riences of Daily Living (nM-EDL)  
 
1.7  SLEEP PROBLEMS 
 
Over the past week, have you had trouble goi ng to sleep at night or staying asleep 
through the night? Consider how rested you fe lt after waking up in the morning.    
 
0:  Normal:  No problems. 
 
1:  Slight: Sleep problems are pres ent but usually do not cause trouble 
getting a full night of sleep.  
 2:  Mild:  Sleep problems usually caus e some difficulties getting a full night 
of sleep.  
 3:  Moderate: Sleep problem s cause a lot of difficulties getting a full night of 
sleep, but I still usually sleep fo r more than half the night.  
 4:  Severe:  I usually do not  sleep for most of the night. SCORE 
 
 

 
 
1.8  DAYTIME SLEEPINESS 
 
Over the past week, have you had trouble staying awake during the daytime?   
 
0:  Normal:  No daytime sleepiness. 
 
1:  Slight: Daytime sleepiness occurs but I can resist and I stay awake.  
 
2:  Mild:  Sometimes I fall asleep w hen alone and relaxing.  For example, 
while reading or watching TV. 
 
3:  Moderate:  I sometimes fall asleep when I should not.  For example, while  
eating or talking with other people. 
 
4:  Severe:  I often fall asleep when I should not.  For example, while eating or 
talking with other people.  
 
July 1, 2008
July 1, 2008
Page 9  
1.9  PAIN AND OTHER SENSATIONS 
 
Over the past week, have you had uncomfortabl e feelings in your body like pain, aches 
tingling or cramps?   
0:  Normal:  No uncomfortable feelings. 
 
1:  Slight:  I have these feelings. Ho wever, I can do things and be with other 
people without difficulty.  
 
2:  Mild:  These feelings cause some  problems when I do things or am with 
other people. 
 
3:  Moderate: These feelings cause a lo t of problems, but they do not stop me 
from doing things or being with other people.  
 
4:  Severe: These feelings stop me from doing things or being with other 
people. 
 SCORE 
 
 

 
 
1.10  URINARY PROBLEMS 
 
Over the past week, have you had trouble with  urine control?  For example, an  urgent 
need to urinate, a need to urinate t oo often, or urine accidents?  
 
0:  Normal: No urine control problems.  1:  Slight: I need to urinate often or  urgently.  However,  these problems do 
not cause difficulties with my daily activities.     
 2:  Mild: Urine problems cause some difficulties with my daily activities. 
However, I do not hav e urine accidents. 
 3:  Moderate: Urine problems cause a lot of difficulties with my daily activities, 
including urine accidents.   
 4:  Severe:  I cannot control my uri ne and use a protective garment or have a 
bladder tube.    
 
 
July 1, 2008
Page 10  
1.11  CONSTIPATION PROBLEMS 
 
Over the past week have you had constipation troubles that cause you difficulty moving your bowels?     
0:  Normal: No constipation. 
 
1:  Slight: I have been constipated.  I use extra effort to move my bowels.  
However, this problem does not dist urb my activities or my being 
comfortable.    
 
2:  Mild:  Constipation causes me to have some troubles doing things or 
being comfortable.    
 3:  Moderate: Constipation causes me to  have a lot of trouble doing things or 
being comfortable.  However, it  does not stop me from doing 
anything.   
 4:  Severe: I usually need physical help from someone else to empty my 
bowels.  SCORE 
 
 

 
 
1.12  LIGHT HEADEDNESS ON STANDING 
 
Over the past week, have you felt faint, di zzy or foggy when you stand up after sitting 
or lying down?   
0:  Normal:  No dizzy or foggy feelings. 
 
1:  Slight:  Dizzy or foggy feelings occur. However, they do not cause me 
troubles doing things. 
 
2:  Mild:  Dizzy or foggy feelings caus e me to hold on to something, but I do 
not need to sit or lie back down.   
 
3:  Moderate: Dizzy or foggy feelings cause me to sit or lie down to avoid 
fainting or falling.    
 
4:  Severe:  Dizzy or foggy feelin gs cause me to fall or faint.   
 
July 1, 2008
Page 11  
July 1, 2008   
1.13  FATIGUE 
 
Over the past week, have you usually felt fatigued?  This feeling is not  part of being 
sleepy or sad   
0:  Normal: No fatigue. 
 
1:  Slight:  Fatigue occurs.  Howeve r it does not cause me troubles doing 
things or being with people. 
  
2:  Mild:  Fatigue causes me some  troubles doing things or being with 
people. 
 
3:  Moderate:    Fatigue causes  me a lot of troubles doing things or being with 
people.  However, it does not st op me from doing anything.   
 
4: Severe: Fatigue stops me from doi ng things or being with people.   
  SCORE 
 
 

 
 
2.1  SPEECH 
 
Over the past week, have you had problems with your speech?  
 
0:  Normal: Not at all (no problems). 
 
1:  Slight: My speech is soft, slurred or uneven, but it does not cause others 
to ask me to repeat myself.  
 
2:  Mild: My speech causes people to ask me to occasionally repeat 
myself, but not everyday.       
 
3:  Moderate:  My speech is unclear e nough that others ask me  to repeat myself 
every day even though most of  my speech is understood.  
 
4:  Severe:  Most or all of my  speech cannot be understood.     
 Part II:  Motor Aspects of Expe riences of Daily Living (M-EDL)    
Page 12  
2.2   SALIVA & DROOLING    
 
Over the past week, have you usually had too much saliva during when you are awake 
or when you sleep?    
0:  Normal: Not at all (no problems). 
 
1:  Slight: I have too much saliva, but do not drool.    
 
2:  Mild: I have some drooling during sleep, but none when I am awake.   
  
3:  Moderate: I have some drooling when I am awake, but I usually do not need 
tissues or a handkerchief.     
 4:   Severe: I have so much drooling t hat I regularly need to use tissues or a 
handkerchief to protect my clothes. SCORE 
 
 

 
 
2.3  CHEWING AND SWALLOWING  
 
Over the past week, have you usually had problems swallowing pills  or eating meals? 
Do you need your pills cut or crushed or your meals to be made soft, chopped or blended to avoid choking?   
0:  Normal: No problems.   
 
1:  Slight: I am aware of slowness in  my chewing or increased effort at 
swallowing, but I do not  choke or  need to have my food specially 
prepared.  
   
2:  Mild: I need to have my pills cut or my food specially prepared because 
of chewing or swallowing problems,  but I have not choked over 
the past week.  
 
3:  Moderate. I choked at least once in the past week.   
 
4:  Severe: Because of chewing a nd swallowing problems, I need a feeding 
tube.  
 
July 1, 2008 
Page 13  
 July 1, 2008   
2.4  EATING TASKS 
 
Over the past week, have you usually had troubles handling your food and using 
eating utensils?  For example, do you hav e trouble handling finger foods or using 
forks, knifes, spoons, chopsticks?    
0:  Normal: Not at all (No problems). 
 
1:  Slight: I am slow, but  I do not  need any help handling my food and have 
not had food spills while eating. 
 
2:  Mild: I am slow with my eating and have occasional food spills.  I may 
need help with a few tasks such as cutting meat.    
 
3:  Moderate: I  need help with many eat ing tasks but can manage some alone.    
 
4:  Severe: I need help for most or all eating tasks. SCORE 
 
 

 
 
2.5  DRESSING 
 
Over the past week, have you usually had problems dressing?  For example, are you slow or do you need help with buttoning, us ing zippers, putting on or taking off your 
clothes or jewelry?   
0:  Normal: Not at all (no problems). 
 
1:  Slight: I am slow but I do not need help. 
 
2:  Mild: I am slow and need help for a few dressing tasks (buttons, 
bracelets).  
 
3:  Moderate: I need help for many dressing tasks.   
 
4:  Severe: I need help for most  or all dressing tasks.  
 
Page 14  
  July 1, 2008   
2.6  HYGIENE 
 
Over the past week, have you usually be en slow or do you need help with washing, 
bathing, shaving, brushing teeth, combing your hair or with other personal hygiene?   
0:  Normal: Not at all (no problems). 
 
1:  Slight: I am slow but I do not need any help. 
 
2:  Mild: I need someone else to help me with some hygiene tasks. 
 
3:  Moderate: I need help for many hygiene tasks.    
 
4: Severe: I need help for most or all of my hygiene tasks. 
 SCORE 
 

 
 
2.7  HANDWRITING 
 
Over the past week, have people usually  had trouble reading your handwriting?  
 
0:  Normal: Not at all (no problems). 
 
1:  Slight: My writing is slow, clum sy or uneven, but all words are clear.  
 
2:  Mild: Some words are unclear and difficult to read. 
 
3:  Moderate: Many words are unclear and difficult to read.   
      
4:  Severe: Most or all words cannot be read. 
 
 
 
2.8  DOING HOBBIES AND OTHER ACTIVITIES 
 
Over the past week, have you usually had trouble doing your hobbies or other things 
that you like to do?   
0:  Normal: Not at all (no problems). 
 
1:  Slight: I am a bit slow but  do these activities easily.   
 
2:  Mild: I have some difficulty doing these activities.  
 
3:  Moderate: I have major problems doi ng these activities, but still do most. 
 
4: Severe: I am unable to do most or all of these activities.  
 
 
Page 15  
 July 1, 2008 
2.9  TURNING IN BED 
 
Over the past week, do you usually have trouble turning over in bed?   
 
0:  Normal: Not at all (no problems). 
 
1:  Slight: I have a bit of trouble turning, but I do not need any help. 
 
2:  Mild I have a lot of trouble turning and need occasional help from 
someone else. 
 
3:  Moderate: To turn over I often need help from someone else. 
 
4:  Severe: I am unable to turn ov er without help from someone else.  
 SCORE 
 

 
 2.10  TREMOR 
 
Over the past week, have you us ually had shaking or tremor?  
 
0:  Normal: Not at all. I have no shaking or tremor. 
 1:  Slight: Shaking or tremor occu rs but does not cause problems with any 
activities.  
 2:  Mild: Shaking or tremor causes problems with only a few activities.   3:   Moderate: Shaking or tremor causes problems with many of my daily 
activities. 
 4:  Severe: Shaking or tremor causes  problems with most or all activities. 
 
 
2.11  GETTING OUT OF BED, A CAR, OR A DEEP CHAIR 
 
Over the past week, have you usually had tr ouble getting out of bed, a car seat, or a 
deep chair?    
0:  Normal: Not at all (no problems). 
 
1:  Slight: I am slow or awkward, but  I usually can do it on my first try. 
 
2:  Mild: I need more than one try to  get up or need occasional help. 
 3:  Moderate: I sometimes need help to get up, but most times I can still do it on 
my own. 
 
4:  Severe: I need help most or all of the time.  
 
 
Page 16  
 July 1, 2008   
2.12  WALKING AND BALANCE 
 
Over the past week, have you usually  had problems with balance and walking?  
 
0:  Normal: Not at all (no problems). 
 
1:  Slight: I am slightly slow or ma y drag a leg. I never use a walking aid. 
 
2:  Mild:   I occasionally use a walking aid, but I do not need any help from 
another person.   
 
3:  Moderate: I usually use a walking ai d (cane, walker) to walk safely without 
falling. However, I do not usually need the support of another person. 
 
4:  Severe: I usually use the support of  another persons to walk safely without 
falling. 
 SCORE 
      

 
 2.13  FREEZING 
 
Over the past week, on your usual day when walking, do you suddenly stop or freeze as if your feet are stuck to the floor.   
0:  Normal:  Not at all (no problems). 
 
1:  Slight: I briefly freeze but I can easily start walking again. I do not need 
help from someone else or a walking aid (cane or walker) because of freezing. 
 2:  Mild: I freeze and have trouble star ting to walk again, but I  do not need 
someone‚Äôs help or a walking aid (cane or walker) because of 
freezing. 
 3:  Moderate: When I freeze I have a lot of trouble starting to walk again and, 
because of freezing, I sometime s need to use a walking aid or 
need someone else‚Äôs help.    
 4:  Severe:  Because of freezing, mo st or all of the time, I need to use a 
walking aid or someone‚Äôs help.    
 
 
This completes the questionnaire.  We may have asked about problems you do not even have, 
and may have mentioned problems that you may never dev elop at all.  Not all patients develop all 
these problems, but because they can occur, it is important to ask all the questions to every 
patient.  Thank you for your time and attent ion in completing this questionnaire.    
Page 17  
  July 1, 2008  Part III:   Motor Examination    
 
Overview:  This portion of the scale assesses the motor signs of PD.  In administering Part III of the MDS-UPDRS  
the examiner sh
ould comply with the following guidelines: 
 At the top of the form, mark whether the patient is 
on m edication for treating the symptoms of Parkinson's disease 
and, if on levodopa, the time since the last dose.   
 
Also, if the patient is receiving medication for treating the symptoms of Parkinson‚Äôs Disease, mark the patient‚Äôs 
clinical state using the following definitions:  
ON is the typical functional state when patients ar e receiving medication and have a good response.   
OFF is the typical functional state when patients hav e a poor response in spite of taking medications. 
 The investigator should ‚Äúrate what you see‚Äù.  Admittedly,  concurrent medical problems such as stroke, paralysis, 
arthritis, contracture, and orthopedic problems such as hip or knee replacement and scoliosis may interfere with 
individual items in the motor examination.  In situations where it is absolutely impossible to test (e.g., amputations, 
plegia, limb in a cast), use the notation ‚Äú UR‚Äù for Unable to Rate.  Otherwise, rate the performance of each task as the 
patient performs in the context of co-morbidities. 
 
All items must have an integer rating (no half points, no missing ratings). 
 
Specific instructions are provided for the testing of each item.  These should be followed in all instances. The 
investigator demonstrates while describing tasks the patient is to perform and rates function immediately thereafter.  For Global Spontaneous Movement and Rest Tremor items (3.14 and 3.17 ), these items have been pla
 ced 
purposefully at the 
end of the scale because clinical inform ation pertinent to the score will be obtained throughout the 
entire examination.  At the end of the rating, indicate if dy skinesia (chorea or dystonia) was present at the time of the examination, and if 
so, whether these movements interfer ed with the motor examination.  
 
 
3a   Is the patient on medication for treating the sy mptoms of Parkinson‚Äôs Disease?        

 No    
 Yes 
   
 
3b    If the patient is receiving medication for tr eating the symptoms of Parkinson‚Äôs Disease,  
          mark the patient‚Äôs clin ical state using the following definitions:  
 

 ON:  On is the typical functional state when patie nts are receiving medication and have a good response.   
 

 OFF:  Off is the typical functional state when patient s have a poor response in spite of taking medications.   
 
3c   Is the patient on  Levodopa ?           
 No    
 Yes 
3.C1 If yes, minutes since last levodopa dose:  _____________   
 
Page 18  
  July 1, 2008   
3.1  SPEECH   
  
Instructions to examiner :    Listen to the patient‚Äôs free-flo wing speech and engage in conversation if 
necessary. Suggested topics: ask about the patient‚Äôs work, hobbies, exercise, or how he got to the 
doctor‚Äôs office. Evaluate volume, modulation (prosody) and clarity, including slurring, palilalia (repetition 
of syllables) and tachyphemia (rapid speech, running syllables together)
.  
 
0:  Normal: No speech 
problems. 
 
1:  Slight: Loss of modulation,  diction or volume, but still a ll words easy to  understand.  
 
2:  Mild: Loss of modulation, diction, or volu me, with a few words unclear, but the overall 
sentences easy to follow.    
 
3:  Moderate:   Speech is difficult to understand to the point that some, but not most, sentences are 
poorly understood.   
 
4:  Severe: Most speech is difficult to understand or unintelligible.  SCORE 
 
 

 
 
3.2  FACIAL EXPRESSION  
 
Instructions to examiner :  Observe the patient sitting at rest fo r 10 seconds,  without talking and also 
while talking.  Observe eye-blink frequency, masked facies or loss of facial expression, spontaneous 
smiling and parting of lips.  
 
0:  Normal: Normal facial expression. 
 
1:  Slight: Minimal masked facies manifested only by decreased frequency of blinking.  
 
2:  Mild: In addition to decreased eye-blink fr equency, Masked facies present in the lower 
face as well, namely fewer movements around the mouth, such as less spontaneous smiling, but lips not parted.  
 
3:  Moderate: Masked facies with lips parted some  of the time when the mouth is at rest.   
 
4:  Severe: Masked facies with lips parted most of the time when the mouth is at rest.  
 
Page 19  
 July 1, 2008   
3.3  RIGIDITY    
 
Instructions to examiner :  Rigidity is judged on slow passive movement of major joints with the patient in 
a relaxed position and the examiner manipulating the limbs and neck.  First, test without an activation 
maneuver.  Test and rate neck and each limb separately.  For arms, test the wrist and elbow joints 
simultaneously. For legs, test the hip and knee joints  simultaneously. If no rigidity is detected, use an 
activation maneuver such as tapping fingers, fist opening/closing, or heel tapping in a limb not being 
tested. Explain to the patient to go as limp as possible as you test for rigidity.   
 
0:  Normal:   No rigidity. 
 
1:  Slight:  Rigidity only detected with activation maneuver.   
 
2:  Mild:  Rigidity detected without the acti vation maneuver, but full range of motion is easily 
achieved.  
 
3:  Moderate: Rigidity detected without the activation maneuver; full range of motion is achieved 
with effort.   
 
4:  Severe: Rigidity detected without the activation maneuver and full range of motion not 
achieved.  
 SCORE 

 
Neck 
 

 
RUE 
 

 
LUE 
 

 
RLE 
 

 
LLE 
 
3.4  FINGER TAPPING    
 
Instructions to examiner : Each hand is tested separately.  Dem onstrate the task, but do not continue to 
perform the task while the patient is being tested.  Instruct the patient to t ap the index finger on the 
thumb 10 times as quickly AND as big as possible.   Rate each side separately, evaluating speed, 
amplitude, hesitations, halts and decrementing amplitude.   
0:  Normal:  No problems. 
 
1:  Slight: Any of the following: a) the regular rhythm is broken with one or two interruptions or 
hesitations of the tapping movement; b) s light slowing; c) the amplitude decrements 
near the end of the 10 taps. 
   
2:  Mild: Any of the following: a) 3 to 5 inte rruptions during tapping; b) mild slowing; c) the 
amplitude decrements midway in the 10-tap sequence.   
 
3:  Moderate: Any of the following: a) more than 5 interruptions during tapping or at least one 
longer arrest (freeze) in ongoing movement; b) moderate slowing; c) the amplitude 
decrements starting after the 1st tap.  
 
4:  Severe: Cannot or can only barely perform t he task because of slowing, interruptions or 
decrements.  
 
R 
 

 
L 
Page 20   July 1, 2008   
3.5  HAND MOVEMENTS 
 
Instructions to examiner : Test each hand separately.  Demons trate the task, but do not continue to 
perform the task while the patient is being tested.  Inst ruct the patient to make a tight fist with the arm 
bent at the elbow so that the palm faces the examiner.  Have the patient open the hand 10 times as fully AND as quickly as possible. If the patient fails to make a tight fist or to open the hand fully, remind him/
her to do so.  Rate each side separately, evaluating speed, amplitude, hesitations, halts and decrementing amplitude.  
0:  Normal:  No problem. 
 
1:  Slight: Any of the following: a) the regular rhythm is broken with one or two interruptions or 
hesitations of the movement; b) slight slowing; c) the amplitude decrements near 
the end of the task.  
 
2:  Mild: Any of the following: a) 3 to 5 inte rruptions during the movements; b) mild slowing; 
c) the amplitude decrements midway in the task.  
 
3:  Moderate: Any of the following: a) more than 5 interruptions during the movement or at least 
one longer arrest (freeze) in ongoing movement; b) moderate slowing; c) the 
amplitude decrements starting after the 1st open-and-close sequence. 
 
4:  Severe:       Cannot or can only barely perfo rm the task because of slowing, interruptions or 
decrements.  
 SCORE 
 
     

 
R 
 

 
L 
 
 3.6   PRONATION-SUPINATION MOVEMENTS OF HANDS     
 
Instructions to examiner
: Test each hand separately.  Demons trate the task, but do not continue to 
perform the task while the patient is being tested. Instruct the patient to extend the arm out in front of 
his/her body with the palms down; then to turn the palm up and down alternately 10 times as fast and as 
fully as possible. Rate each side separately, evaluating speed, amplitude, hesitations, halts and 
decrementing amplitude. 
 
0:  Normal:  No problems. 
 
1:  Slight: Any of the following: a) the regular rhythm is broken with one or two interruptions or 
hesitations of the movement; b) slight slowing; c) the amplitude decrements near 
the end of the sequence.  
 
2:  Mild: Any of the following: a) 3 to 5 inte rruptions during the movements; b) mild slowing; 
c) the amplitude decrements midway in the sequence.  
 
3:  Moderate: Any of the following: a) more than 5 interruptions during the movement or at least 
one longer arrest (freeze) in ongoing movement; b) moderate slowing c) the amplitude decrements starting after the 1st supination-pronation sequence. 
 
4:  Severe: Cannot or can only barely perform t he task because of slowing, interruptions or 
decrements.  
 
R 
 

 
L 
Page 21  
  July 1, 2008   
3.7  TOE TAPPING 
 
Instructions to examiner : Have the patient sit in a straight-backe d chair with arms, both feet on the floor. 
Test each foot separately. Demonstrate the task, but do not continue to perform the task while the 
patient is being tested. Instruct the patient to plac e the heel on the ground in a comfortable position and 
then tap the toes 10 times as big and as fast as po ssible. Rate each side separately, evaluating speed, 
amplitude, hesitations, halts and decrementing amplitude.  
0: Normal:  No problem. 
 
1:  Slight: Any of the following: a) the regular  rhythm is broken with one or two interruptions 
or hesitations of the tapping movement; b) slight slowing; c) amplitude decrements near the end of the ten taps.  
 
2:  Mild: Any of the following: a) 3 to 5 inte rruptions during the tapping movements; b) mild 
slowing; c) amplitude decrements midway in the task.  
 
3:  Moderate: Any of the following: a) more than 5 interruptions during the tapping movements 
or at least one longer arrest (freeze) in ongoing movement; b) moderate slowing; c) amplitude decrements after the first tap.   
 
4:  Severe: Cannot or can only barely perform t he task because of slowing, interruptions or 
decrements.  SCORE 
      

 
R 
 

 
L 
 
3.8 LEG AGILITY     
 
Instructions to examiner : Have the patient sit in a straight-backe d chair with arms.  The patient should 
have both feet comfortably on the floor. Test each leg separately. Demonstrate the task, but do not 
continue to perform the task while the patient is being tested. Instruct the patient to place the foot on the 
ground in a comfortable position and then raise and stomp the foot on the ground 10 times as high and 
as fast as possible. Rate each side separately , evaluating speed, amplitude, hesitations, halts and 
decrementing amplitude.  
 
0:  Normal:  No problems. 
 
1:  Slight:   Any of the following: a) the regular rhythm is broken with one or two interruptions 
or hesitations of the movement; b) slight slowing; c) amplitude decrements near the end of the task.  
 
2:  Mild:  Any of the following: a) 3 to 5 interruptions during the movements; b) mild 
slowness; c) amplitude decrements midway in the task.   
 
3:  Moderate: Any of the following: a) more than 5 interruptions during the movement or at least 
one longer arrest (freeze) in ongoing movement; b) moderate slowing in speed; c) 
amplitude decrements after the first tap.  
 
4:  Severe: Cannot or can only barely perform t he task because of slowing, interruptions or 
decrements.  
 
R 
 

 
L 
Page 22   July 1, 2008   
3.9  ARISING FROM CHAIR     
Instructions to examiner:
 Have the patient sit in a straight-backed chair with arms, with both feet on the 
floor and sitting back in the chair (if the patient is not too short).  Ask the patient to cross his/her arms 
across the chest and then to stand up.  If the patient  is not successful, repeat this attempt a maximum 
up to two more times.  If still unsuccessful, allow the patient to move forward in  the chair to arise with 
arms folded across the chest.  Allow only one attempt in this situation.  If unsuccessful, allow the patient to push off using his/her hands on the arms of the chai r.  Allow a maximum of three trials of pushing off.  
If still not successful, assist the patient to arise.  After the patient  stands up, observe the posture for item 
3.13  
0:  Normal:  No problems. Able to arise quickly without hesitation.   1:  Slight: Arising is slower than normal ; or may need more than one attempt; or may 
need to move forward in the chair to arise.  No need to use the arms of the chair.  
 
2:  Mild:  Pushes self up from arms of chair without difficulty. 
 3:  Moderate:   Needs to push off, but tends to fall back; or may have to try more than one time 
using arms of chair, but can get up without help. 
 4:  Severe:   Unable to arise without help.  SCORE 
 
 

  
 
3.10  GAIT         
Instructions to examiner:
  Testing gait is best performed by having the patient walking away from and 
towards the examiner so that both right and left sides of the body can be easily observed 
simultaneously.  The patient should walk at least 10 meters (30 feet), then turn around and return to the 
examiner. This item measures multiple behaviors: stride amplitude, stride speed, height of foot lift, heel 
strike during walking, turning, and arm swing, but not freezing. Assess also for ‚Äúfreezing of gait‚Äù (next 
item 3.11) while patient is walking.    Observe posture for item 3.13 
 
0:  Normal:   No problems. 
 
1:  Slight:  Independent walking with minor gait impairment.    
  
2:  Mild:  Independent walking but with substantial gait impairment.  
 
3:  Moderate:   Requires an assistance device for safe walking (walking stick, walker) but not a 
person.   
 
4: Severe:  Cannot walk at all or only with another person‚Äôs assistance.  
    Testing gait is best performed by having the patient walking away from and 
towards the examiner so that both right and left sides of the body can be easily observed 
simultaneously.  The patient should walk at least 10 meters (30 feet), then turn around and return to the 
examiner. This item measures multiple behaviors: stride amplitude, stride speed, height of foot lift, heel strike during walking, turning, and arm swing, but not freezing. Assess also for ‚Äúfreezing of gait‚Äù (next 
item 3.11) while patient is walking.    Observe posture for item 3.13 
 
0:  Normal:   No problems. 
 
1:  Slight:  Independent walking with minor gait impairment.    
  
2:  Mild:  Independent walking but with substantial gait impairment.  
 
3:  Moderate:   Requires an assistance device for safe walking (walking stick, walker) but not a 
person.   
 
4: Severe:  Cannot walk at all or only with another person‚Äôs assistance.  
  
Page 23     
   July 1, 2008   
3.11  FREEZING OF GAIT  
Instructions to examiner:
  While assessing gait, also assess for the presence of any gait freezing 
episodes.  Observe for start hesitation and stuttering movements especially when turning and reaching the end of the task.  To the extent  that safety permits, patients may NOT use sensory tricks during the 
assessment.   
 
0:  Normal:           No freezing. 
 
1:  Slight:              Freezes on starting, tu rning or walking through doorway with a single halt during 
any of these events, but t hen continues smoothly without freezing during straight 
walking. 
 
2:  Mild:                 Freezes on starting, turning or walking through doorway with more than one halt 
during any of these activities, but c ontinues smoothly without freezing during 
straight walking. 
 
3:  Moderate:         Freezes once during straight walking.  
 4:  Severe:             Freezes multiple times during straight walking.  SCORE 
 
   

  
 3.12 POSTURAL STABILITY    
   
Instructions to examiner
:  The test examines the response to sudden body displacement produced by a 
quick, forceful  pull on the shoulders while the patient is  standing erect with eyes open and feet 
comfortably apart and parallel to each other.  Test  retropulsion.  Stand behind the patient and instruct 
the patient on what is about to happen. Explain that s/he is allowed to take a step backwards to avoid 
falling. There should be a solid wall behind the examiner, at least 1-2 meters away to allow for the observation of the number of retropulsive steps. The first pull is an instructional demonstration and is purposely milder and not rated.  The second time the shoulders are pulled briskly and forcefully towards 
the examiner with enough force to displace the cent er of gravity so that patient MUST take a step 
backwards.  The examiner needs to be ready to catch t he patient, but must stand sufficiently back so as 
to allow enough room for the patient to take severa l steps to recover independently.  Do not allow the 
patient to flex the body abnormally forward in antici pation of the pull.  Observe for the number of steps 
backwards or falling.  Up to and including two steps for recovery is considered normal, so abnormal 
ratings begin with three steps.  If the patient fails to understand the test, the examiner can repeat the 
test so that the rating is based on an assessment that the examiner feels reflects  the patient‚Äôs limitations 
rather than misunderstanding or lack of prepar edness.  Observe standing posture for item 3.13 
 
0:  Normal:  No problems:  Recovers with one or two steps.   
 
1:  Slight:  3-5 steps, but subject recovers unaided.   
 
2:  Mild: More than 5 steps, but subject recovers unaided. 
 
3:  Moderate: Stands safely, but with absence of  postural response; falls if not caught by 
examiner. 
 
4:  Severe:  Very unstable, tends to lose bal ance spontaneously or with just a gentle pull on 
the shoulders.  
  
Page 24   July 1, 2008   
3.13  POSTURE  
   
Instructions to examiner : Posture is assessed with the patient st anding erect after arising from a chair, 
during walking , and while being tested for postural refl exes.  If you notice poor posture, tell the patient 
to stand up straight and see if the posture improves (see option 2 below).  Rate the worst posture seen in these three observation points.  Observe for flexion and side-to-side leaning.  
 
0:  Normal:  No problems. 
 
1:  Slight:   Not quite erect, but posture could be normal for older person. 
 
2:  Mild:   Definite flexion, scoliosis or leaning to one side, but patient can correct posture to 
normal posture when asked to do so.  
 3:   Moderate: Stooped posture, scoliosis or leaning to one side that cannot be corrected 
volitionally to a normal posture by the patient.  
 
4: Severe: Flexion, scoliosis or leanin g with extreme abnormality of posture.  
 SCORE 
 
 

  
 
3.14  GLOBAL SPONTANEITY OF MOVEMENT (BODY BRADYKINESIA) 
 Instructions to examiner
:  This global rating combines all observations on slowness, hesitancy, and 
small amplitude and poverty of movement in general, including a reduction of gesturing and of crossing the legs.  This assessment is based on the exam iner‚Äôs global impression after observing for 
spontaneous gestures while sitting, and the nature of arising and walking.  
 
0:  Normal:   No problems. 
 
1:  Slight:   Slight global slowness and poverty of spontaneous movements.  
 
2:  Mild:  Mild global slowness an d poverty of spontaneous movements.  
 
3:  Moderate: Moderate global slowness  and poverty of spontaneous movements.   
 
4: Severe:  Severe global slowness and  poverty of spontaneous movements.  
 
  
 3.15  POSTURAL TREMOR  OF THE HANDS   
 Instructions to examiner
: All tremor, including re-emergent rest tremor , that is present in this posture is 
to be included in this rating.  Rate each hand separa tely. Rate the highest amplitude seen.  Instruct the 
patient to stretch the arms out in front of the body  with palms down.  The wrist should be straight and 
the fingers comfortably separated so that they do not touch each other. Observe this posture for 10 seconds. 
 
0:  Normal:   No tremor.  
 
1:  Slight:  Tremor is present but less than 1 cm in amplitude.  
 
2:  Mild:   Tremor is at least 1 but less than 3 cm in amplitude.  
 
3:  Moderate: Tremor is at least 3 but less than 10 cm in amplitude.  
 
4: Severe:   Tremor is at least 10 cm in amplitude.  
 
 
R 
 

 
L , that is present in this posture is 
to be included in this rating.  Rate each hand separa tely. Rate the highest amplitude seen.  Instruct the 
patient to stretch the arms out in front of the body  with palms down.  The wrist should be straight and 
the fingers comfortably separated so that they do not touch each other. Observe this posture for 10 seconds. 
 
0:  Normal:   No tremor.  
 
1:  Slight:  Tremor is present but less than 1 cm in amplitude.  
 
2:  Mild:   Tremor is at least 1 but less than 3 cm in amplitude.  
 
3:  Moderate: Tremor is at least 3 but less than 10 cm in amplitude.  
 
4: Severe:   Tremor is at least 10 cm in amplitude.  
 
 
R 
 

 
L : All tremor, including re-emergent rest tremor
Page 25  
 July 1, 2008   
3.16  KINETIC TREMOR OF THE HANDS   
 
Instructions to examiner :  This is tested by the finger-to-nose maneuver. With the arm starting from the 
outstretched position, have the pati ent perform at least three finger-to-nose maneuvers with each hand 
reaching as far as possible to touch the exam iner‚Äôs finger. The finger-to-nose maneuver should be 
performed slowly enough not to hide any tremor that c ould occur with very fast arm movements. Repeat 
with the other hand, rating each hand separately.  The tremor can be present throughout the movement 
or as the tremor reaches either target (nose or finger).  Rate the highest amplitude seen.  
0:  Normal:   No tremor.   
1:  Slight:   Tremor is present but less than 1 cm in amplitude.  
 
2:  Mild:   Tremor is at least 1 but less than 3 cm in amplitude.  
 
3:  Moderate: Tremor is at least 3 but less than 10 cm in amplitude.  
 
4: Severe: Tremor is at least 10 cm in amplitude.  
 SCORE 
 

 
R 
 

 
L 
 
3.17   REST TREMOR AMPLITUDE     
Instructions
 to examine r: This and the next item have been placed purposefully at the end of the
e rater to gather observations on rest tremor that may appear at any time
en quietly sitting, during walkin g and during activities when some body p
t rest.  Score the maximum amp litude that is seen at any time as the fin
 and not the persistence or the intermittency of the tremor. 
e patient should sit quietly  in a chair with the hands placed on the arms  
examination to allow th  during 
the exam, including wh arts are 
moving but others are a al score. 
Rate only the amplitude
As part of this rating, th of the 
chair (not in the lap) and the feet comfortably supported on the floor for 10 seconds with no other 
directives.  Rest tremor is assessed separately for a ll four limbs and also for the lip/jaw.  Rate only the 
maximum amplitude that is seen at any time as the final rating.       
 
Extremity ratings    
0:  Normal:  No tremor.  
 1:  Slight.: < 1 cm in maximal amplitude.  
 
2:  Mild: > 1 cm but < 3 cm in maximal amplitude.  
 
3:  Moderate: 3 - 10 cm in maximal amplitude.    
       
4:  Severe: > 10 cm in maximal amplitude.  
   
Lip/Jaw ratings  0:  Normal:  No tremor.  
  
1:  Slight: < 1 cm in maximal amplitude.  
  
2:  Mild: > 1 cm but < 2 cm in maximal amplitude.  
  
3:  Moderate: > 2 cm but < 3 cm in maximal  amplitude.  
   
4:  Severe: > 3 cm in maximal amplitude.    
  
 
RUE 
 

 
LUE 
 

 
RLE 
 

 
LLE 

 
Lip/Jaw 
Page 26   July 1, 2008   
3.18  CONSTANCY OF REST TREMOR   
Instructions to examiner
: This item receives one rating for all rest tremor and focuses on the constancy 
of rest tremor during the examination period when differ ent body parts are variously at rest.  It is rated 
purposefully at the end of the examination so that se veral minutes of information can be coalesced into 
the rating. 
 
0:  Normal:   No tremor.  
 
1:  Slight:   Tremor at rest is present  < 25% of the entire examination period.  
 
2:  Mild:   Tremor at rest is present 26-50% of the entire examination period.  
 
3:  Moderate: Tremor at rest is present 51-75% of the entire examination period.  
 
4:  Severe: Tremor at rest is present > 75% of the entire examination period.  
 SCORE 
 
  
 
  
 
 

  
 
DYSKINESIA IMPACT ON PART III RATINGS  
A.  Were dyskinesias (chorea or dystonia) present during examination?       
 No    
 Yes 
 
B.  If yes, did these movements interfere with your ratings?                          
 No    
 Yes  
 
 
HOEHN AND YAHR STAGE 
       0:  Asymptomatic. 
       1:  Unilateral involvement only.        2:  Bilateral involvement without impairment of balance.        3:  Mile to moderate involvement; so me postural instability but physically independent; needs 
assistance to recover from pull test. 
       4:  Severe disability; still able to walk or stand unassisted.        5:  Wheelchair bound or bedridden unless aided.  
  
  July 1, 2008                                                                                                                                                                                                                                        Page 27 Part IV:  Motor Complications   
 
Overview and Instructions:  In this section, the rater us es historical and objective information to assess two motor 
complications, dyskinesias and motor fluctuations that incl ude OFF-state dystonia.  Use all information from patient, 
caregiver, and the examination to ans wer the six questions that summarize function over the past week including 
today.  As in the other sections, rate using only integers ( no half points allowed) and leave no missing ratings.  If the 
item cannot be rated, place UR for Unable to Rate. You will need to choose some answers based on percentages, 
and therefore you will need to establis h how many hours generally are awake hours and use this figure as the 
denominator for ‚ÄúOFF‚Äù time and Dyskinesias.  For ‚ÄúOFF dy stonia‚Äù, the total ‚ÄúOff‚Äù time will be the denominator.    
Operational definitions for examiner‚Äôs use.    
Dyskinesias: Involuntary random movements 
Words that patients often recognize for dyskinesias include ‚Äúirre gular jerking‚Äù, ‚Äúwiggling‚Äù, ‚Äútwi tching‚Äù.  It is essential to 
stress to the patient the difference between dyskinesia s and tremor, a common error when patients are assessing 
dyskinesias .   
 
Dystonia: contorted posture, oft en with a twisting component:   
Words that patients often recognize for dystoni a include ‚Äúspasms‚Äù, ‚Äúcramps‚Äù, ‚Äúposture‚Äù.   
 Motor fluctuation:  Variable response to medication:  
Words that patients often recognize for motor fluctuation in clude ‚Äúwearing out‚Äù, ‚Äúwearing off‚Äù, ‚Äúroller-coaster effect‚Äù, 
‚Äúon-off‚Äù,  ‚Äúuneven medication effects‚Äù.   
 
OFF:  Typical functional state when pati ents have a poor response in spite of ta king mediation or the typical functional 
response when patients are on NO treatment for parkinsonism.  Words that patients often recognize include ‚Äúlow 
time‚Äù, ‚Äúbad time‚Äù, ‚Äúshaking time‚Äù, ‚Äúslow ti me‚Äù, ‚Äútime when my medications don‚Äôt work.‚Äù 
 
ON:  Typical functional state when patients are receiving medication and have a good response:  
Words that patients often recognize include ‚Äúgood time‚Äù,  ‚Äúwalking time‚Äù, ‚Äútime when my medications work.‚Äù 
 
A .  DYSKINESIAS [exclusive of OFF-state dystonia]   
 
4.1 TIME SPENT WITH DYSKINESIAS  
Instructions to examiner:
  Determine the hours in the usual  waking day and then the hours of 
dyskinesias.  Calculate the percenta ge.  If the patient has dyskinesias in the office, you can point them 
out as a reference to ensure that patients and caregivers understand what they are rating. You may also 
use your own acting skills to enact the dyskinetic mo vements you have seen in the patient before or 
show them dyskinetic movements typical of other pat ients.  Exclude from this question early morning 
and nighttime painful dystonia.  Instructions to patient [and caregiver].
   Over the past week,  how many hours do you usually sleep on a 
daily basis, including nighttime sleep and daytime napping? Alright, if you sleep ___ hrs, you are awake ____ hrs.  Out of those awake hours, how many hours in total do you have wiggling, twitching or jerking 
movements?  Do not count the times when you have tremor, which is a regular back and forth shaking 
or times when you have painful foot  cramps or spasms in 
 the early mo rning or at nighttime.  I will ask 
about those later.   Concentrate only on these types of wigg ling, jerking and irregular m ovements.  Add 
up all the time during the waking day when these usually occur.  How many hours ____ (use this 
number for your calculation).   
 
0:  Normal:   No dyskinesias. 
 
1:  Slight:  ‚â§ 25% of waking day. 
 
2:  Mild: 26 - 50% of waking day. 
 
3:  Moderate: 51 - 75% of waking day. 
 
4:  Severe: > 75% of waking day.  
 
 

  
1.  Total Hours Awake:                     _____ 
 
2.  Total Hours with Dyskinesia:       _____  
3.  % Dyskinesia = ((2/1)*100):      _____    Over the past week,  how many hours do you usually sleep on a 
daily basis, including nighttime sleep and daytime napping? Alright, if you sleep ___ hrs, you are awake 
____ hrs.  Out of those awake hours, how many hours in total do you have wiggling, twitching or jerking 
movements?  Do not count the times when you have tremor, which is a regular back and forth shaking 
or times when you have painful foot  cramps or spasms in the early mo rning or at nighttime.  I will ask 
about those later.   Concentrate only on these types of wigg ling, jerking and irregular movements.  Add 
up all the time during the waking day when these usually occur.  How many hours ____ (use this 
number for your calculation).   
 
0:  Normal:   No dyskinesias. 
 
1:  Slight:  ‚â§ 25% of waking day. 
 
2:  Mild: 26 - 50% of waking day. 
 
3:  Moderate: 51 - 75% of waking day. 
 
4:  Severe: > 75% of waking day. SCORE 
 
 

  
1.  Total Hours Awake:                     _____ 
 
2.  Total Hours with Dyskinesia:       _____  
3.  % Dyskinesia = ((2/1)*100):      _____ 
Page 28   July 1, 2008   
4.2 FUNCTIONAL IMPACT OF DYSKINESIAS  
 
Instructions to examiner:   Determine the degree to which dyskinesias impact on the patient‚Äôs daily 
function in terms of activities and social interactions.  Use the patient‚Äôs and caregiver‚Äôs response to your 
question and your own observations during the o ffice visit to arrive at the best answer.  
  Instructions to patient [and caregiver]:
 Over the past week, did you usually have trouble doing things or 
being with people when these jerking movements occurred?  Did they stop you from doing things or from being with people? 
 
0:  Normal: No dyskinesias or no impact by dyskinesias on activities or social interactions.  
1:  Slight: Dyskinesias impact on a few acti vities, but the patient usually performs all 
activities and participates in all social interactions during dyskinetic periods.   
 2:  Mild: Dyskinesias impact on many activi ties, but the patient usually performs all 
activities and participates in all social interactions during dyskinetic periods.    
 3:  Moderate: Dyskinesias impact on activities to the point that the patient usually does not 
perform some activities or does not usually participate in some social activities 
during dyskinetic episodes.    
 
4:  Severe: Dyskinesias impact on function to the point that the patient usually does not 
perform most activities or participate in most social interactions during dyskinetic episodes.  
 SCORE 
 
 

  
 
4.3  TIME SPENT IN THE OFF STATE   
Instructions to examiner:
  Use the number of waking hours deri ved from 4.1 and determine the hours 
spent in the ‚ÄúOFF‚Äù state.  Calcul ate the percentage.  If the patient has an OFF period in the office, you 
can point to this state as a reference. You may al so use your knowledge of the patient to describe a 
typical OFF period.  Additionally you may use y our own acting skills to enact an OFF period you have 
seen in the patient before or show them OFF function  typical of other patients.  Mark down the typical 
number of OFF hours, because you will need this number for completing 4.6   Instructions to patient [and caregiver]:     Some patients with Parkinson's disease have a good effect 
from their medications throughout their awake hours and we call that ‚ÄúON‚Äù time.   Other patients take their medications but still have some hours of low ti me, bad time, slow time or shaking time.  Doctors 
call these low periods ‚ÄúOFF‚Äù time. Ov er the past week, you told me before that you are generally awake  
____ hrs each day. Out of these awake hours,  how many  hours in total do you usually have this type of 
low level or OFF function  ____ (Use this number for your calculations). 
 0:  Normal:   No OFF time. 
 
1:  Slight:  ‚â§ 25% of waking day. 
 
2:  Mild: 26 - 50% of waking day. 
 
3:  Moderate: 51 - 75% of waking day. 
 
4:  Severe: > 75% of waking day. 
  B . MOTOR FLUCTUATIONS 
1.  Total Hours Awake:       _____ 
 
2.  Total Hours OFF:           _____  
3.  % OFF = ((2/1)*100):      _____   Use the number of waking hours deri ved from 4.1 an d determi ne 
 the hours 
spent in the ‚ÄúOFF‚Äù state.  Calcul ate the percentage.  If the patient has an OFF period in the office, you 
can point to this state as a reference. You may al so use your knowledge of the patient to describe a 
typical OFF period.  Additionally you may use y our own acting skills to enact an OFF period you have 
seen in the patient before or show them OFF function  typical of other patients.  Mark down the typical 
number of OFF hours, because you will need this number for completing 4.6  
 Instructions to patient [and caregiver]:
1.  Total Hours Awake:       _____ 
 
2.  Total Hours OFF:           ____ _ 
 
3. 
 % OFF = ((2/1)*100):      _____ 
Page 29    
   July 1, 2008   
4.4  FUNCTIONAL IMPACT OF FLUCTUATIONS   
Instructions to examiner:
  Determine the degree to which motor fluctuations impact on the patient‚Äôs daily 
function in terms of activities and social interact ions.  This question concentrates on the difference 
between the ON state and the OFF state.  If the pat ient has no OFF time, the rating must be 0, but if 
patients have very mild fluctuations, it is still possible to be rated 0 on th is item if no impact on activities 
occurs. Use the patient‚Äôs and caregiver‚Äôs response to your question and your own observations during 
the office visit to arrive at the best answer.    Instructions to patient [and caregiver]:
 Think about when those low or ‚ÄúOFF‚Äù periods have occurred over 
the past week.  Do you usually have more problems doing things or being with people than compared to the rest of the day when you feel your medicati ons working? Are there some things you usually do 
during a good period that you have trouble with or stop doing during a low period?  
0:  Normal: No fluctuations or No impact by  fluctuations on performance of activities or 
social interactions.  
 
1:  Slight: Fluctuations impact on a few acti vities, but during OFF, the patient usually 
performs all activities and participates in all social interactions that typically 
occur during the ON state.   
 2:  Mild: Fluctuations impact many activiti es, but during OFF, the patient still usually 
performs all activities and participates in all social interactions that typically 
occur during the ON state.   
 
3:  Moderate: Fluctuations i
mpact on the performan ce of activities during OFF to the point that 
the patient usually does not perform some activities or participate in some social interactions that are performed during ON periods.    
   
4:  Severe: Fluctuations impact on function to the point that, during OFF, the patient usually 
does not perform most activities or partic ipate in most social interactions that 
are performed during ON periods.  
 SCORE 
 
  
 
  
 
  
 
 
  

  
 4.5  COMPLEXITY OF MOTOR FLUCTUATIONS  
 
Instructions to examiner:
  Determine the usual predictability of OFF function whether due to dose, time 
of day, food intake or other factors.  Use the information provid ed by the patients and caregiver and 
supplement with your own observations. You will ask if the patient can count on them always coming at 
a special time, mostly coming at a special time (in wh ich case you will probe furt her to separate slight 
from mild), only sometimes coming at a special time  or are they totally unpredictable?   Narrowing down 
the percentage will allow you to find the correct answer.   Instructions to patient [and caregiver]:
  For some patients, the low or ‚ÄúOFF‚Äù periods happen at  certain 
times during day or when they do activities like eati ng or exercising. Over the past week, do you usually 
know when your low periods will occur?  In other words, do your low periods always  come at a certain 
time?  Do they mostly  come at a certain time? Do they only sometimes  come at a certain time?  Are 
your low periods totally unpredictable?‚Äù  
0:  Normal: No motor fluctuations.  
 
1:  Slight:   OFF times are predictable all or almost all of the time (> 75%). 
 
2:  Mild:   OFF times are predictable most of the time (51-75%). 
 
3:  Moderate: OFF times are predictable some of the time (26-50%).  
4: Severe: OFF episodes are rarely predictable. (<
 25%).  
  
Page 30  
 July 1, 2008C. ‚ÄúOFF‚Äù DYSTONIA    
 
4.6  PAINFUL OFF-STATE DYSTONIA   
 
Instructions to examiner :  For patients who have motor fluctuat ions, determine what proportion of the 
OFF episodes usually includes painful dystonia? Y ou have already determined the number of hours of 
‚ÄúOFF‚Äù time (4.3). Of these hours, determine how ma ny are associated with dy stonia and calculate the 
percentage.  If there is no OFF time, mark 0. 
 
Instructions to patient [and caregiver]:    In one of the questions I asked earlier, you said you generally 
have ___ hours of low or ‚ÄúOFF‚Äù time when your Parkinso n's disease is under poor control.  During these 
low or ‚ÄúOFF‚Äù periods, do you usually have painful cramps or spasms?  Out of the total ____ hrs of this 
low time, if you add up all the time in a day when these painful cramps come, how many hours would 
this make?  
 
0:  Normal:  No dystonia OR NO OFF TIME.    
1:  Slight: < 25% of time in OFF state.  
2:  Mild:  26-50% of time in OFF state. 
 3:  Moderate: 51-75% of time in OFF state.  
 
4:  Severe: > 75% of time in OFF state. 
  
Summary statement to patient :  READ TO PATIENT 
 This completes my rating of your Parkinson‚Äôs disease.  I know the questions and tasks have taken several minutes, 
but I wanted to be complete and cover all possibilities. In  doing so, I may have asked about problems you do not even 
have, and I may have mentioned problems that you may never develop at all.  Not all patients develop all these 
problems, but because they can occur, it is important to ask all the questions to every patient.  Thank you for your time 
and attention in completing this scale with me.  
 1.  Total Hours Off:                       _____ 
 
2.  Total Off Hours w/Dystonia:           _____ 
                   
3.  % Off Dystonia = ((2/1)*100):         _____  
Copyright ¬© 2008 Movement Disorder Society.  All rights reserved. 
This chart may not be copied, distributed or otherwise used in whole or in part without prior written consent of the Movement D isorder Society  
________________________ _ ___ ___ ___ ___ ___ - ___ ___  - ___ ___ ___ ___ ___ ___ ___ 
Patient Name or Subject ID Site ID  (mm-dd-yyyy) 
Assessment Date Investigator‚Äôs Initials 
     MDS UPDRS Score Sheet   
3.3b  Rigidity‚Äì RUE   
1.A  Source of information     Patient   
  Caregiver 
  Patient + Caregiver  3.3c  Rigidity‚Äì LUE   
Part I 3.3d  Rigidity‚Äì RLE   
1.1  Cognitive impairment   3.3e  Rigidity‚Äì LLE   
1.2  Hallucinations and psychosis   3.4a  Finger tapping‚Äì Right hand   
1.3  Depressed mood   3.4b  Finger tapping‚Äì Left hand   
1.4  Anxious mood   3.5a  Hand movements‚Äì Right hand    
1.5  Apathy   3.5b  Hand movements‚Äì Left hand    
1.6  Features of DDS   3.6a  Pronation- supination movements‚Äì Right hand   
3.6b  Pronation- supination movements‚Äì Left hand    
1.6a  Who is filling out questionnaire    Patient   
  Caregiver 
  Patient + Caregiver  3.7a  Toe tapping‚ÄìRight foot   
1.7  Sleep problems   3.7b  Toe tapping‚Äì Left foot    
1.8  Daytime sleepiness   3.8a  Leg agility‚Äì Right leg    
1.9  Pain and other sensations   3.8b  Leg agility‚Äì Left leg   
1.10  Urinary problems   3.9  Arising from chair   
1.11  Constipation problems   3.10  Gait   
1.12  Light headedness on standing   3.11  Freezing of gait   
1.13  Fatigue   3.12  Postural stability   
Part II 3.13  Posture   
2.1  Speech   3.14  Global spontaneity of movement    
2.2  Saliva and drooling   3.15a Postural tremor‚Äì Right hand   
2.3  Chewing and swallowing   3.15b Postural tremor‚Äì Left hand   
2.4  Eating tasks   3.16a Kinetic tremor‚Äì Right hand   
2.5  Dressing   3.16b Kinetic tremor‚Äì Left hand   
2.6  Hygiene   3.17a Rest tremor amplitude‚Äì RUE   
2.7  Handwriting   3.17b Rest tremor amplitude‚Äì LUE   
2.8  Doing hobbies and other activities   3.17c Rest tremor amplitude‚Äì RLE   
2.9  Turning in bed   3.17d Rest tremor amplitude‚Äì LLE   
2.10  Tremor   3.17e Rest tremor amplitude‚Äì Lip/jaw   
2.11  Getting out of bed   3.18  Constancy of rest    
2.12  Walking and balance    Were dyskinesias presen    No  Yes  
2.13  Freezing    Did these movements interfere with ratings?    No  Yes  
3a  Is the patient on medication?    No   Yes   Hoehn and Yahr Stage  
3b  Patient‚Äôs clinical state   Off     On  Part IV 
3c  Is the patient on Levodopa?   No   Yes  4.1  Time spent with dyskinesias    
3.C1  If yes, minutes since last dose:   4.2  Functional impact of dyskinesias    
Part III 4.3  Time spent in the OFF state   
3.1  Speech   4.4  Functional impact of fluctuations    
3.2  Facial expression   4.5  Complexity of motor fluctuations    
3.3a  Rigidity‚Äì Neck   4.6  Painful OFF-state dystonia    
 July 1, 2008  
Sunovion Pharmaceuticals Inc.   
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 19.5 APPENDIX V: Columbia Suicide Severity Rating Scale (C -SSRS)  
 
  
 
 
 
 
 
 
 
 
COLUMBIA-SUICIDE SEVERITY  
RATING SCALE  
(C-SSRS) 
Screening 
Version 1/14/09 
 
 Posner, K.; Brent, D.; Lucas, C.; Gould, M.; Stanley, B.; Brown, G.; Fisher, P.; Zelazny, J.; 
Burke, A.; 
Oquendo, M.; Mann, J.   
 
 
Disclaimer: 
This scale is intended to be used by individuals who have received training in its administration. The questions contained 
in the Columbia-Suicide Severity Rating Scale are suggested probes. Ultimately, the determination of the presence of 
suicidal ideation or behavior depends on the judgment of the individual administering the scale. 
 
 
Definitions of behavioral suicidal events in this scale are based on those used in The Columbia Suicide History 
Form , developed by John Mann, MD and Maria Oquendo, MD, Conte Center for the Neuroscience of Mental Disorders 
(CCNMD), New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY, 10032. (Oquendo M. A., 
Halberstam B. & Mann J. J. , Risk factors for suicidal behavior: utility and limitations of research instruments. In M.B. First 
[Ed.] Standardized Evaluation in Clinical Practice , pp. 103 -130, 2003.) 
 
For reprints of the C-SSRS contact Kelly Posner, Ph.D., New York State Psychiatric Institute, 1051 Riverside Drive, New 
York, New York, 100
32; inquiries and training requirements contact posnerk@nyspi.columbia.edu 
 
¬© 2008 The Research Foundation for Mental Hygiene, Inc.  
SUICIDAL IDEATION  
Ask questions 1 and 2.  If both are negative, proceed to ‚ÄúSuicidal Behavior‚Äù section. If t he answer to question 2 is ‚Äúyes ‚Äù, 
ask questions 3, 4 and 5.  I f the answer to question 1  and/or 2 is ‚Äúyes‚Äù, complete ‚ÄúIntensity of Ideation‚Äù section below.  
 Past  
X Months  
1.  Wish to be Dead   
Subject endorses thoughts about a wish to be dead or not alive anymore, or wish to fall asleep and not wake up.  
Have you wi shed you were dead or wished you could go to sleep and not wake up?  
   
If yes, describe:  
  
Yes       No 
 ‚ñ°    ‚ñ° 
2.  Non -Specific Active Suicidal Thoughts  
General , non-specific thoughts of wanting to end one‚Äôs life/commit suicide (e.g. , ‚ÄúI‚Äôve thought about killing myself‚Äù ) without thoughts of ways to kill 
oneself/associated methods, intent, or plan.  
Have you  actually  had any thoughts of killing yourself?  
 
If yes, describe:   
 Yes      No 
  ‚ñ°    ‚ñ°  
3.  Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act  
Subject endorses thoughts of suicide and has thought of at least one method during the  assessment period. This is different than a specific plan with time, 
place or method details worked out (e.g. , thought of method to kill self but not a specific plan).  Includes person who would say, ‚ÄúI thought about taking an 
overdose but I never made a specific plan as to when, where or how I would actually do it‚Ä¶..and I would never go through with it .‚Äù 
Have you been thinking about how you might do this?  
 
If yes, describe:  
  
 Yes      No 
  ‚ñ°    ‚ñ° 
4.  Active Suicidal Ideation with Some Intent to Act, without Specific  Plan  
Active suicidal thoughts of killing oneself and subject reports having some intent to act on such thoughts , as opposed to ‚ÄúI have the thoughts but I 
definitely will not do anything about them .‚Äù 
Have you had these thoughts and had some intention of acting on them ?  
 
If yes, describe:  
  
Yes       No 
  ‚ñ°    ‚ñ° 
5.  Active Suicidal Ideation with Specific Plan and Intent  
Thoughts of killing oneself with details of plan fully or pa rtially worked out and subject has some intent to carry it out.  
Have you started to work out or worked out the details of how to kill yourself? Do you intend to carry out this plan?  
                                                                        
If yes, describe:  
  
 Yes      No 
  ‚ñ°    ‚ñ° 
INTENSITY OF IDEATION  
The following features should be rated with respect to the most severe type of ideation (i.e.,  1-5 from above, with 1 being the least severe 
and 5 being the most severe). Ask about time he/she was feeling the most suicidal.  
                                             
Most Severe Ideation:             _____                      _________________________________________________                                                 
                                                                                                           Type # (1 -5)                                         Description of  Ideation  Most 
Severe  
Frequency  
How many times have you had these thoughts?   
(1) Less than once a week    (2) Once a week   (3)  2 -5 times in week    (4) Daily or almost daily    (5) Many times each day   
____  
Duration  
When you have the thoughts , how long do they last?  
(1) Fleeting - few seconds or minutes                                                 (4) 4 -8 hours/most of day  
(2) Les s than 1 hour/some of the time                                                 (5) More than 8 hours/persistent or continuous  
(3) 1 -4 hours/a lot of time  ____  
Controllability  
Could/can you stop thinking about killing yourself or wanting to die if you want  to? 
(1) Easily able to control thoughts                                                      (4) Can control thoughts with a lot of difficulty  
(2) Can control thoughts with little difficulty                                     (5) Unable to control though ts 
(3) Can control thoughts with some difficulty                                    (0) Does not attempt to control thoughts  ____  
Deterrents  
Are there things - anyone or anything (e.g. , family, religion, pain of death) - that stopped you from wanting to d ie or acting on 
thoughts of committing suicide?  
(1) Deterrents definitely stopped you from attempting suicide            (4) Deterrents most likely did not stop you  
(2) Deterrents probably stopped you                                                    (5) Deterrents definitely did not stop you  
(3) Uncertain that deterrents stopped you                                             (0) Does not apply  ____  
Reasons for Ideation  
What sort of reasons did you have for thinking about wanting to die or killing your self?  Was it to end the pain or stop the way 
you were feeling (in other words you couldn‚Äôt go on living with this pain or how you were feeling) or was it to get attention , 
revenge or a reaction from others? Or both?  
(1) Completely to get attention, reveng e or a reaction from others        (4) Mostly to end or stop the pain (you couldn‚Äôt go on  
(2) Mostly to get attention, re venge or a reaction from others                      living with the pain or how you were feeling)  
(3) Equally to get attention, revenge or a reaction from others               (5) Completely to end or stop the pain (you couldn‚Äôt go on  
       and to end/stop the pain                                                                          living with the  pain or  how you were feeling)  
                                                                                                                 (0)  Does not apply   
 
 
 
____  
¬© 2008  Research Foundation for Mental Hygiene, Inc.           C-SSRS ‚ÄîScree ning ( Version 1/14/09)                                                   Page 1 of 2  
 
SUICIDAL BEHAVIOR  
(Check all that apply, so long as these are separate events; must  ask about all types)  Past X Year s 
or 
Lifetime  
Actual Attempt:   
A potentially self -injurious act committed with at least some wish to die, as a result of act.  Behavior was in part thought of as method to kill oneself. Intent 
does not have to be 100%.  If there is any intent/desire to di e associated with the act, then it can be considered an actual suicide attempt. There does not 
have to be any injury or harm , just the potential for injury or harm. If person pulls trigger while gun is in mouth but gun is broken so no injury results , 
this is considered an attempt.   
Inferring Intent: Even if an individual denies intent/wish to die, it may be inferred clinically from the behavior or circums tances. For example, a highly lethal 
act that is clearly not an accident so no other intent but suicide  can be inferred (e.g. , gunshot to head, jumping from window of a high floor/story). Also, if 
someone denies intent to die, but they thought that what they did could be lethal, intent may be inferred.  
Have you made a suicide attempt?  
Have you done anythin g to harm yourself?  
Have you done anything dangerous where you could have died?  
What did you do?  
Did you______ as a way to end your life?  
Did you want to die (even a little) when you_____?  
Were you trying to end your life when you _____?  
Or did you think  it was possible you could have died from _____ ? 
Or did you do it purely for other reasons / without ANY int ention of killing yourself (like to relieve stress, feel better, get sympathy, 
or get something else to happen)?   (Self-Injurious Behavior without su icidal intent)  
If yes, describe:  
 
 
Has subject engaged in Non -Suicidal Self -Injurious Behavior?   
Yes      No  
‚ñ°   ‚ñ°  
 
 
 
 
 
 
 
Total # of  
Attempts  
 
____ __ 
 
 
 
 
 
 
 
Yes    No 
‚ñ°   ‚ñ°  
Interrupted Attempt:    
When the person is interrupted (by an outside circumstance)  from starting the potentially self -injurious act  (if not for that, actual attempt would have 
occurred).  
Overdose: Person has pills in hand but is stopped from ingesting.  Once they ingest any pills, this becomes an attempt rather  than an interrupted attem pt. 
Shooting: Person has gun pointed toward self, gun is taken away by someone else, or is somehow prevented from pulling trigger . Once they pull the trigger, 
even if the gun fails to fire, it is an attempt. Jumping: Person is poised to jump, is grabbed an d taken down from ledge. Hanging: Person has noose around neck 
but has not yet started to hang - is stopped from doing so.  
Has there been a time when you started to do something to end your life but someone or something stopped you before you 
actually did anything?  
If yes, describe:   
Yes      No  
‚ñ°   ‚ñ°  
 
 
Total # of 
interrupted  
 
____ __ 
 
Aborted Attempt:   
When person begins to take steps toward making a suicide attempt, but stops themselves before they actually have engaged in a ny self -destructive behavior. 
Examples are similar to interrupted attem pts, except that the individual stops him/herself, instead of being stopped by something else.  
Has there been a time when you started to do something to try to end your life but you stopped yourself before you actually d id 
anything?  
If yes, describe:  
  
Yes      No 
‚ñ°   ‚ñ°  
 
Total # of  
aborted  
 
____ __ 
Preparatory Acts or Behavior:  
Acts or preparation towards imminently making a suicide attempt. This can include anything beyond a verbalization or thought,  such as assembling a specific 
method (e.g. , buying pills, purchas ing a gun) or preparing for one‚Äôs death by suicide (e.g. , giving things away, writing a suicide note).  
Have you taken any steps towards making a suicide attempt or preparing to kill yourself (such as collecting pills, getting a gun, 
giving valuables away or writing a suicide note )? 
If yes, describe:  
  
Yes      No  
‚ñ°   ‚ñ°  
Suicidal Behavior : 
Suicidal behavior was prese nt during the assessment period?  Yes      No  
‚ñ°   ‚ñ°  
Answer for Actual Attempts Only  Most Recent  
Attempt  
Date:  Most Lethal           
Attempt  
Date:  Initial/First  
Attempt  
Date:  
Actual Lethality/Medical D amage:   
0.  No physical damage or very minor physical damage (e.g. , surface scratches).  
1.  Minor physical damage (e.g. , lethargic speech; first -degree burns; mild bleeding; sprains).  
2.  Moderate physical damage; medical attention needed (e.g. , conscious  but sleepy, somewhat responsive; second -degree 
burns; bleeding of major vessel).  
3.  Moderately severe physical damage; medical  hospitalization and likely intensive care required (e.g. , comatose with 
reflexes intact; third -degree burns less than 20% of bo dy; extensive blood loss but can recover; major fractures).  
4.  Severe physical damage; medical  hospitalization with intensive care required (e.g. , comatose without reflexes; third -
degree burns over 20% of body; extensive blood loss with unstable vital sig ns; major damage to a vital area).  
5.  Death   
Enter Code  
 
 
 
______  
 
  
Enter Code  
 
 
 
______  
 
  
Enter Code  
 
 
 
______  
 
 
Potential Lethality: Only Answer if Actual Lethality=0  
Likely lethality of actual attempt if no medical damage (the following examples, wh ile having no actual medical damage, 
had potential for very serious lethality: put gun in mouth and pulled the trigger but gun fails to fire so no medical damage;  
laying on train tracks with oncoming train but pulled away before run over).  
 
0 = Behavior no t likely to result in injury  
1 = Behavior likely to result in injury but not likely to cause death  
2 = Behavior likely to result in death despite available medical care   
Enter Code  
 
 
 
______  
  
Enter Code  
 
 
 
______  
  
Enter Code  
 
 
 
______  
 
 
¬© 2008 Research Foundation for Mental Hygiene, Inc.          C-SSRS‚ÄîScreening (Version 1/14/09)                                                   Page 2 of 2 
 
 
 
 
 
 
 
 
COLUMBIA-SUICIDE SEVERITY  
RATING SCALE  
(C-SSRS) 
Since Last Visit 
Version 1/14/09 
 
Posne
r, K.; Brent, D.; Lucas, C.; Gould, M.; Stanley, B.; Brown, G.; Fisher, P.; Zelazny, J.; 
Burke, A.; Oquendo, M.; Mann, J.   
 
 
Disclaimer: 
This scale is intended to be used by individuals who have received training in its administration. The questions contained 
in the Columbia-Suicide Severity Rating Scale are suggested probes. Ultimately, the determination of the presence of 
suicidal ideation or behavior depends on the judgment of the individual administering the scale. 
 
 
Definitions of behavioral suicidal events in this scale are based on those used in The Columbia Suicide History 
Form , developed by John Mann, MD and Maria Oquendo, MD, Conte Center for the Neuroscience of Mental Disorders 
(CCNMD), New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY, 10032. (Oquendo M. A., 
Halberstam B. & Mann J. J. , Risk factors for suicidal behavior: utility and limitations of research instruments. In M.B. Firs t 
[Ed.] Standardized Evaluation in Clinical Practice , pp. 103 -130 , 2003.) 
 
For reprints of the C-SSRS contact Kelly Posner, Ph.D., New York State Psychiatric Institute, 1051 Riverside Drive, New 
York, New York, 100
32; inquiries and training requirements contact posnerk@nyspi.columbia.edu 
 
¬© 2008 The Research Foundation for Mental Hygiene, Inc.  
SUICIDAL IDEATION  
Ask questions 1 and 2.  If both are negative, proceed to ‚ÄúSuicidal Behavior‚Äù section. If t he answer to question 2 is ‚Äúyes ‚Äù, 
ask questions 3, 4 and  5.  If the answer to question 1 and/or 2 is ‚Äúyes‚Äù, complete ‚ÄúIntensity of Ideation‚Äù section below.  
 Since Last 
Visit  
1.  Wish to be Dead   
Subject endorses thoughts about a wish to be dead or not alive anymore, or wish to fall asleep and not wake up.  
Have you wished you were dead or wished you could go to sleep and not wake up?  
 
If yes, describe:  
  
Yes       No 
 ‚ñ°    ‚ñ° 
2.  Non -Specific Active Suicidal Thoughts  
General , non-specific thoughts of wanting to end one‚Äôs life/commit suicide (e.g. , ‚ÄúI‚Äôve thought about killing myself‚Äù ) without thoughts of ways to kill 
oneself/associated  methods, intent, or plan during the  assessment period.  
Have you actually had any thoughts of killing yourself?  
 
If yes, describe:   
 Yes      No 
  ‚ñ°    ‚ñ°  
3.  Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act  
Subject endorses thoughts of suicide and has thought of a t least one method during the assessment period. This is different than a specific plan with time, 
place or method details worked out (e.g. , thought of method to kill self but not a specific plan).  Includes person who would say, ‚ÄúI thought about taking an  
overdose but I never made a specific plan as to when, where  or how I would actually do it‚Ä¶ and I would never go through with it .‚Äù 
Have you been thinking about how you might do this?  
 
If yes, describe:   
 Yes      No 
  ‚ñ°    ‚ñ° 
4.  Active Suicidal Ideation with Some I ntent to Act, without Specific Plan  
Active suicidal thoughts of killing oneself and subject reports having some intent to act on such thoughts , as opposed to ‚ÄúI have the thoughts but I 
definitely will not do anything about them .‚Äù 
Have you had these thoughts and had some intention of acting on them ?  
 
If yes, describe:  
  
Yes       No 
  ‚ñ°    ‚ñ° 
5.  Active Suicidal Ideation with Specific Plan and Intent  
Thoughts of killing oneself with details of plan fully or pa rtially worked out and subject has some intent to carry it out.  
Have you started to work out or worked out the details of how to kill yourself? Do you intend to carry out this plan?  
                                                                        
If yes, describe:  
  
 Yes      No 
  ‚ñ°    ‚ñ° 
INTENSITY OF IDEATION  
The following features should be rated with respect to the mos t severe type of ideation (i.e., 1-5 from above, with 1 being the least sev ere 
and 5 being the most severe ).  
                                             
Most Sev ere Ideation:             _____                      _________________________________________________                                                 
                                                                                                           Type # (1 -5)                                         Description of  Ideation  Most 
Severe  
Frequency  
How many times have you had these thoughts?   
(1) Less than once a week    (2) Once a week   (3)  2 -5 times in week    (4) Daily or almost daily    (5) Man y times each day   
____  
Duration  
When you have the thoughts , how long do they last?  
(1) Fleeting - few seconds or minutes                                                 (4) 4 -8 hours/most of day  
(2) Less than 1 hour/some of the time                                                 (5) More than 8 hours/persistent or continuous  
(3) 1 -4 hours/a lot of time                                                                     ____  
Controllability  
Could /can you stop thinking about killing yourself or wanting to d ie if you want to?  
(1) Easily able to control thoughts                                                      (4) Can control thoughts with a lot of difficulty  
(2) Can control thoughts with little difficulty                                     (5) Unable to control thoughts  
(3) Can control thoughts with some difficulty                                    (0) Does not attempt to control thoughts  ____  
Deterrents  
Are there things - anyone or anything (e.g. , family, religion, pain of death) - that stopped you fro m wanting to die or acting on 
thoughts of committing suicide?  
(1) Deterrents definitely stopped you from attempting suicide            (4) Deterrents most likely did not stop you  
(2) Deterrents probably stopped you                                                    (5) Deterrents definitely did not stop you  
(3) Uncertain that deterrents stopped you                                             (0) Does not apply  ____  
Reasons for Ideation  
What sort of reasons did you have for thinking about wanting to die o r killing yourself?  Was it to end the pain or stop the way 
you were feeling (in other words you couldn‚Äôt go on living with this pain or how you were feeling) or was it to get attention , 
revenge or a reaction from others? Or both?  
(1) Completely to get att ention, re venge or a reaction from others        (4) Mostly to end or stop the pain (you couldn‚Äôt go on  
(2) Mostly to get attention, re venge or a reaction from others                      living with the pain or how you were feeling)  
(3) Equally to get atten tion, revenge or a reaction from others               (5) Completely to end or stop the pain (you couldn‚Äôt go on  
       and to end/stop the pain                                                                          living with the pain or  how you w ere feeling)  
                                                                                                                 (0)  Does not apply   
 
 
 
____  
¬© 2008  Research Foundation for Mental Hygiene, Inc.           C-SSRS ‚ÄîSince Last Visit ( Version 1/14/09)                                 Page 1 of 2                                     
 
SUICIDAL BEHAVIOR  
(Check all that apply, so long as these are separate events; must  ask about all types ) Since Last 
Visit  
Actual Attempt:   
A potentially self -injurious act committed with at least some wish to die, as a result of act.  Behavior was in part thought of as method to kill oneself. Intent 
does not have to be 100%.  If there is any intent/desire t o die associated with the act, then it can be considered an actual suicide attempt. There does not 
have to be any injury or harm , just the potential for injury or harm. If person pulls trigger while gun is in mouth but gun is broken so no injury results , 
this is considered an attempt.   
Inferring Intent: Even if an individual denies intent/wish to die, it may be inferred clinically from the behavior or circums tances. For example, a highly 
lethal act that is clearly not an accident so no other intent but sui cide can be inferred (e.g. , gunshot to head, jumping from window of a high floor/story). 
Also, if someone denies intent to die, but they thought that what they did could be lethal, intent may be inferred.  
Have you made a suicide attempt?  
Have you done any thing to harm yourself?   
Have you done anything dangerous where you could have died?  
What did you do?  
Did you______ as a way to end your life?  
Did you want to die (even a little) when you_____?  
Were you trying to end your life when you _____?  
Or did you think it was possible you could have died from_____?  
Or did you do it purely for other reasons / without ANY intention of killing yourself (like to relieve stress, feel better, g et 
sympathy, or get something else to happen)?  (Self-Injurious Behavior witho ut suicidal intent)  
If yes, describe:  
 
 
Has subject engaged in Non -Suicidal Self -Injurious Behavior?   
Yes      No  
‚ñ°   ‚ñ°  
 
 
 
 
 
 
 
Total # of  
Attempts  
 
____ __ 
 
 
 
 
 
 
 
Yes     No 
‚ñ°   ‚ñ°  
Interrupted Attempt:    
When the person is interrupted (by an outside circums tance) from starting the potentially self -injurious act  (if not for that, actual attempt would have 
occurred).  
Overdose: Person has pills in hand but is stopped from ingesting.  Once they ingest any pills, this becomes an attempt rather  than an interrupted  attempt. 
Shooting: Person has gun pointed toward self, gun is taken away by someone else, or is somehow prevented from pulling trigger . Once they pull the trigger, 
even if the gun fails to fire, it is an attempt. Jumping: Person is poised to jump, is grab bed and taken down from ledge. Hanging: Person has noose around 
neck but has not yet started to hang - is stopped from doing so.  
Has there been a time when you started to do something to end your life but someone or something stopped you before you 
actuall y did anything?  
If yes, describe:   
Yes      No  
‚ñ°   ‚ñ°  
 
 
Total # of 
interrupted  
 
____ __ 
Aborted Attempt:   
When person begins to take steps toward making a suicide attempt, but stops themselves before they actually have engaged in a ny self -destructive behavior. 
Examples are similar to interrupted attemp ts, except that the individual stops him/herself, instead of being stopped by something else.  
Has there been a time when you started to do something to try to end your life but you stopped yourself before you 
actually did anything?  
If yes, describe:  
  
Yes      No 
‚ñ°   ‚ñ°  
 
Total # of  
aborted  
 
____ __ 
Preparatory Acts or Behavior:  
Acts or preparation towards imminently making a suicide attempt. This can include anything beyond a verbalization or thought,  such as assembling a 
specific method (e.g. , buying pills, purchas ing a gun) or preparing for one‚Äôs death by suicide (e.g. , giving things away, writing a suicide note).  
Have you taken any steps towards making a suicide attempt or preparing to kill yourself (such as collecting pills, getting a gun, 
giving valuables away or writing a suicide note )? 
If yes, describe:  
  
Yes      No  
‚ñ°   ‚ñ°  
Suicidal Behavior : 
Suicidal behavior was prese nt during the assessment period?  Yes      No  
‚ñ°   ‚ñ°  
Suicide:     Yes    No  
‚ñ°   ‚ñ°  
Answer for Actual Attempts Only  Most Lethal  
Attempt  
Date:  
Actual Lethality/Medical Damage:   
0.  No physical damage or very minor physical damage (e.g. , surface scratches).  
1.  Minor physical damage (e.g. , lethargic speech; first -degree burns; mild bleeding; sprains).  
2.  Moderate physical damage; medical attention needed (e.g. , conscious but sleepy, somewhat responsive; second -degree burns; bleeding of major vessel).  
3.  Moderately severe physical damage; medical  hospitalization and likely intensive care required (e.g. , comatose with reflexes intact; third -degree bu rns 
less than 20% of body; extensive blood loss but can recover; major fractures).  
4.  Severe physical damage; medical  hospitalization with intensive care required (e.g. , comatose without reflexes; third -degree burns over 20% of body; 
extensive blood loss with unstable vital signs; major damage to a vital area).  
5.  Death   
Enter Code  
 
 
 
______  
Potential Lethality: Only Answer if Actual Lethality=0  
Likely lethality of actual attempt if no medical damage (the following examples, while having no actual medica l damage, had potential for very serious 
lethality: put gun in mouth and pulled the trigger but gun fails to fire so no medical damage; laying on train tracks with on coming train but pulled away 
before run over).  
 
0 = Behavior not likely to result in injur y 
1 = Behavior likely to result in injury but not likely to cause death  
2 = Behavior likely to result in death despite available medical care   
Enter Code  
 
 
 
______  
¬© 2008 Research Foundation for Mental Hygiene, Inc.          C-SSRS‚ÄîSince Last Visit (Version 1/14/09)                                Page 2 of 2                                     
Sunovion Pharmaceuticals Inc.   
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 19.6 APPENDIX VI : United Kingdom Parkinson‚Äôs Disease Brain Bank Clinical 
Diagnostic Criteria  
Step 1 - Diagnosis of Parkinsonian Syndrome 
‚Ä¢ Bradykinesia  
‚Ä¢ At least one of the follo wing 
o Muscular rigidity 
o 4-6 Hz rest tremor  
o Postural instability not caused by primary visual, vestibular, cerebellar, or  
proprioceptive dysfunction 
Step 2 - Exclusion criteria for PD 
‚Ä¢ History of repeated strokes with stepwise progression of Parkinsonian feat ures 
‚Ä¢ History of repeated head injury 
‚Ä¢ History of definite encephalitis  
‚Ä¢ Oculogyric crises  
‚Ä¢ Neuroleptic treatment at onset of symptoms  
‚Ä¢ Sustained remission  
‚Ä¢ Strictly unilateral features after 3 years  
‚Ä¢ Supranuclear gaze palsy  
‚Ä¢ Cerebellar signs  
‚Ä¢ Early severe autonomic involvement 
‚Ä¢ Early severe dementia with disturbances of memory, language, and praxis  
‚Ä¢ Babinski sign 
‚Ä¢ Presence of cerebral tumor or communication hydrocephalus on imaging study 
‚Ä¢ Negative response to large doses of L-Dopa in absence of malabsorption 
‚Ä¢ MPTP expos ure 
Sunovion Pharmaceuticals Inc.   
CTH -201 
28 Aug 2017  CONFIDENTIAL  Version: 5.00 Step 3 - Supportive prospective positive criteria for PD 
Three or more required for diagnosis of definite Parkinson‚Äôs disease in combination with step 
one 
‚Ä¢ Unilateral onset  
‚Ä¢ Rest tremor present  
‚Ä¢ Progressive disorder 
‚Ä¢ Persistent asymmetry affecting side of onset most 
‚Ä¢ Excellent response (70 -100%) to L-Dopa 
‚Ä¢ Severe L-Dopa- induced chorea  
‚Ä¢ L-Dopa response for 5 years or more 
‚Ä¢ Clinical course of ten years or more 
 
Reference: Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of 
idiopathi c Parki nson‚Äôs disease:  a clinico -pathological study of 100 cases. J Neurol Neurosurg 
Psychiatry.  1992;55(3):181-4. 
 
 